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ABSTRACT 
Nicotinic acetylcholine receptors (nAChR) are an important family of ligand gated ion 
channels found throughout the CNS and the PNS. They have been indicated in a series of 
physiological functions and pathological states. nAChRs have received extensive study in 
the past as a prototype of the Cys loop LGIC member. Growing interest in developing 
subtype specific agents targeting nAChRs to treat neurological diseases require more 
detailed structural and functional information in the numerous members of the nAChR 
family. 
 We performed structure-function studies on the chemical scale of several of the most 
important members of this family using a powerful combination of conventional 
mutagenesis and unnatural amino acid incorporations. Chapter 2 describes our research in 
studying the channel gating mechanism of the prototypic nAChR, the muscle type 
(α1)2βγδ. We studied thoroughly the gating interface of the receptor and concluded that the 
overall charging pattern of the gating interface, and not any specific pairwise electrostatic 
interactions, controls the gating process in the Cys loop superfamily. Chapter 3 reports our 
studies in the ligand binding mechanism of the most prevalent neuronal type α4β2 and α7 
nAChR. We identified a cation-π interaction and a hydrogen bond employed by nicotine 
with the α4β2 receptor. These two key interactions are absent or significantly diminished 
in both the muscle type receptors and in the α7 form of neuronal receptor. In Chapter 4 we 
studied the ligand binding mechanism of a relatively newly characterized neuronal 
receptor ,α4β4.  
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From these studies, we found that in the Cys loop superfamily, homology in amino 
acid sequences and structures do not translate into a shared functional mechanism. In fact, 
different sets of chemical interactions are adopted between ligands and the receptor, and 
between amino acids within the ion channel proteins, both in ligand binding and channel 
gating.  
Ion channels are membrane bound multi-subunit macromolecules. We are able to 
carry out such exhaustive detailed structure-function studies by means of the fast-
developing methodology of unnatural amino acid incorporation by nonsense suppression. 
This thesis also describes our effort to improve the efficiency of nonsense suppression. In 
particular, we designed multiple 21nt small interfering RNA (siRNA) targeting release 
factor 1 (eRF1) in both HEK cells and Xenopus oocytes, and monitored the nonsense 
suppression efficiency change in vivo and in vitro by RNA PCR, Western blotting, 
fluorescence, and electrophysiology (Chapter 5). 
 
  ix
TABLE OF CONTENTS 
Acknowledgements ............................................................................................ iv 
Abstract ..............................................................................................................vii 
Table of Contents................................................................................................ ix 
List of Figures ...................................................................................................xiii 
List of Tables ..................................................................................................... xv 
Chapter 1: Introduction........................................................................................ 1 
1.1 Molecular neurobiology and chemistry .................................................. 1 
1.2 Muscle type and neuronal nAChR receptors.......................................... 3 
1.3 Gating of the Cys loop ligand gated ion channels.................................. 8 
1.4 Nonsense suppression to incorporate unnatural amino acids............... 12 
1.5 Thesis summary..................................................................................... 16 
1.6 References ............................................................................................. 18 
Chapter 2: A unified view of the role of electrostatic interactions in  
             modulating the gating of Cys loop receptors ....................................... 22 
2.1 Abstract.................................................................................................. 22 
2.2 Introduction ........................................................................................... 23 
2.3 Results.................................................................................................... 28 
      2.3.1 Electrostatics at the gating interface ............................................ 28 
      2.3.2 Studies of the muscle-type nAChR α subunit ............................. 33 
      2.3.3 Studies of the muscle-type nAChR non-α subunits.................... 47 
      2.3.4 Studies of a partial agonist ........................................................... 48 
      2.3.5 Previous work on the GABAA and glycine receptors ................. 51 
2.4 Discussion.............................................................................................. 55 
2.5 Materials and methods .......................................................................... 58 
      2.5.1 Mutagenesis and mRNA synthesis .............................................. 58 
      2.5.2 Electrophysiology and data analysis............................................ 58 
      2.5.3 Unnatural amino acid suppression............................................... 59 
  x
      2.5.4 Bungarotoxin binding................................................................... 59 
2.6 References ............................................................................................. 60 
Chapter 3: Nicotine in the CNS vs. the neuromuscular junction: a cation-π  
            interaction and a hydrogen bond make the difference.......................... 67 
3.1 Abstract.................................................................................................. 67 
3.2 Introduction ........................................................................................... 67 
3.3 Results.................................................................................................... 70 
      3.3.1 Background and approach............................................................ 70 
      3.3.2 Challenges in studying neuronal nAChRs................................... 75 
      3.3.3 A cation-π interaction in the α4β2 receptor ................................ 79 
      3.3.4 A strong hydrogen bond in the  α4β2 receptor ........................... 82 
      3.3.5 Single channel measurements ...................................................... 83 
      3.3.6 Differential binding behavior in the α7 receptor......................... 84 
3.4 Discussion.............................................................................................. 88 
3.5 Experimental procedures....................................................................... 94 
      3.5.1 mRNA synthesis and mutagenesis............................................... 94 
      3.5.2 Ion channel expression................................................................. 94 
      3.5.3 Unnatural amino acid / α-hydroxy acid incorporation................ 95 
      3.5.4 Electrophysiological characterizations of the channels .............. 95 
3.6 References ............................................................................................. 97 
Chapter 4: Contrasting drug-receptor interactions at neuronal vs. muscle- 
            type nicotinic acetylcholine receptors: the α4β4 neuronal receptor. .101 
4.1 Background..........................................................................................101 
4.2 Results..................................................................................................104 
      4.2.1 Establishing the viability of unnatural amino acid  
               incorporation in the α4β4 receptor ............................................104 
      4.2.2 TrpB............................................................................................105 
      4.2.3 TyrA............................................................................................106 
      4.2.4 TyrC1 and TyrC2 .......................................................................107 
  xi
     4.2.5 TrpD.............................................................................................108 
4.3 Discussion............................................................................................109 
4.4 References ...........................................................................................114 
Chapter 5: Improving nonsense suppression by suppressing eRF-1 with  
             siRNA..................................................................................................115 
5.1 Abstract................................................................................................115 
5.2 Introduction .........................................................................................115 
      5.2.1 Unnatural amino acid incorporation by nonsense suppression.115 
      5.2.2 Nonsense suppression efficiency ...............................................117 
      5.2.3 Improving  nonsense suppression efficiency in Xenopus  
               oocytes ........................................................................................118 
      5.2.4 Improving  nonsense suppression efficiency in mammalian  
               cells .............................................................................................119 
      5.2.5 Improving nonsense suppression efficiency by suppressing  
               eRF1............................................................................................120 
      5.2.6 Using RNA interference (RNAi) to suppress eRF1 in  
               mammalian cells.........................................................................122 
      5.2.7 Using RNAi to suppress endogenous proteins in Xenopus 
               laevis oocytes..............................................................................122 
      5.2.8 RNA interference .......................................................................123 
5.3 Experimental design............................................................................124 
      5.3.1 siRNA molecules designed to target human and Xenopus  
               laevis eRF1 .................................................................................124 
      5.3.2 Coinjection of siRNA molecules with nonsense suppression  
               experiments into Xenopus oocytes.............................................126  
      5.3.3 Recording currents in Xenopus oocytes of nAChR introduced  
               by 50 μM ACh and 250 μM ACh. .............................................126 
      5.3.4 RNA PCR on eRF1 both in Xenopus oocytes and in HEK  
               cells .............................................................................................127 
      5.3.5 SDS-PAGE and Western blot in Xenopus laevis oocytes.........130 
  xii
      5.3.6 Co-electroporation of siRNA with TAG29 GFP-TAG  
                plasmid DNA and HSAS tRNA and microscopy in  
                HEK cells...................................................................................131 
5.4 Results and discussion.........................................................................132 
      5.4.1 Electrophysiology of siRNA treated oocytes ............................132 
      5.4.2 RNA PCR results of uninjected oocytes and siRNA treated  
               oocytes ........................................................................................135 
      5.4.3 Western blots for siRNA treated oocytes. .................................138 
      5.4.4 HSAS/TAG EGFP experiments. ...............................................138 
5.5 Conclusion and future direction..........................................................139   
5.6 References ...........................................................................................140 
 
     
 
 
 
 
  xiii
LIST OF FIGURES 
 
Figure 1.1 A simplified view of a chemical synapse.................................... 3 
Figure 1.2 Topology and diversity of nAChR subtypes............................... 5 
Figure 1.3 Unnatural amino acid incorporation by nonsense suppression.14 
Figure 1.4 Expression system mostly used in our lab for structure- 
                 function of ion channels ...........................................................   15 
Figure 2.1 Views of the gating interface..................................................... 26 
Figure 2.2 Plot of log(EC50) vs. side chain physicochemical properties  
                  at site α V46.. ........................................................................... 38 
Figure 2.3 A variety of mutations at α E45 are well tolerated................... 40 
Figure 2.4 Plot of log(EC50) vs. side chain physicochemical properties  
                 at site α E45.. ............................................................................. 41 
Figure 2.5 Charge reversal at α D138 of the nAChR is rescued by  
                  charge swap at either of two sites: R429 (postM4) or K276  
                  (M2-M3).. .................................................................................. 44 
Figure 2.6 Relative efficacy (ε) of succinylcholine for several variants  
                  of the nAChR............................................................................. 50 
Figure 2.7 Analysis of previously published results for the GABAA  
                  receptor α1 subunit.................................................................... 52 
Figure 3.1 Sequence alignments in the immediate vicinity of the  
                  agonist binding sites from AChBP, mouse muscle type,  
                  rat α4β2, and rat α7nAChR. ..................................................... 69 
Figure 3.2 Fluorination plots demonstrating a cation-π interaction of TrpB 
                  in the muscle nAChR with the cationic centers of ACh and 
                  Epibatidine, but not with nicotine... .......................................... 72 
Figure 3.3 The “aromatic box” of the Cys-loop receptor........................... 73 
Figure 3.4 Establishing a hydrogen bond of the backbone carbonyl  
  xiv
                  with the agonists in the muscle nAChR... ................................. 74 
Figure 3.5 Rectification behaviors of A2B3 and A3B2 α4L9’Aβ2 
                  nAChR in Xenopus oocytes.. .................................................... 78 
Figure 3.6 Fluorination plots demonstrating cation-π interactions of  
                  TrpB in α4β2 nAChR with nicotine (left) and ACh (right).... . 81 
Figure 3.7 Fluorination plots demonstrating cation-π interactions of  
                 TyrA in α7 nAChR with ACh (left) and Epibatidine (right)... . 85 
Figure 3.8 Fluorination plots demonstrating cation-π interactions of 
                  TyrC2 in α7 nAChR with epibatidine.. .................................... 86 
Figure 4.1 Compounds tested in the current study. ..................................103 
Figure 4.2 Tryptophan and phenylalanine analogs incorporated in the  
                 current study .............................................................................105 
Figure 5.1 Schematics of the unnatural amino acid incorporation in vivo by 
                   nonsense suppression.... ..............................................................116 
Figure 5.2 A general scheme of the translation termination complex  
                 and a scheme of RNA interference mechanism... ...................121 
Figure 5.3 Different positions of siRNA targets on eRF1 mRNA and  
                  different time delays between the siRNA injection and the  
                  mRNA/tRNA injections were applied. ...................................125 
Figure 5.4 Strategy of RNA PCR experiments to detect eRF1 mRNA  
                  decrease by injecting siRNAs. ................................................129 
Figure 5.5 The average currents of mouse muscle nAChR α1 149 TAG  
                  mutant recovered by tryptophan charged tRNA with and  
                   without siRNA injected...... ....................................................134 
Figure 5.6 RNA PCR and Western blottting show different effects of  
                  designed siRNA molecules in Xenopus oocytes and in HEK 
                  cells..... .....................................................................................136 
Figure 5.7 Preliminary results of Ser29TAG EGFP suppressed by  
                  HSAS... ....................................................................................139 
  xv
LIST OF TABLES 
 
Table 2.1 Selected sequences in the gating interface, highlighting  
                cationic (blue) and anionic (red) residues.. ................................. 30 
Table 2.2 Charge characteristics of the gating interface. ........................... 30 
Table 2.3 Mutations in the nAChR α subunits... .......................................... 35 
Supplementary Table S 2.1: Sequences in the gating interface of the  
                 whole LGIC family, highlighting cationic (blue) and anionic  
                 (red) residues. ............................................................................. 63 
Table 3.1 Injection of various mRNA ratios α4(L9’A):β2 resulting in  
                receptors of different stoichiometry.. .......................................... 77 
Table 3.2 EC50 values (μM), Hill coefficients, and normalized current  
                 size at +70mV (normalized to current size at -100mV as -1)  
                  for selected mutants in α4L9’Aβ2 nAChR A2B3 receptors....80 
Table 3.3 EC50 values (μM) and Hill coefficients for selected mutants in  
                 α7T6’S nAChR.. ........................................................................ 87 
Table 4.1 Amino acids in the aromatic box of the agonist binding site in  
                 five different Cys-loop receptors. ............................................103 
Table 4.2 Comparison of muscle type nAChR (α1)2β1γδ and the  
                neuronal nAChR α4β4 EC50s in Xenopus oocytes... ................105 
Table 4.3 Ratios of mutant EC50 over the wild type EC50 for selected  
                mutants in α4β4 receptors.........................................................108 
 
  1
 
Chapter 1 
 
INTRODUCTION 
1.1. Molecular Neurobiology and Chemistry 
The brain is the most complex organ of the human body and it is comprised of about 1011 
neurons [1]. A synapse is the basic unit of signal transmission between the neurons and between 
one neuron to non-neural cells such as those in muscles or glands. Each neuron usually has 
multiple dendrites; serving as the postsynaptic component, but only one axon, which forms the 
presynaptic component. It is estimated that one neuron forms 103~104 synapses with other neurons. 
The vast volume of information transmission between these numerous neural cells is largely 
dependent on small molecules called neurotransmitters, the most studied of which is acetylcholine 
[2]. 
At rest, neurotransmitter-containing vesicles are stored in the presynaptic cell either close to 
the presynaptic membranes in places called active zones, or further away from the active zones by 
cytoskeleton elements until they are needed. At a synaptic cleft, signal transmission is triggered by 
the arrival of an electric signal from the cell body of a presynaptic cell, causing the membrane 
potential to rise from its resting state. An electric signal large enough to open voltage-gated 
calcium channels on the cell membrane of the presynaptic neuron results in the inflow of calcium 
ions, causing the docking of the vesicles at the active zones and then the fusion of the vesicle 
membrane and the presynaptic membrane, and finally causing the release of the neurotransmitters 
into the cleft from the storage vesicles[1]. 
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The released neurotransmitters diffuse across the thin synaptic cleft where they bind their 
corresponding receptors embedded in the postsynaptic membrane of the neighboring neuron. This 
binding causes a conformational change in the receptors, opening an ion pore in the receptor, 
allowing a selection of ions to flow through. This ion flow changes the membrane potential of the 
postsynaptic cell, either exciting it or inhibiting it. Thus the electric-chemical-electric transmission 
of the information is completed from one cell to the next.  
In this process, a ligand gated ion channel could play important roles at two locations: the 
presynaptic part and the postsynaptic part. The presynaptic channels are usually regulatory, the 
opening of which contributes to raising the membrane potential of the presynaptic cell, thus easing 
the opening of the voltage gated calcium channels, finally resulting in the transmitter release [3-5]. 
The postsynaptic channels contribute to the fast electric signal transmission between two cells, 
converting the chemical signal carried by the small molecule neurotransmitter into an electric 
signal. Despite the variable locations and functions of different families of ligand ion channels, the 
ability to bind a small molecule neurotransmitter and to allow ion flow upon opening is essential 
for a ligand gated ion channel (Figure 1.1). 
  3
 
Figure 1.1 A simplified view of a chemical synapse. Both presynaptic and postsynaptic ligand 
gated ion channels are shown in green and the voltage gated calcium channels are shown in brown. 
The bolts show the direction of electric signal transmission. The arrow in the ion channel shows 
the direction of ion flow in the case of an open postsynaptic nAChR.  
 
The structure-function study of these highly specialized ion channels at the molecular level 
requires chemistry to combine with structural biology, molecular biology, and electrophysiology. 
In our lab, we take advantage of recent advances in high-resolution structural data, fast-developing 
protein modification techniques (in particular, incorporation of unnatural amino acids), and the 
sensitive functional assay of electrophysiology to monitor the functional changes induced by 
structural modifications.  
1.2 Muscle type and neuronal nAChR receptors 
 The acetylcholine receptor family has two members: the muscarinic acetylcholine receptor 
(mAChR) which is a G-protein coupled receptor, and the nicotinic acetylcholine receptor (nAChR) 
which is a ligand gated ion channel. nAChRs purified from the electric organ of Torpedo were 
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resolved into four different subunits designated α, β, γ(ε), and δ. These subunits were later 
sequenced and cloned, paving the way for the molecular analysis of nicotinic receptors, especially 
for those at the neuromuscular junction, which show a stoichiometry of α2βγ(ε)δ, γ in the fetal 
form and ε in the adult form [6]. 
The muscle type nicotinic receptor turns out to be the best studied and thus the prototypic 
nAChR so far. This pentameric ion channel carries two inequivalent ligand binding sites at the 
large extracellular N-terminal domain subunit interfaces. Following the N-terminal domain are 
four α-helices within the membrane, the third and the fourth of which are separated by a large 
cytoplasmic loop carrying the phosphorylation sites and the trafficking signals for the receptor 
transport [7] (Figure 1.2 A). The α subunits differ from the others by the two adjacent cysteines 
close to the ligand binding site [8]. 
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Fig 1.2 Topology and diversity of nAChR subtypes. A: Topology of one subunit of nAChR. The 
green M2 transmembrane domain lines the ion pore of the channel. B: The subunit arrangements of 
various heteromeric and homomeric nAChR subtypes. The green and yellow circles represent the 
subunits that carry the principle and complementary parts of the ligand binding domain, 
respectively. The gray subunits are mainly structural subunits that don’t contribute directly to 
ligand binding. The dark circles represent the ligand binding sites. C: Saturating dose of 
acetylcholine induced electric signals recorded in Xenopus oocytes expressing various nAChR 
subtypes. B and C adapted from Fig. 1 in [9], except for the mouse muscle trace which is from our 
recording.  
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In the 1980s, almost a decade after the muscle type nAChRs were discovered, nAChRs were 
characterized in the central nervous system with a much more complex subunit composition. 
Although subunits from only the α and β families were found, the pentameric combinations of α2-
α10 and β2-β4 make possible the existence of a great number of neuronal nicotinic receptors [10, 
11] (Figure 1.2 B and C). Adding to this complexity is the variable stoichiometry of many neuronal 
nAChRs, the most well known example being the existence of at least two subgroups of α4β2 
receptors: (α4)2(β2)3 and (α4)3(β2)2 [9, 12]. 
While distributed throughout the nervous system, neuronal receptors are preferentially located 
presynaptically, regulating the release of neurotransmitters, in contrast to the mainly postsynaptic 
location of the muscle type nAChR. A particular kind of neurotransmitter can be regulated by 
different neuronal nAChR subtypes at different CNS regions. For instance, α4β2-containing 
receptors are important both at the striatum and the thalamus in regulating the release of the 
pleasure-inducing dopamine; α6β2β3-containing receptors were found to also play an important 
role at the striatum [5, 12].  
More than 90 percent of the nAChR in the CNS contain the α4 and β2 subunits, and the other 
major group contains α7. In the PNS, the most abundant subunits are α3 and β4, which colocalize 
with α5 and/or β4; α7 are also found in the ganglia in the PNS. The α4β2-containing, α7-
containing, and α3β4-containing receptors are the best characterized subtypes in terms of ligand 
selectivity, as they can be purified from animal tissues and studied by radio-labeled ligands. [3H]-
cytisine, [3H]-nicotine, or [3H]-epibatidine can label α4β2-containing receptors, and [125I]-Bgtx or 
[3H]-methyllycaconitine ([3H]-MLA) are used to label α7-containing receptors. However, 
  7
complication could be caused by the lack of high selectivity of these ligands. For example, α-Bgtx 
binds to α7-containing, α8-containing, and α9-containing homomeric and heteromeric receptors, 
and MLA also recognizes receptors that contain α3 or α6 subunits. Also, epibatidine binds α2−α4 
and β2-β4 subunits with high affinity [9, 12]. 
The addictive properties of nicotine lead to over 5,000,000 smoking-related deaths annually, 
producing the largest source of preventable mortality in the western world. One of the earliest uses 
of nicotinic drugs dates back to 1932 when the antinociceptive activity of nicotine was discovered. 
Later epibatidine was discovered, displaying outstanding analgesic properties and high affinity for 
the nicotinic receptors [13]. However, lack of selectivity for specific subtypes compromised the 
wide use of epibatidine, due to the serious side effects. Other physiological functions and 
pathological effects are also mediated by one or a small selection of neuronal nAChR subtypes. 
The heterogeneity of the native nAChR populations in the CNS presents major challenges in 
developing therapeutics targeting these receptors. Targeting one or a few nAChR subtypes without 
affecting other subtypes avoids the cardiovascular, gastrointestinal, and other side effects, making 
such targeting a main goal of designing such agents [6]. The main role of nicotinic receptors in the 
brain seems to be that of enhancing neurotransmitter release of several kinds; therefore, several 
pathological states could be alleviated by the activation of neuronal nAChRs.  
Targeting presynaptic nicotinic receptors to enhance the release of neurotransmitters such as 
ACh and dopamine may be advantageous for treating neurodegenerative diseases and for 
improving cognition. In fact, epidemiological evidence has identified several pathological states 
that might benefit from nicotinic drugs [14]. For instance, a negative correlation between smoking 
and the incidence of Alzheimer’s disease or Parkinson’s disease has been supported by in vitro and 
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in vivo studies [15, 16]. There has also been a consistent observation of widespread decline in 
nicotinic receptors in aging normal human brains or the brains of neurodegenerative disease 
patients [17].  The nicotinic cholinergic systems have been shown to be involved in several 
cognitive functions including attention, learning, and memory [18]. Among the many subtypes 
present in the brain, the α4β2-containing and α7-containing subtypes seem particularly important.  
In the post-mortem brains of schizophrenic patients, it was found that nicotinic receptors, in 
particular the α7-containing receptors, are reduced in number [19]. Association between smoking 
and major depression and anxiety has also been shown by several studies. Despite the complex 
effects of nicotine on these pathological psychiatric states, cholinergic agonists and antagonists 
aiming to treat several psychiatric disorders have been proposed recently [20]. 
In addition to the therapeutic potentials of targeting nicotinic receptors mentioned above, 
using nicotinic drugs including nicotinic antagonists such as mecamylamine or partial agonists 
such as varenicline are the most popular strategies to aid smoking cessation [21]. The possibility of 
treating epilepsy and Tourette’s syndrome has been explored as well [18, 22].  
1.3 Gating of the Cys loop ligand gated ion channels 
Ligand gated ion channels are membrane-bound macromolecules capable of 1) binding 
ligands of various sizes and properties, 2) structural changes that produce dramatically different 
functional states identified as open, closed, or desensitized, and 3) selectively allowing ions to flow 
through a pore region usually far away from the ligand binding region. Ion channels perform these 
functions on the time scale of milliseconds, enabling them to fine-tune the fast electric transmission 
of the complicated nervous network [23]. 
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When we talk about the gating of an ion channel, we generally refer to the channel opening 
and closing processes (desensitization is usually considered part of the gating, but is not stressed 
here), which involves multiple structural elements in the protein, including the ligand binding site, 
the channel gate, and many other structural elements of the protein [24]. There are several critical 
and important questions to ask when studying the gating mechanisms.  Which structural elements 
are involved in this process?  What is the nature of the chemical interactions employed to transmit 
these interactions from one amino acid to another?  In what order or fashion do these changes 
occur?  Are these changes conserved in structurally/functionally related proteins, and so on and so 
forth.  
The Cys loop superfamily of neurotransmitter-gated ion channels includes receptors for 
acetylcholine (nicotinic ACh receptor, nAChR), serotonin (5-HT3 receptor), γ-aminobutyric acid 
(GABA, types A and C receptors), and glycine. These receptors are classified as excitatory (cation-
conducting; nAChR and 5-HT3) or inhibitory (anion-conducting; GABA and glycine) [25]. 
Tremendous efforts have been put into revealing structures at different states of the receptor or 
receptor analogs, aiming to find changes that may help in defining different functional stages of the 
protein. Apart from the difficulty of envisioning dynamic and continuous movements of a 
complicated macromolecule by generating static “snapshots”, there are innate difficulties of getting 
the crystal structure of this membrane-bound protein.  
Despite these difficulties and inaccuracies, there have been suggestive structural data from 
several labs.  AChBP is a secretory protein from glia cells in the CNS of the fresh water snail, 
Lymnaea stagnailis, where it modulates synaptic transmission. Being highly homologous to the 
extracellular domain of the nAChRs and carrying high pharmacological similarity to nAChRs, α7 
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in particular, AChBP structures from multiple organisms with various ligands bound have provided 
great insight into the ligand binding mechanism of the nicotinic receptors for the past few years 
[26-33]. Agonist and antagonist bound forms of AChBP show dramatic differences in certain 
structural elements. This protein lacks completely the transmembrane part where the ion pore is 
located, however it was shown to be a “gate-able” protein when conjugated with the 
transmembrane part of the serotonin receptor [34]. Unwin and co-workers refined the cryo-EM 
model of the whole receptor from the electric organ of Torpedo to a resolution of 4Ǻ [35]. 
However, the model still lacks the resolution to draw any conclusion at the mobile loops which are 
of critical importance when it comes to the channel gating study [35-37]. Furthermore, it has not 
been determined whether the agonist bound form of AChBP structures is in the active or 
desensitized state; therefore, conclusions from the structural data alone seem imprudent [38].  
By looking at the several AChBP crystal structures with or without different ligands bound, 
loop C seems to be a structural unit that moves significantly. An “uncapped” conformation of C 
loop corresponds to a closed or resting state of the receptor, while a “capped” loop C corresponds 
to an open or desensitized receptor. Other elements indicated to have moved include β1−β2 loop 
(loop 2), Cys loop (loop 7) and β8−β9 loop (loop 9) [38].  
Recently, a 1.94 Ǻ crystal structure of the mutated single monomer of the extracellular 
domain of mouse muscle α1 nAChR subunit bound with α-bungarotoxin provided interesting new 
results suggesting important structural features. A water molecule buried in the core of the subunit 
and a well ordered carbohydrate chain are seen. Functional studies indicate that both features are 
important in regulating the gating of the channel [39].  
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In addition to structural biology, chemistry, biochemistry, chemical labeling, and 
electrophysiology come into play to study the gating of this family of receptors. In earlier days, 
using SCAM (substituted cystein accessibility mutagenesis), Karlin suggested that during gating 
the α M2 domain undergoes significant changes in secondary structure, from a nonhelical to an α-
helical conformation [40]. Backbone amide-to-ester mutations disrupting backbone hydrogen 
bonds performed in our lab supported this mechanism, with a few modifications to Karlin’s model 
of the exact locations where the largest conformational changes are seen [41].  
From mutational studies, it was proposed by Sine et al. that after ligand binding, a conserved 
tyrosine residue (Y185, Lymnaea AChBP) in the C-loop is drawn closer to a conserved lysine 
residue (K139) in the β7 strand, breaking an interaction between this lysine and an aspartate 
residue (D194) in the β10 strand (K145 and D200 in the mouse muscle α subunit) [34, 42].  
For the 5-HT3 receptor, Lummis and co-workers from our lab have proposed that structural 
changes induced by ligand binding lead to the cis-trans isomerization of a conserved proline 
residue (Pro 8*) on the M2-M3 linker and subsequent channel opening [43]. Thus it has been 
proposed that upon agonist binding, the C-loop is pulled into to a “capped” position leading to an 
interaction between K139 and Y185, a disruption of a salt bridge between the β10 strand and the 
β1−β2 linker, followed by the isomerization of a proline residue on the M2-M3 linker, leading to 
channel opening [42]. However, although this proline exists for nAChRs, no similar proline exists 
in either the GABA or glycine members of this superfamily. Instead, electrostatic and hydrophobic 
interactions might be responsible for gating of these receptors [42, 44-48]. 
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“A stepwise mechanism for channel gating” or what was previously called a “conformational 
wave” has become more complete as more regions are explored by a combination of point 
mutation and single channel recording in the Auerbach lab [49-52]. By looking at a “Linear Free 
Energy Relationship”, Auerbach and co-workers applied model-based kinetic analyses to quantify 
the effects of mutations made on various domains of the mouse α1 subunit of nAChR. It is 
proposed that nAChR gating occurs as a series of stepwise movements of such domains that link 
the low-to-high affinity conformational change in the agonist binding site with the low-to-high 
conductance conformational change in the pore. Specifically, they suggested blocks of coordinated 
motions starting with the β4-β5 linker, the β7-β8 linker, and loop C, through the Cys loop and the 
β1-β2 linker to the pore region M2, and finally the gating of the channel. This stepwise motion 
propagates throughout the nAChR via Brownian motion [49, 53]. This model provides a more 
complete view of nAChR gating than previous studies. 
1.4 Nonsense suppression to incorporate unnatural amino acids 
Site-specific incorporation of unnatural amino acids in vitro or in vivo is a powerful extension 
of conventional site-directed mutagenesis to study structure-function relations of macromolecules, 
and also it enables addition of biophysical probes and photo-reactive cross-linking reagents when 
the mutant proteins are produced in large enough quantities [54, 55]. The chemically synthesized 
unnatural amino acids are either chemically ligated to a “suppressor tRNA”, an engineered 
orthogonal tRNA that cannot be acylated by an endogenous aminoacyl-tRNA synthetase (aaRS ) in 
the expression system used, or recognized by an engineered twenty-first aaRS [56].  
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Our lab uses the first methodology, so that a wide variety of amino acids with distinctly 
different properties can be incorporated in a similar fashion (Figure 1.3). The limitation of this 
method is that the chemically ligated tRNA is a stoichiometric reagent, so that the quantities of 
protein produced are limited to the amount of tRNA introduced. Using the high-sensitivity assay of 
electrophysiology, large electric currents can be seen from Xenopus oocytes that are expressing as 
little as 10 attomol of receptor on their surface. A patch clamp experiment has also made the 
detection of a single channel possible [57, 58]. 
Our lab described the first incorporation of an unnatural amino acid into a protein expressed 
in a living cell [59]. In this method, the unnatural amino acid is introduced after it is chemically 
acylated to an in vitro transcribed tRNA, transferred to the site of interest, which is engineered as a 
stop codon. Specifically, both mRNA and tRNA can be injected into Xenopus oocyte (Figure 1.4). 
More recently, unnatural amino acids are site-specifically expressed into neuroreceptors expressed 
in mammalian cells [60]. Other labs have previously reported the application of this method in 
vitro, when translation mixtures from E. coli and rabbit reticulocyte were used.  
 
 
  14
 
Figure 1.3 Unnatural amino acid incorporation by nonsense suppression (adapted from [55]). A: 
76mer tRNA chemically ligated with an unnatural amino acid binds components of the 
translational machinery (represented by elongation factor EF-1α). B: An unnatural amino acid is 
incorporated at the desired position engineered as a 3 or 4 base stop codon. C: Undesired loss of 
the unnatural amino acid. D: Addition of dinucleotide CA to the injected 74mer tRNA (Chapter 3, 
control experiments for nonsense suppression). E: Undesired amino acylation of the tRNA with a 
natural amino acid. F: Undesired natural amino acid acylated tRNA binds to the translational 
machinery. G: Undesired incorporation of a natural amino acid. H: Used tRNA from nonsense 
suppression could be reacylated by a natural amino acid.  
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Fig 1.4 Expression system mostly used in our lab for structure-function studies of ion channels. 1: 
Mutating the gene at the site of interest into a stop codon. Amber (UAG) codon is the most widely 
used but four base condons and Opal (UGA) are also used. 2: A chemically synthesized amino acid 
is enzymatically ligated to an engineered tRNA carrying the appropriate anti-codon. 3: 
Microinjections into the Xenopus oocyte of both the tRNA and mRNA. 4: The translational 
machineries of the Xenopus oocyte synthesize, fold, assemble, and transport to the cell surface the 
mutant ion channels incorporated with the unnatural amino acid at the desired position. 5: 
Although patch clamp experiments are also carried out in our lab, most electrophysiology 
characterization experiments are performed on OpusXpress 6000A (Molecular Devices Axon 
Instruments) which allows simultaneous recording of 8 oocytes.  
 
One requirement of this methodology is that the tRNA is strictly orthogonal so that it is not 
recognized by any of the endogenous aaRSs, which could result in delivering a natural amino acid 
at the site of interest. In different expression systems, a variety of such tRNAs have been 
developed. In the E. coli translation system, the Schultz group developed different tRNAs from the 
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yeast system or from E.coli [61, 62]. Chamberlin and co-workers engineered an E. coli tRNA 
suppressor in a rabbit reticulocyte system [63]. In our lab, great nonsense efficiency increase was 
seen after a mutation U73G was engineered into a Tetrahymena thermophila amber suppressor 
tRNA, producing THG73 and reducing recognition by the oocyte’s endogenous glutamine 
acyltransferease [64]. 
Suppressor tRNAs that recognize the amber stop codon (UAG) have been the most widely 
used both in vitro and in vivo [59, 65]. In the Chamberlin group [62, 63], the Schultz group [62], 
RajBhandary group [66] and in our group [55, 67], opal (UGA) and ochre (UAA) suppressor have 
been explored. Four-base codons and corresponding frame shift suppressor tRNAs have also 
been developed [54, 68, 69] This frameshift suppression method can avoid the competition 
between the suppressor tRNA and endogenous release factors. It has also enabled the ability to 
incorporate multiple unnatural amino acids simultaneously. In our lab, we established the 
simultaneous incorporation of three amino acids in vivo by frameshift suppression [54]. 
Our most recent developments in nonsense suppression include the development of  a 
Tetrahymena thermophila Gln amber suppressor (TQAS) tRNA library with increased 
orthogonality and nonsense suppression efficiency, which allows for screening in eukaryotic cells. 
The creation of a T. thermophila opal suppressor TQOpS’ shows about 50 percent suppression 
efficiency relative to THG73, allowing for multiple incorporation of unnatural amino acids [55, 67]. 
1.5 Thesis summary 
Nicotinic acetylcholine receptors (nAChR) are an important family of ligand gated ion 
channels found throughout the CNS and the PNS. They have been indicated in a series of 
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physiological functions and pathological states. nAChRs have received extensive study in the 
past as a prototype of the Cys loop LGIC member. Growing interest in developing subtype- 
specific agents targeting nAChRs to treat neurological diseases require more detailed structural 
and functional information in the numerous members of the nAChR family. 
 This thesis contains structure-function studies on the chemical scale of several of the most 
important members of this family: the muscle type (α1)2βγδ, which has been the representative 
receptor of the family (Chapter 2); the most prevalent neuronal types α4β2 and α7 (Chapter 3); 
and a relatively newly characterized neuronal receptor α4β4 (Chapter 4). A large amount of 
research has been performed on other Cys loop receptors which share significant structural 
resemblance to the nicotinic receptors. Using a powerful combination of conventional 
mutagenesis and unnatural amino acid incorporations, we aim to look at the potential 
conservation of important channel functions, particularly ligand binding mechanism (Chapter 3 
and 4) and channel opening mechanism (Chapter 2). We found that homology in amino acid 
sequences and structures does not translate into a shared functional mechanisms. In fact, 
different sets of chemical interactions are adopted between ligands and the receptor, and between 
amino acids within the ion channel proteins both in ligand binding and channel gating.  
Ion channels are membrane-bound multi-subunit macromolecules. We are able to carry out 
such exhaustive detailed structure-function studies due to the fast-developing methodology of 
unnatural amino acid incorporation by nonsense suppression. This thesis also describes our effort 
to improve the efficiency of nonsense suppression. In particular, we designed multiple 21nt small 
interfering RNA (siRNA) targeting release factor 1 (eRF1) in both HEK cells and Xenopus 
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oocytes, and monitored the nonsense suppression efficiency change in vivo and in vitro by RNA 
PCR, western blotting, fluorescence, and electrophysiology (Chapter 5). 
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C h a p t e r  2  
A UNIFIED VIEW OF THE ROLE OF ELECTROSTATIC 
INTERACTIONS IN MODULATING THE GATING OF CYS LOOP 
RECEPTORS 
2.1 Abstract 
    In the Cys loop superfamily of ligand-gated ion channels, a global conformational change, initiated 
by agonist binding, results in channel opening and the passage of ions across the cell membrane. The 
detailed mechanism of channel gating is a subject that has lent itself to both structural and 
electrophysiological studies. Here we defined a gating interface that incorporates elements from the 
ligand binding domain and transmembrane domain previously reported as integral to proper channel 
gating. An overall analysis of charged residues within the gating interface across the entire superfamily 
showed a conserved charging pattern, although no specific interacting ion pairs were conserved. We 
utilized a combination of conventional mutagenesis and the high-precision methodology of unnatural 
amino acid incorporation to study extensively the gating interface of the mouse muscle nicotinic 
acetylcholine receptor. We found that charge reversal, charge neutralization, and charge introduction at 
the gating interface are often well tolerated. Furthermore, based on our data and a re-examination of 
previously reported data on γ-aminobutyric acid, type A, and glycine receptors, we concluded that the 
* This chapter is reproduced from A Unified View of the Role of Electrostatic Interactions in Modulating the Gating of Cys 
Loop Receptors, by X. Xiu, A. P. Hanek, J. Wang, H. A. Lester, and D. A. Dougherty, The Journal of Biological 
Chemistry, 280, 50, 41655-41666 (2005). Copyright 2005 by the American Society for Biochemistry and Molecular 
Biology. 
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overall charging pattern of the gating interface, and not any specific pairwise electrostatic interactions, 
controls the gating process in the Cys loop superfamily. 
2.2 Introduction 
The Cys loop superfamily of neurotransmitter-gated ion channels plays a prominent role in 
mediating fast synaptic transmission.  Receptors for acetylcholine (nicotinic ACh receptor, nAChR), 
serotonin (5-HT3 receptor), γ-aminobutyric acid (GABAA and GABAC receptors), and glycine are 
known, and the receptors are classified as excitatory (cation-conducting; nAChR and 5-HT3) or 
inhibitory (anion-conducting; GABA and glycine).  Malfunctions in these receptors are responsible for 
a number of “channelopathies”, and the receptors are targets of pharmaceutical efforts toward 
treatments for a wide range of neurological disorders, including Alzheimer’s disease, Parkinson’s 
disease, addiction, schizophrenia, and depression [1, 2]. The receptors share a common architecture, are 
significantly homologous, and are known to have evolved from a single ancestral gene that coded for 
an ACh receptor.  
The gating mechanism for the Cys loop superfamily is one of the most challenging questions in 
molecular neuroscience.  At issue is how the binding of a small-molecule neurotransmitter can induce a 
structural change in a large, multisubunit, integral membrane protein sufficient to open (gate) a 
previously closed ion channel contained within the receptor [3, 4].  All evidence indicates that the 
neurotransmitter binding site is quite remote (50-60Å) from the channel gate, the region that blocks the 
channel when the neurotransmitter is absent and that must move to open the channel. 
The quest for a gating mechanism has been greatly aided by several recent structural advances.  First, 
crystal structures of the soluble acetylcholine binding protein (AChBP) [5-7], which is homologous to 
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the extracellular domain of the nAChR and, by extension, other members of the superfamily, provide a 
good sense of the layout of the agonist binding site and its relationship to the rest of the receptor.  
Second, continued refinement of cryoEM images of the Torpedo nAChR by Unwin [8-10], 
incorporating insights gained from the AChBP structure, has produced a full atomic-scale model, 2BG9, 
of the nAChR.  It is important to appreciate from the outset that 2BG9, while heuristically quite 
valuable, is not a crystal structure of the nAChR.  It is a model built from low-resolution data and 
homology modeling.  Nevertheless, it represents a substantial advance for the field, and all modern 
attempts to obtain molecular-scale information on the structure and function of Cys loop receptors must 
consider this as a starting point. 
The full 2BG9 model of the nAChR [10] immediately suggested ways in which the agonist binding 
site could couple to the transmembrane region and thus initiate gating.  As summarized in Figure 2.1, 
loops 2, 7, and 9 from the AChBP structure are oriented toward the transmembrane region, and, indeed, 
in 2BG9 these loops make contacts with parts of the transmembrane domain.  Note that loop 7 is the 
eponymous Cys loop.  The transmembrane region consists of four α helices per subunit, labeled M1-
M4.  It is accepted that M2 lines all or most of the channel.  Helix M1 extends out of the 
transmembrane region toward the extracellular domain, creating a segment termed preM1.  While M4 
is somewhat separated from the rest of the protein in 2BG9, recent modeling studies produce a more 
compact structure in which M4 is more intimately involved [11].  In particular, the C-terminus of M4, a 
region we will term postM4, can contact the extracellular domain.  A key structure is the M2-M3 loop, 
a short connector between the two transmembrane helices.  Topological considerations have long 
placed this loop at the interface between the transmembrane and extracellular domains.  That 
expectation was resoundingly confirmed by 2BG9, and many workers have anticipated that this loop 
could play an important role in gating.  Indeed, recent work [12]  has established that a key proline at 
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the apex of the M2-M3 loop provides the conformational switch that gates the channel in the 5-HT3 
receptor. 
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Figure 2.1 Views of the gating interface. Structure is the full model of an α subunit of the Torpedo 
nAChR developed by Unwin [10] (Protein Data Bank code 2BG9). Regions of the gating interface, as 
defined in text, are color-coded. A: Ribbon diagram, also including pairwise interactions from various 
studies that have been proposed to contribute to the gating mechanism. Even though they are from 
different receptors and could be important in different states of the receptor, they are mapped onto the 
Torpedo structure to provide some sense of relative spatial relationships. Distances range from  6 to 
20 Å. Interactions are as follows: 1, Asp-138 to Lys-276 of muscle α nAChR; 2, Asp-138 to Arg-429 
of muscle α nAChR; 3, Asp-57 to Lys-279 of GABAA α1 subunit; 4, Asp-149 to Lys-279 of GABAA 
α1 subunit; 5, Lys-215 to Asp-146 of GABAA β2 subunit; 6, Lys-215 to Asp-139 of GABAA β2 
subunit; and 7, Lys-215 to Asp-56 of GABAA β2 subunit. Interactions 1, 2, 4, and 5 all involve the 
same highly conserved Asp residue in loop 7. See text for discussion of these interactions. B: Same 
view as A but with gating interface residues in space filling. C: View in B rotated 180° around vertical 
axis. 
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Several groups have attempted to identify key interactions in the interface between the extracellular 
domain and the transmembrane domain, and we discuss some of these results below. This interface 
contains a large number of charged residues, and most efforts have focused on these, attempting to find 
crucial electrostatic interactions that regulate gating.  Specific hydrophobic interactions have also been 
proposed [9, 13].  Several interacting pairs have been identified in various receptors [14, 15], and 
specific gating models based on critical electrostatic interactions have been proposed [16-19]. We note 
from the start, however, the curious fact that none of the proposed interactions is conserved across the 
superfamily.  We have been puzzled by the notion that in this closely related family of receptors, the 
mechanism of action of the essential function of the receptors seems to vary from system to system. 
In the present work we argue that specific, pairwise electrostatic interactions at the interface between 
the transmembrane and extracellular domains are not critical to gating.  Rather, we argue it is the global 
charging of this region and the network of interacting ionic residues that are critical to receptor function.  
We present an overall analysis of charged interfacial residues in the Cys loop superfamily; extensive 
mutagenesis studies of potential electrostatic interactions in the nAChR; and a reconsideration of 
previously published data on other receptors to support the model.  From such an analysis, a more 
nearly unified, but less precise, image of the gating mechanism in the Cys loop superfamily emerges. 
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2.3. Results 
2.3.1 Electrostatics at the gating interface 
For the purposes of discussion and analysis, we have defined a “gating interface” between the 
extracellular domain and the transmembrane domain.   It is comprised of six segments:  three from the 
extracellular domain (all or parts of loops 2, 7, and 9) and three from the transmembrane domain 
(preM1, M2-M3, and postM4).  The precise residues considered are given in Table 2.1. Unless 
otherwise noted, we will use the residue numbering system accepted for the nAChR α1 subunit.  The 
selection criterion for the gating interface was geometric; only residues that could reasonably be 
considered to experience a meaningful electrostatic interaction with another component of the gating 
interface were included. Because of the low resolution of the nAChR structure and the further 
uncertainty introduced by extrapolating to other Cys loop receptors, precise distance constraints were 
not applied.  Rather, as illustrated in Figure 2.1, we chose a contiguous belt of residues in the region 
where the extracellular and transmembrane domains meet.  Some leeway must be given in selecting 
possible interactions, as residues that are not in direct contact in 2BG9 could become so on transit from 
the closed state to the open, or on going from one receptor to another.  We recognize there is some 
arbitrariness to this assignment, but our studies suggest that extending the definition further out from 
the interface does not significantly impact the analysis.  We will refer to the extracellular component 
(from loops 2, 7, and 9) and the transmembrane component (from preM1, M2-M3, and postM4) when 
discussing the gating interface.   
 To search for patterns of charged residues, we considered the sequences of 124 subunits from the 
Cys loop superfamily - 74 cationic and 50 anionic channel subunits (see supplementary table S2.1 at 
the end of this chapter). Table 2.1 shows 22 representative subunits, 11 cationic (excitatory) channels 
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and 11 anionic (inhibitory) channels, and also serves to define the various segments. Table 2.2 
summarizes the analysis of the full collection of the 124 subunits.  Shown for each segment of the 
interface are:  the number of cationic residues (K, R); the number of anionic residues (D, E); the net 
charge (Z); and the number of charged residues (N).   
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 Loop 2   Loop 7     L9 preM1 M2-M3 linker    postM4 
Tor α DEVNQI  IIVTHFPFDQ EW MQIRP STSSAVPLIGKY FAGRLIELSQEG 
Tor β NEKIEE IKVMYFPFDW QW  IQRKP ETSLSVPIIIRY FLDASHNVPPDN 
Tor γ NEKEEA IAVTYFPFDW EW IQRKP ETSLNVPLIGKY FLTGHFNQVPEF 
Tor δ KETDET INVLYFPFDW EW IRRKP ETALAVPLIGKY FVMGNFNHPPAK 
nACh α1 DEVNQI IIVTHFPFDE EW MQRLP STSSAVPLIGKY FAGRLIELHQQG 
nACh β1 NEKDEE IQVTYFPFDW QW IRRKP ETSLAVPIIIKY FLDATYHLPPPE 
nACh γ  NEREEA ISVTYFPFDW EW IQRKP ETSQAVPLISKY FLMAHYNQVPDL 
nACh δ  KEVEET ISVTYFPFDW EW IRRKP ATSMAIPLVGKF FLQGVYNQPPLQ 
nACh α4 DEKNQM IDVTFFPFDQ EW IRRLP STSLVIPLIGEY FLPP--WLAGMI 
nACh α7 DEKNQV IDVRWFPFDV EW  MRRRT ATSDSVPLIAQY LMSAPNFVEAVS 
5HT3A DEKNQV LDIYNFPFDV EW IRRRP ATAIGTPLIGVY VMLWSIWQYA-- 
GABA α1 SDHDME MHLEDFPMDA QY LKRKI KVAYATAM-DWF LNREPQLKAPTP 
GABA α2 SDTDME MHLEDFPMDA QY LKRKI KVAYATAM-DWF LNREPVLGVSP- 
GABA α3 SDTDME MHLEDFPMDV QY LKRKI KVAYATAM-DWF VNRESAIKGMIR 
GABA α4 SDVEME MRLVDFPMDG QY  LRRKM KVSYLTAM-DWF LSKDTMEKSESL 
GABA α5 SDTEME MQLEDFPMDA QY LKRKI KVAYATAM-DWF LNREPVIKGAAS 
GABA α6 SDVEME MRLVNFPMDG QY LQRKM KVSYATAM-DWF LSKDTMEVSSSV 
GABA β1 SEVNMD MDLRRYPLDE QF  LKRNI KIPY-VKAIDIY VN---------- 
GABA β2 SEVNMD MDLRRYPLDE QF LKRNI KIPY-VKAIDMY VN---------- 
GABA β3 SEVNMD MDLRRYPLDE QF LKRNI KIPY-VKAIDMY VN---------- 
Gly α1  AETTMD MDLKNFPMDV QF  LERQM KVSY-VKAIDIW KIVRREDVHNQ- 
Gly α2  TETTMD MDLKNFPMDV QF  LERQM KVSY-VKAIDIW KIIRHEDVHKK- 
 44  49 130    139  175 207 211  266      277  426 
Table 2.1 Selected sequences in the gating interface, highlighting cationic (blue) and anionic (red) 
residues. The abbreviations used are as follows Tor:  nAChR from Torpedo californica;  nACh:  
nicotinic ACh receptor; 5-HT3A:  5-HT3 receptor, type A. All sequences are from human receptors 
except:  Tor and  nACh α1, β1, γ, δ, which are mouse muscle. 
 
 + – Z N 
Loop 2 0.5 2.3 -1.8 2.8 
Loop 7 0.4 1.9 -1.5 2.4 
Loop 9 0.0 0.5 -0.5 0.5 
preM1 2.3 0.1 2.2 2.3 
M2-M3 1.0 0.8 0.2 1.8 
postM4 0.6 0.7 -0.1 1.3 
Extracellular 0.9 4.8 -3.9 5.7 
Transmembrane 3.9 1.6 2.3 5.5 
Gating Interface 4.8 6.4 -1.6 11.1
Table 2.2  Charge characteristics of the gating interface. The abbreviations used are as follows:  + = 
number of cationic residues (K, R); – = number of anionic residues (D, E); Z = overall charge;  N = 
number of ionic residues.
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Although there is some variation, the typical gating interface contains 47 residues:  18 in the 
extracellular component and 29 in the transmembrane component.  On average, 11.1 or 24% of these 
residues are charged.   This is not significantly different from expectation based on the overall 
frequencies of occurrence of D, E, R, and K in proteins (July, 2004, Swiss Protein Database). Most of 
the residues of the gating interface are, or can be easily imagined to be, water exposed to some extent, 
therefore this global result is not surprising.  Of the ~11 charged residues found in the gating interface 
only two are universally conserved: D138 and R209.  So, while all Cys loop receptors have a large 
number of ionic residues in the gating interface, their locations and absolute charges are variable. 
Although the two regions of the gating interface do not have the same number of amino acids, the 
total number of charges is essentially the same (5.7 vs. 5.5) for the two regions.  There is, however, a 
dramatic difference in the net charge of the two components.  The extracellular component has an 
overall negative charge, averaging -3.9 over the 124 subunits considered.  The transmembrane 
component has an overall positive charge, averaging +2.3.  Thus, there is a global electrostatic 
attraction in the interface, holding together the extracellular component and the transmembrane 
component.  This interfacial electrostatic interaction is not created by simply putting anions in the 
extracellular component and cations in the transmembrane component; typically, there are one cationic 
and five anionic side chains in the extracellular component, but four cationic and two anionic side 
chains in the transmembrane component.  We propose that it is the balance among all these charges that 
controls receptor function.  With all these charges packed into a fairly compact space, we feel it is more 
reasonable to consider a network of electrostatic interactions, rather than emphasizing any particular 
charged pair, as we will discuss below.  
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There is variability in the charging pattern.  Considering only GABAA subunits, α1 shows Z = -6 in 
the extracellular component, and Z = +4 in the transmembrane component.  In contrast, the α4 subunit 
shows Z = -4 in the extracellular component and Z = +2 in the transmembrane component.  Despite the 
smaller Z values, the α4 subunit actually has more ionic residues overall than α1 (N = 16 vs. 14).   
Looking in more detail, it is clear that loop 2 carries the most negative charge per residue, followed 
by loop 7.  The largest net positive charge is associated with preM1. The total number of charges (N) is 
slightly larger for the inhibitory channels (average of 11.8 vs. 10.7).  The “additional charge” is usually 
cationic, as the net charge is slightly more positive for the inhibitory channels (-1.1 vs. -1.9).   
We propose that Cys loop receptors can function as long as the essential features of the electrostatic 
network are intact.  As we will see below, mutations that alter the charge balance are often well 
tolerated, apparently because they can be absorbed by the larger collection of charges.  In fact full 
charge reversals (replacing a plus with a minus or vice versa) are often quite acceptable.  It appears that 
the important thing is to have a number of charges in this region, rather than any specific interaction.   
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2.3.2 Studies of the muscle-type nAChR α subunit 
We have evaluated a number of residues in the gating interface by both conventional mutagenesis 
and unnatural amino acid mutagenesis [20].  Many mutations are meant to parallel studies in other 
receptors, but, as noted above, conservation is not strong across the family.  We study the embryonic 
mouse muscle nAChR, with a subunit composition of (α1)2β1γδ. This receptor shows extremely high 
homology with and is thus directly comparable to the Torpedo receptor modeled by 2BG9.  A goal of 
this work is to conduct an extensive survey of the gating interface, complementing the statistical 
analysis presented above.  As such, we report the results of two-electrode voltage clamp determinations 
of EC50, rather than the more time-consuming patch clamp studies of single-channel behaviors.   Since 
EC50 is a measure of channel function, it reflects contributions from agonist binding and gating.  
However, the residues studied are not part of the agonist binding site, and so seem unlikely to directly 
contribute to binding. Furthermore, we show that representative mutations in the gating interface alter 
the relative efficacy of succinylcholine, a partial agonist of the mouse muscle nAChR [21], supporting 
a change in the gating of the mutants [14, 22].  In addition, we recently showed that a range of 
mutations of a key proline at the heart of the gating interface in the M2-M3 loop of the 5HT3A receptor 
significantly affected EC50, but did not alter the binding properties of the receptor, establishing a role in 
gating [12].   Extensive mutagenesis studies by Auerbach [23] on loops 2 and 7 show that mutations of 
the sort considered here affect the gating equilibrium.   As such, we conclude that the most reasonable 
interpretation of the changes in EC50 reported here is that they reflect alterations in channel gating 
behavior. 
Our primary focus has been on the α subunits, as these make the largest contribution to the agonist 
binding site and are thought to play a prominent role in the gating mechanism [24]. In this section all 
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mutations occur in both copies of the mouse muscle α subunit; the results are given in Table 2.3.  In a 
subsequent section we will briefly discuss the non-α subunits.   
The 2BG9 model features a particularly intimate interfacial interaction:  that between V46 on loop 2 
and a portion of the M2-M3 loop [9].  A “pin-into-socket” arrangement was proposed, ascribing a 
critical gating role to V46.  While it was immediately appreciated by many workers that V46 is not 
conserved in the Cys loop superfamily, the proposal merited investigation.  Studies by Harrison, 
Trudell, and coworkers on analogous residues in the GABAA α1 and β2 subunits and the glycine 
receptor α1 subunit (the residue is H, V, and T, respectively) provided no support for the “pin-into-
socket” proposal [13].  
We have explicitly evaluated V46 in the nAChR (Table 2.3).  We wished to determine whether a 
precise geometrical arrangement of the sort implied by a pin-into-socket interaction was essential for 
proper receptor function.  Not surprisingly, the V46A mutation is substantially deleterious, while the 
more subtle V46I mutant shows near wild type behavior. 
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mutant EC50 nH mutant EC50 nH 
Wild type  50 ± 2 1.6±0.1 D138K/R429D 50 ± 3 1.45±0.1 
D44K 14.3 ± 0.6 1.4±0.1 D138R/R429E LE  
D44N 20 ± 4 0.80± 0.08 D138E/R429K 63 ± 9 1.31±0.2 
E45A 210 ± 20 1.1±0.1 D138K/K276D/R429D 67 ± 10 1.03±0.2 
E45W 117 ± 7 1.3±0.1 K276D 45 ± 6 1.39±0.2 
E45V 49 ± 4 1.9±0.2 K276E 38 ± 2 1.28±0.07 
E45D 19.2 ± 0.5 1.4±0.1 K276D/R429D 51 ± 3 1.52±0.1 
E45N 6.3 ± 0.1 1.4±0.1 R429D 57 ± 5 1.46±0.1 
E45K 6.5 ± 0.3 1.4±0.1 R429E 69 ± 5 1.29±0.09 
E45Q 1.9 ± 0.1 1.3±0.1 R429K 83 ± 4 1.48±0.09 
E45R 1.6 ± 0.1 1.0±0.1 R429A 90 ± 4 1.48±0.08 
V46A >1000 1.6±0.1 S266K 62 ± 6 1.54±0.2 
V46I 59 ± 7 1.1±0.1 T267A 36 ± 5 1.94±0.4 
V46allo-I 48 ± 2 1.7 ± 0.1 T267D 24 ± 2 1.21±0.1 
V46OMeT 169 ± 9 1.4 ± 0.1 T267K 26 ± 2 1.35±0.05 
V46OMe-allo-T 32 ± 2 1.5 ± 0.1 T267OMeT 200 ± 10 1.37±0.1 
V46T >1000 1.4±0.1 S268D 0.59 ± 0.02 1.82±0.09 
V46K 0.94 ± 0.07 1.5±0.1 S268E 0.18 ± 0.01 1.56±0.1 
V46R 120 ± 10 1.4 ±0.1 S268K 7.5 ± 1 1.36±0.2 
V46D >1000  S269D 12 ± 0.5 1.56±0.08 
V46E >1000  S269E 0.08 ± 0.01 1.34±0.2 
E45K/V46D >1000  S269K 9 ± 0.6 1.22±0.08 
E45K/V46E >1000  S269OMeS 23±2 1.79±0.3 
E45R/V46D NE  R209A NE  
E45R/V46E NE  R209D NF   
D138A NF  R209E NF   
D138R NF  R209K 18 ± 1 1.66±0.2 
D138K NF  D138K/R209D NF  
D138S NF  D138R/R209D NS  
D138N NF  E175R 120 ± 7 1.35±0.08 
D138E 28 ± 2 1.45±0.1 E175R/R209E NS   
D138K/K276D 66 ± 10 1.01±0.1 E45R/R209E NS  
Table 2.3 Mutations in the nAChR α subunits.  EC50 in μM. Key:  NF:  nonfunctional; no response 
to applied ACh, but surface expression of receptor confirmed by α-bungarotoxin binding; LE:  
functional; responses to applied ACh are seen, but are too weak to obtain EC50; NS:  no signal; no 
response to applied ACh, surface expression not independently verified;  NE:  no expression, as 
judged by lack of α-bungarotoxin binding. 
 
An advantage of the unnatural amino acid methodology is that it allows subtle stereochemical 
issues to be probed.  If a V or, by extension, I side chain at position 46 points into a well-defined 
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binding pocket, one might anticipate that the isomeric allo-I, in which the side chain methyl and ethyl 
groups swap position relative to I, would show a significantly different interaction.  In the event, the 
difference between I and allo-I is insignificant (Table 2.3).  The unnatural amino acid O-methyl-
threonine (OMeT) is isosteric with I, but inserts a more polar O in place of a CH2 group [25]. This 
subtle change is deleterious, raising EC50 more than 3-fold.  The isomeric OMe-allo-T introduces a 
stereochemical swap that parallels the I/allo-I pair, but now the effect is substantial.  The difference 
between OMeT and OMe-allo-T is roughly 5-fold, corresponding to 1 kcal/mol at room temperature.  
This suggests that perhaps the side chain of position 46 is in a sterically well-defined pocket, but one 
that can only be probed by polar oxygen atoms, not by hydrophobic groups such as CH2.  
 
Replacing V46 with much more polar groups like T (essentially isosteric to V)  and the anionic D 
and E seriously compromises receptor function. Radiolabeled α-bungarotoxin binding studies show 
that V46D and V46E channels are expressed in large enough quantities to detect macroscopic currents, 
but electrophysiology studies show only small (< 300 nA) currents at 1 mM ACh, suggesting a shift to 
a much higher EC50. Surprisingly, though, the cationic residues R and K produce, in the first case, only 
a modest rise in EC50, while the V46K mutant gives an EC50 ~50-fold below wild type. The V46K 
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mutation of the nAChR α1 subunit produces a loop 2 pattern equivalent to those of the α7 and α4 
nicotinic and 5-HT3 serotonin receptors, and so perhaps it is not surprising that it can be tolerated. 
We have sought a correlation between various physicochemical properties of the mutant side chains 
and the mutant EC50s at V46 (Figure 2.2) and find that there is no apparent correlation to the side chain 
hydrophobicity [26, 27]  or size [28, 29]. Auerbach et al. previously reported single channel recordings 
on several mutations at V46, and a very rough tendency was observed that more polar side chains have 
smaller gating equilibrium constants [23]. However, the new mutations that we made, V46K and V46R, 
do not follow this pattern. Our results suggest that while the side chain of V46 may be docked into a 
sterically well-defined pocket as implied by the “pin-into-socket” mechanism, a full description of the 
role V46 plays in gating is more complicated. 
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Figure 2.2 Plot of log(EC50) vs. side chain physicochemical properties at site αV46. A: log(EC50) vs. 
side chain hydrophobicity. B: log(EC50) vs. side chain size. Three hydrophobicity scales were used. 
Hydrophobicity is measured as the change in free energy upon transfer from water to octanol 
(R=0.26), hydrophobic burial (R=0.58), and transfer from octanol to water (R=0.011). Attempts to 
explain EC50 shifts for aV46 mutants by changes in side chain size according to two measures of 
surface area (R=0.667, 0.674 respectively) as well as volume (R=0.782) resulted in no significant 
correlation. 
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As noted above, Loop 2 is highly charged across the Cys loop superfamily, with an overall negative 
charge.  As others have done in different receptors within the superfamily, we have evaluated some of 
these charged residues. Position 45 is very highly conserved as anionic (D or E), and our studies of E45 
in the muscle α subunit are summarized in Figure 2.3.  Quite surprisingly, we find that full charge 
reversal (E45K or E45R) substantially lowers EC50.  Substitution by a neutral, but polar residue (E45Q 
or E45N) also lowers EC50, while conversion to a hydrophobic residue gives a small effect, raising 
EC50, if anything.  The logarithms of the mutant EC50 at E45 were plotted against the physicochemical 
properties of the mutant side chains as done for V46, and no apparent correlation was found (Figure 
2.4). 
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Figure 2.3 A variety of mutations at αE45 are well tolerated. Charge neutralization (N,Q) and charge 
reversal (K,R) both lower EC50 substantially, while mutations to hydrophobic residues (A,W,V) leave 
EC50  little changed. A: Dose-response curves.  B: Ratios of mutant to wild type EC50s plotted for 
comparison.  
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Figure 2.4 Plot of log(EC50) vs. side chain physicochemical properties at site αE45. A: log(EC50) vs. 
side chain hydrophobicity. B: log(EC50) vs. side chain size. Four hydrophobicity scales were utilized: 
transfer from water to octanol (R=0.64), octanol to water (R=0.63), cyclohexane to water (R=0.78), 
and hydrophobic burial (R=0.36). Two measures of surface area (R=0.29, 0.24) as well as a volume 
scale (R=0.09) were used. 
 
D44 is conserved in nicotinic α subunits, and position 44 is generally a polar residue in other 
nicotinic subunits and other receptors.  Although the D44 side chain points in the opposite direction to 
the E45 side chain in 2BG9, the mutation pattern is similar.  Both charge reversal and introducing a 
neutral but polar side chain lower EC50. 
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N47 in loop 2 of the nAChR α subunit aligns with D57 of the GABAA α1 subunit, which, as 
discussed below, has been proposed to experience important electrostatic interactions [15].  Auerbach 
and co-workers have studied mutations at this site in the nAChR, including extensive single-channel 
measurements [23].  Auerbach found that N47K shows a decrease in EC50, but N47D shows an 
increase. As noted above, Auerbach’s single-channel studies of this and other loop 2 residues establish 
a role in setting the gating equilibrium for residues in this region. 
Thus, at four consecutive residues in loop 2 – D44, E45, V46, and N47 – introducing a positive 
charge lowers EC50.  At N47 and V46 it has also been shown that introducing a negative charge has the 
opposite effect.  These various side chains point in quite different directions in 2BG9.  While is it 
possible that all make specific electrostatic contacts that are being modulated in similar ways by the 
mutations introduced, we conclude instead that it is the global negative charge of loop 2, not any 
specific pairwise interaction, that is essential to proper receptor function.  
D138 on loop 7 is completely conserved in the Cys loop superfamily.  Others have investigated this 
site in other receptors [14, 15, 23].  In the nAChR α subunit, charge reversal at this site incapacitates 
the receptor.  Both D138K and D138R give non-functional receptors, in that no response to ACh is 
seen but labeling with radioactive α-bungarotoxin shows that properly assembled receptors have 
reached the surface. Furthermore, milder disruptions of D138 such as mutation to N, A, or S also give 
non-functional receptors. The charge-conserving mutation D138E, however, gives near wild type 
behavior. All evidence shows that a negative charge at this site is essential to form a functional receptor.   
A classic test for a specific ion pair interaction is the charge swapping experiment.  That is, if D138 
experiences an electrostatic interaction with a specific cationic residue, then the non-functional mutant 
often can be “rescued” by converting the cationic partner to an anion.  In the nAChR, we considered 
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two possible cationic partners to D138:  K276 on M2-M3 and R429 on postM4 (pairwise interactions 1 
and 2, respectively, in Figure 2.1 A).  Both are reasonably close to D138 in 2BG9.  Interestingly, the 
non-functional D138K mutant can be returned to essentially wild type behavior by combination with 
either K276D or R429D (Tables 2.1, and 2.3, Figure 2.5).  This suggested that perhaps the 138/276/429 
grouping should be considered as a charge triad, rather than a collection of pairwise interactions.  As 
such, we evaluated all eight possible charge combinations for these three residues.  The wild type is -
/+/+ (138/276/429); the nonfunctional D138K/R mutants are +/+/+.  The described double mutants that 
rescue the channel are +/+/- and +/-/+.  In fact, all seven combinations other than the +/+/+ mutant give 
near wild type behavior (Figure 2.5).  It appears that the 138/276/429 grouping can compensate for a 
range of charge patterns, as long as +/+/+ is avoided.  It may seem surprising that the -/-/- combination 
is viable.  If these residues are physically close, we can anticipate that having three negative charges in 
proximity would alter the effective pKa of one or more residues.  This could lead to protonation of a 
carboxylate side chain, and lessening of the electrostatic interaction.  It is also possible that one or more 
water molecules mediate the interactions among 138/276/429.  As will be discussed below, D138 
appears to be associated with a different charge triad in the GABAA receptor. 
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Figure 2.5  Charge reversal at αD138 of the nAChR is rescued by charge swap at either of two sites: 
R429 (postM4) or K276 (M2-M3). A charge triad is examined. Of the eight possible combinations, 
seven give near wild type behavior. Only the all-positive triad is deleterious. 
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Position 276 is conserved as a charged residue, either positive or negative, in the majority of ACh 
receptor subunits, but not in other members of the superfamily. Position 429 is often, but not always 
charged, being anionic in GABA receptors, cationic in glycine receptors, but neutral in nicotinic, non-α 
subunits. Thus, the triad considered here is most likely specific to nAChR α subunit. The M4 
transmembrane helix is the furthest separated from the rest of the protein. In 2BG9, the C terminus of 
M4 is roughly 10 Å from the tip of loop 7.  However, as mentioned above, computational studies move 
M4 closer to the rest of the protein and explicitly identify contacts between M4 and loop 7 [11].  Also, 
it has been proposed from the computational work that during channel opening, M4 of the α7 receptor 
moves closer to the other three transmembrane helices. In Auerbach’s linear free energy relation (LFER) 
analysis, the movement of α M4 precedes that of α M2 [30].  Based on the observations reported here, 
we conclude that in the open state of the nAChR, R429 on postM4 is one of the electrostatic interaction 
partners of D138. 
We have also studied other positions of the M2-M3 linker. Four consecutive hydroxyl-containing 
residues, STSS, appear at positions 266 to 269 of the nAChR α1 subunit. Various mutations at S266 
and T267 do not shift EC50 significantly (Table 2.3).  This includes mutations that would typically be 
considered fairly dramatic, in that a neutral residue is changed to an ionic residue.  At T267, conversion 
to a positive charge or a negative charge both result in halving EC50. 
Position S269 has been probed previously by Auerbach, who reported that an S269I mutation causes 
an EC50  decrease of approximately 10-fold, mainly by increasing the channel opening rate constant 
[31]. Based on this observation, it was proposed that position 269 moves from a polar to a non-polar 
environment on channel opening, and so increasing hydrophobicity should favor the open state and 
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lower EC50.  To probe this further, we incorporated the unnatural amino acid O-methyl serine at 
position 269, an arguably more subtle way to reduce polarity than S269I.  The mutant channel shows a 
2-fold drop in EC50, consistent with the expectation that an increase in hydrophobicity lowers EC50, and 
the less perturbing Ser/OMeSer has a smaller effect.   
Against this background, we were surprised to find that a change in the opposite direction - 
introducing either a positive or a negative charge at 269 – also lowers EC50; S269D and S269K show 4-
5-fold drops, while S269E shows an astonishing 600-fold drop in EC50.  Certainly, D, E, and K are 
more polar than S, and so these results contradict the just reached conclusion that hydrophobicity 
controls the behavior at 269.  We see the same pattern for S268; S268D, S268E, and S268K all show 
lower EC50s, with the E mutant again showing a very large drop.  It is remarkable that at two 
consecutive sites in the M2-M3 loop, a region universally accepted to be involved in the gating 
transition, a serine can be converted to a cationic or an anionic residue and the result is the same – EC50 
drops. 
PreM1 provides the covalent connection between the extracellular and transmembrane domains in 
the primary sequence, and there are 1 to 4 positive charges in this region throughout the LGIC family. 
One R (R209 in the nAChR α1 subunit)  is completely conserved.  Mutation to glutamine at the 
analogous arginine in the glycine receptor α1 subunit causes hyperekplexia, an inherited neurological 
channelopathy, and greatly diminishes receptor function [32]. Among all the mutations at this site in 
the nAChR, only a charge-conserving mutation, R209K, gave a functional channel; charge reversal 
mutants were nonfunctional. In 2BG9 the R209 side chain projects between E175 on loop 9 and E45 on 
loop 2. Charge swapping experiments at this triad, however, show that the non-functional mutant 
R209E cannot be “rescued” by either E175R or E45R.  
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Loop 9 is located close to the transmembrane domain, between preM1 and loop2. Chimera studies in 
Cys loop family members have characterized it as an indispensable contributor to proper channel 
coupling and functioning [33]. In 2BG9 loop 9 has moved significantly closer to the transmembrane 
domain compared to the AChBP structure, suggesting that it is arranged differently when the 
transmembrane domain is present.  Position 175 is located very close to the transmembrane domain and 
is counted as part of the charged interface. E175 is conserved in the majority of excitatory channel 
subunits, while in inhibitory channels it is frequently replaced by a Q. Mutation studies at this site show 
that a charge reversal increased the EC50, but by a modest factor.  
2.3.3 Studies of the muscle-type nAChR non-α subunits 
We have evaluated a large number of charged residues in the non-α subunits (data not shown, but 
can be found in [34]). Typically, the changes seen in non-α subunits are not as dramatic as those seen 
in α. For instance, in loop 2, most of the charged residues are fairly tolerant of substitution, producing 
changes in EC50 usually 2-fold or less, in contrast to the 10-30-fold changes often seen in α.  At almost 
every site charge reversal/neutralization is generally tolerated  
While αD138K gives nonfunctional receptors that can be rescued by compensating charge-reversal 
mutations,  D138K in β or δ subunits gives functional receptors with no large change in EC50. The 
γD138K mutant gave very low currents in response to acetylcholine.   Similarly, charge reversals in 
pre-M1 at R208, R209, or K210 are generally well tolerated in non-α subunits. Finally, charge 
reversal/neutralization is well tolerated throughout the M2-M3 region in non-α subunits.  Almost all 
changes lower EC50, but the effects are all less than 3-fold.   
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It is clear that, functionally, the non-α gating interfaces play a less important role than the α 
interfaces.  Auerbach and coworkers concluded that, in the M2-M3 loop, homology in sequence does 
not coincide with homology in function [31], and mutations in the δ subunit do not affect gating, 
consistent with our observations [30, 35, 36]. From a structural perspective, however, the overall results 
from studies of non-α subunits highlight the remarkable tolerance of the gating interface.  Dozens of 
charge reversal/neutralization perturbations are well tolerated, with the most common outcome being a 
small drop in EC50.  No evidence for highly specific, structurally or functionally important ion pair 
interactions is seen.   
2.3.4 Studies of a partial agonist  
To support our contention that mutations at the gating interface perturb the gating of the receptor 
rather than the agonist binding site, we measured the relative efficacy (ε) of succinylcholine (SuCh), an 
nAChR partial agonist [21], for wild type receptor as well as for several representative mutants. The 
relative efficacy is defined as the ratio of the maximal current elicited by the partial agonist to the 
maximal current elicited by a full agonist (ACh) (equation 1). Equation 2 shows a highly simplified 
model of the agonist binding and receptor gating process (R: receptor; c: closed; o: open; A: agonist, β 
and α are the opening and closing rate constants, respectively). At saturating doses of agonist, all the 
receptors are forced into a diliganded state (RA2), so differences in Imax for the two agonists are due to 
differences in Popen.  As such, ε reflects the ratio of Popen values for the partial and full agonists 
(equation 1). If a mutation has not altered the gating, but only the ligand binding of the receptor, the 
relative efficacies should be identical for the wild type and mutant receptors [14, 22] 
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For the wild type nAChR, Popen for ACh is very nearly 1 but Popen for succinylcholine is only 7.5% of 
that for acetylcholine (ε = 0.075). As a control, we examined a previously studied mutant known to 
affect gating.  Mutation of a universally conserved leucine at the 9’ position of M2 to a more polar 
residue such as serine (βL251S) substantially reduces EC50 [25, 37, 38].  This residue forms part of the 
hydrophobic gate of the channel and is quite remote from the agonist binding site, establishing it as a 
gating residue.  As shown in Figure 2.6, the relative efficacy of βL251S is substantially increased over 
that of wild type.  This indicates that Popen for SuCh has increased in the mutant, as expected for a 
mutation that substantially affects gating. 
In the α subunit, the loop 2 mutations E45R and E45Q and the M2-M3 mutation S268E all decrease 
EC50 more than 25-fold.  All three mutations greatly increase ε, giving values near 1 (Figure 2.6).  This 
indicates that these mutations ease receptor opening, allowing SuCh to act as a full agonist. Importantly, 
the mutation E45V, which has no affect on EC50, does not alter the efficacy of SuCh.  The K210Q 
mutation in preM1 of the δ subunit shows only a small increase in the relative efficacy.  We evaluated 
this mutation both in the context of the otherwise wild type receptor, and in receptors that contain the 
βL251S mutation, which moves the EC50 values into a more manageable range.  The small change in 
efficacy at this site supports the idea that the non-α subunits are less of a factor in channel gating.  
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Figure 2.6 Relative efficacy (ε) of succinylcholine for several variants of the nAChR. 
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2.3.5 Previous work on the GABAA and Glycine receptors 
Several important studies of possible electrostatic interactions in Cys loop receptors have appeared 
from Harrison, Trudell, and coworkers [14, 15] and Schofield and co-workers [18].  In each case, a 
specific electrostatic interaction was identified by mutagenesis studies, emphasizing charge-
reversal/charge-rescue strategies.  While we do not disagree with the fundamental observations of these 
efforts, we feel the results can be reinterpreted in the context of the charged interface model proposed 
here. 
In the GABAA receptor α1subunit, Harrison, Trudell, and coworkers propose ion pair interactions 
between K279 on the M2-M3 loop and two aspartates: D57 on loop 2 and D149 on loop 7 (pairwise 
interactions 3 and 4, respectively, in Figure 2.1A) [15]. Here we use the GABAA numbering.  The 
analogous residues in the nAChR α subunit are:  S266, N47, and the previously discussed D138; the 
proposed electrostatic interactions are not conserved.  In the GABAA receptor it is proposed that these 
“specific electrostatic interactions provide an intramolecular coupling mechanism” for the receptor. The 
K279D mutation results in a ~10-fold increase in EC50.  However, full receptor function is regained 
when K279D is coupled with either D57K or D149K. In addition, it is proposed that D149 and K279 
move closer to one another during the transition from closed to open state, presumably strengthening 
the ion paring interaction. 
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Figure 2.7 Analysis of previously published results for the GABAA receptor α1 subunit [15] in the 
same manner as in Figure 2.5, suggesting a charge triad interaction.  ND = not determined. 
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In Figure 2.7 we present these results in the same format as in our discussion of the charge triad of 
the nAChR given in Figure 2.5.  The mutation data, and the generally accepted notion that loop 2 and 
loop 7 straddle M2-M3, imply a triangular relationship between D57, D149, and K279.  Thus, the 
K279D mutation puts three negative charges in an array, which is apparently unfavorable.  What is 
initially surprising, however, is that K279D is fully rescued by the single D/K mutations at either site 57 
or site 149, producing receptors that actually function “better” (lower EC50) than wild type.  That is, 
while the D57K compensating mutation does rescue the 57•••279 interaction, 149•••279 is still a 
repulsive D•••D interaction, yet the receptor shows EC50 below wild type.  The exact same situation 
holds with the single D149K mutation.  Also, if 149 and 279 move closer to each other during gating, 
how could a structure in which they are both aspartates (D57K/K279D) gate more efficiently than wild 
type?  If the key interactions are D57•••K279 and D149•••K279, the highly efficient gating of the 
D47K/K279D and D149K/K279D double mutants is difficult to understand.   
We propose that no specific ion pair interaction influences gating, but instead a cluster of charges 
similar to that described in Figure 2.5 is important.  The single K279D mutation puts three negative 
charges in a cluster, and that is apparently unfavorable.  In contrast, the wild type has a –/–/+ pattern 
(57/149/279), while the double mutants are +/–/– and –/+/–.  Any pattern of three charges adding up to 
–1 gives wild type behavior (or better).  Other mutants were also evaluated (Figure 2.7).  Apart from –
/–/– (the original K279D mutant), the only severely deleterious cluster is –/–/0 (K279A), with a charge 
of –2.  Clusters with three charges that sum to +1 are not overly harmful.  The +/–/+ mutant (D57K) 
shows only a 10% increase in EC50, and –/+/+ (D149K) is much less than 2-fold higher.  Surely these 
models are not of high enough precision to interpret such small differences.  It seems the important 
thing is simply to have a cluster of charges that are not all the same, with specific ion pairing 
interactions being nonessential.  Note the parallel behaviors of the 57/149/279 triad in the GABAA α1 
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subunit and the 138/276/429 triad in the nAChR α1 subunit (recall that nAChR 138 and GABAA 149 
are aligned residues).  Great variation in the charging pattern is tolerated, with nonfunctional receptors 
resulting only from clusters with very high overall charge.  
Evidence for a cluster can also be seen in the GABAA β2 subunit [14]. The mutation K215D (pre-
M1; aligns with nAChR α1 Q208) is deleterious; EC50 goes up 6.1-fold relative to wild type, 
corresponding to a penalty of 1.1 kcal/mol.  This is substantially rescued by a compensating D146K 
mutation (loop 7; aligns with nAChR α1 D138; pairwise interaction 5 in Figure 2.1A); EC50 is only 
1.5-fold higher than wild type, corresponding to a 0.25 kcal/mol penalty.  Thus, 77% ((1.1-0.25)/1.1) of 
the K215D penalty is rescued by D146K.  However, other charge reversal mutations in the interfacial 
region also significantly rescue K215D.  D139K (aligns with nAChR α1 D131; pairwise interaction 6 
in Figure 2.1A) rescues 64%; D56K (loop 2; aligns with nAChR α1 I49; pairwise interaction 7 in 
Figure 2.1A) rescues 49%; E147K (aligns with nAChR α1 Q139) rescues 29%; and E52K (aligns with 
nAChR α1 E45) rescues 25%.  Stated differently, the range of EC50 values for the three best rescue 
mutants (D146K, D139K, and D56K) is substantially less than 2-fold.  It seems risky to ascribe a 
special relationship to the 146•••215 pair.  Again, an image of K215 as presenting a positive charge to a 
cluster of negative charges, such that it cannot itself be a negative charge, seems more sensible.  
Studies of the glycine receptor from Schofield and coworkers [18] identified several charged 
residues on loops 2 and 7 that appeared to be important for gating.  However, no particular pairwise 
relationships were uncovered, leading to the conclusion that these residues played a key role, but not 
through a “direct electrostatic” interaction. 
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2.4. Discussion 
We have defined for the Cys loop superfamily of receptors a “gating interface” comprised of 
segments from the extracellular domain and the transmembrane domain that, based on mutagenesis 
data and the best available structural information, can reasonably be assumed to be juxtaposed.  
Analysis of representative subunits from the superfamily indicates that there are a large number of ionic 
residues in the interface, but for the most part their precise locations and particular charges are not 
conserved.   Many workers, including ourselves, have sought specific ion pair interactions that exert 
precise control over the gating process.  However, we have come to believe that, with such a large 
number of charges clustered in a fairly compact region, it is not meaningful to isolate specific ion pairs.  
Rather, the global charging pattern of the gating interface is what controls gating.  Receptors have 
evolved to create a compatible collection of charged residues that allow the receptor to assemble and 
also facilitates the existence of and interconversions among multiple states. 
Although specific ionic residues are generally not conserved, overall charging patterns are.  Within 
the gating interface the extracellular component carries a net negative charge and the transmembrane 
component carries a net positive charge.  This creates a global electrostatic attraction at the interface 
that maintains the integrity of the receptor as it transitions from the mostly β-sheet, relatively polar 
extracellular domain to the α-helical, nonpolar transmembrane domain.  
Several lines of evidence support this way of thinking about the gating interface.  We have studied a 
number of mutations that reverse, neutralize, or introduce charges.  Typically, these are considered to 
be dramatic mutations, and they might be expected to be disruptive at a functionally important interface.  
However, one of the more remarkable features of the mutagenesis data of Tables 2.3 is the tolerance of 
the gating region to such charge disruptions. In fact, very often EC50 is lowered by such strong 
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perturbations.  It seems hard to imagine that dramatic mutations involving the introduction or reversal 
of charge just happen to lead to a viable ion pair that is tolerated by the receptor.  Rather, we believe the 
entire gating interface is tolerant of charge up to a point.  A delicate balancing act is in operation. By 
distributing a large number of charges across an interface, it is possible to have movement along that 
interface without creating adverse situations of like charges interacting strongly or a single charge in 
isolation in a poorly solvated environment.  Consider T267.  Introducing charge is not deleterious at 
this site.  In fact, converting the neutral T to a cation (T267K) or an anion (T267D) has the same effect:  
EC50 is halved.  It appears that it is the number of charges, not their particular identities, that matters.  
The same pattern is seen at S268 and S269.  These residues are on the M2-M3 loop, a region that is 
universally accepted to be important in gating in the Cys loop superfamily of receptors [15, 31, 33, 39, 
40]. Loop 2 always carries a significant negative charge, and we showed here that introducing a 
positive charge at any of four locations (D44-N47) lowers EC50.  It thus appears that the negative 
charge stabilizes the closed state of the nicotinic receptor by interacting with a positive region.  Based 
on 2BG9 [8, 9], the M2-M3 loop seems the likely candidate for the positive region, but again the 
precise positioning of residues may be different.  
A few charge reversals have been shown to be deleterious, and they can often be rescued by 
compensating charge reversals.  The universally conserved D138 is one such residue.  In the nAChR 
α1, the GABAA α1 [15] (where it is D149), and GABAA β2 [14] (where it is D146) compensating 
charge reversals can rescue the initial mutant (pairwise interactions 1, 2, 4, and 5 in Figure 2.1A).  
However, the systems use completely different residues from apparently very different regions of the 
interface.  There is certainly no universal pattern, and it appears that rather than conserving some 
specific pairwise interaction, it is the global charging pattern of the trio of residues that is most 
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important.  At another site, D139 of GABAA β2 [14] (I131 of nAChR α1), as many as 5 different sites 
can contribute to compensating a charge reversal, with a gradation of efficiencies.   
We conclude that no one ion pair interaction is crucially important to gating across the entire Cys 
loop superfamily; clearly each receptor is different.   However, it may be that there is a consistent 
mechanism across the superfamily, but one that does not single out any particular ion pair.  Several 
groups have suggested that the extracellular domain and the transmembrane domain change relative 
positions on going from the closed to the open state.  Harrison and Trudell propose that a residue on 
loop 7 moves closer to a residue on M2-M3 in the GABAA receptor α1 subunit (D149 and K279, 
GABAA numbering; pairwise interaction 4 in Figure 2.1A).  Unwin’s detailed gating model emphasizes 
differential interactions between loops 2/7 (extracellular domain) and M2-M3 (transmembrane domain) 
along the gating pathway.  We have recently proposed [12] that loop 2 and especially loop 7 interact 
with a specific proline on M2-M3 differentially in the open and closed states. In order to accommodate 
the structural rearrangement at the gating interface, the many charges involved must be comfortable in 
the environments provided by both the open and closed states and must also experience no highly 
adverse interactions in the transition state separating the two.  With a large number of charges 
distributed throughout the interface, the extracellular domain and the transmembrane domain can slide 
past one another (or twist or turn or unclamp…) while maintaining an acceptable network of 
compensating charges throughout the process.  During the movement, some ion pair interactions will 
strengthen, some will weaken, but crucial on/off interactions seem less critical.  There are clearly many 
ways to achieve the proper balance, and each system has evolved an ionic array that supports the 
desired gating behavior.  The essential mechanism is universal across the Cys loop superfamily, but the 
precise details vary from system to system.  
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2.5 Materials and methods 
2.5.1 Mutagenesis and mRNA synthesis 
The mRNA that codes for the muscle type nAChR subunits (α, β, γ, and δ) was obtained by 
linearization of the expression vector (pAMV) with Not 1, followed by in vitro transcription using 
mMessage mMachine kit purchased from Ambion (Austin, TX). The mutations in all subunits were 
made following the QuickChange mutagenesis protocol (Stratagene).  
2.5.2. Electrophysiology and data analysis 
mRNAs of α, β, γ, and δ subunits were mixed in the ratio of 2:1:1:1 and microinjected into stage VI 
oocytes of Xenopus laevis. Electrophysiology recordings were performed 24-48 h after injection in 
two-electrode voltage clamp mode using the OpusXpress 6000A (Molecular Devices Axon 
Instruments). The holding potential was -60mV and agonist was applied for 15 s [41]. Acetylcholine 
chloride and succinylcholine chloride dihydrate were purchased from Sigma/Aldrich/RBI (St. Louis, 
MO). All drugs were diluted to the desired concentrations with calcium-free ND96 buffer. Dose-
response data were obtained for at least 8 concentrations of agonists and for a minimum of 5 oocytes. 
Mutants with Imax equal to or greater than 100 nA were defined as functional. EC50 and Hill coefficient 
were calculated by fitting the dose response relation to the Hill equation. All data are reported as mean 
± S.E.  
If saturation was not reached at 1000 μM concentrations of acetylcholine, the EC50 could not be 
calculated.  For two mutations, αV46A and αV46T, a second mutation was incorporated at the 9’ 
position of the β subunit (βL251S). This mutation is known to reduce the wild type EC50 to 1.2 μM 
[25].  The EC50 of the double mutant was then determined as described.  For scatter plots (Figure 2.2 
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and 2.4) the EC50 of the double mutant was multiplied by 41.7 (50/1.2) to get a corrected EC50.  The 
corrected EC50 was used for the linear regression analysis. 
EC50s for succinylcholine were measured in the same manner. Maximal currents elicited by 
acetylcholine Imax(acetylcholine) and by succinylcholine Imax(succinylcholine) were measured sequentially at 
saturating concentrations on the same cells. The ratio of Imax(succinylcholine)/ Imax(acetylcholine)  was calculated 
for each cell and is reported as mean ± S.E. 
2.5.3 Unnatural amino acid suppression 
The preparation of the unnatural amino acid O-methyl threonine is described elsewhere [25]. O-
methyl serine was purchased from Sigma/Aldrich/RBI (St. Louis, MO) and was protected and activated 
as described [42]. Unnatural amino acids were conjugated to the dinucleotide dCA and ligated to 
truncated 74 nt tRNA THG73. The aminoacyl tRNA was deprotected by photolysis immediately prior 
to co-injection with mRNA containing an amber (TAG) stop codon at the site of interest.  Negative and 
positive controls were employed as previously reported [41]. 
2.5.4 Bungarotoxin binding  
48-72 h after injection, oocytes were prewashed with calcium-free ND96 buffer with 1 mg/mL 
bovine serum albumin, then transferred to the same buffer with the addition of 10 nM [125I] α-
bungarotoxin (Perkin Elmer), and incubated for 1 h at room temperature [43]. Oocytes were then 
washed four times and counted individually in a gamma counter.  Oocytes injected with 50 nL of water 
were used to determine background. Mutants with more than 5 times the background reading are 
regarded to have sufficient expression. 
 
  60
2.6 References 
1. Leite, J.F., N. Rodrigues-Pinguet, and H.A. Lester, Insights into channel function via channel 
dysfunction. J Clin Invest, 2003. 111(4): p. 436-7. 
2. Paterson, D. and A. Nordberg, Neuronal nicotinic receptors in the human brain. Prog 
Neurobiol, 2000. 61(1): p. 75-111. 
3. Changeux, J.P. and S.J. Edelstein, Allosteric mechanisms in normal and pathological 
nicotinic acetylcholine receptors. Current Opinion In Neurobiology, 2001. 11(3): p. 369-377. 
4. Lester, H.A., et al., Cys-loop receptors: new twists and turns. Trends In Neurosciences, 2004. 
27(6): p. 329-336. 
5. Brejc, K., et al., Crystal structure of an ACh-binding protein reveals the ligand-binding 
domain of nicotinic receptors. Nature, 2001. 411(6835): p. 269-76. 
6. Celie, P.H.N., et al., Crystal Structure of Acetylcholine-binding Protein from Bulinus 
truncatus Reveals the Conserved Structural Scaffold and Sites of Variation in Nicotinic 
Acetylcholine Receptors. J. Biol. Chem., 2005. 280(28): p. 26457-26466. 
7. Celie, P.H.N., et al., Nicotine and Carbamylcholine Binding to Nicotinic Acetylcholine 
Receptores as Sutdied in AChBP Crystal Structures. Neuron, 2004. 41: p. 907-914. 
8. Unwin, N., et al., Activation of the nicotinic acetylcholine receptor involves a switch in 
conformation of the α subunits. J Mol Biol, 2002. 319(5): p. 1165-76. 
9. Miyazawa, A., Y. Fujiyoshi, and N. Unwin, Structure and gating mechanism of the 
acetylcholine receptor pore. Nature, 2003. 423: p. 949-955. 
10. Unwin, N., Refined Structure of the Nicotinic Acetylcholin receptor at 4 A Resolution. J Mol 
Biol, 2005. 346: p. 967-989. 
11. Taly, A., et al., Normal mode analysis suggests a quaternary twist model for the nicotinic 
receptor gating mechanism. Biophysical Journal, 2005. 88(6): p. 3954-3965. 
12. Lummis, S.C., et al., Cis-trans isomerization at a proline opens the pore of a 
neurotransmitter-gated ion channel. Nature. 2005 Nov 10;438(7065):248-52. 
13. Kash, T.L., et al., Evaluation of a proposed mechanism of ligand-gated ion channel 
activation in the GABAA and glycine receptors. Neurosci Lett, 2004. 371: p. 230-234. 
14. Kash, T.L., et al., Charged Residues in the β2 Subunit Involved in GABAA Receptor 
Activation. J. Biol. Chem., 2004. 279(6): p. 4887-4893. 
15. Kash, T.L., et al., Coupling of agonist binding to channel gating in the GABA(A) receptor. 
Nature, 2003. 421(6920): p. 272-5. 
16. Schofield, C.M., A. Jenkins, and N.L. Harrison, A Highly Conserved Aspartic Acid Residue 
in the Signature Disulfide Loop of the α1 Subunit Is a Determinant of Gating in the Glycine 
Receptor. J. Biol. Chem., 2003. 278(36): p. 34079-34083. 
17. Kash, T.L., J.R. Trudell, and N.L. Harrison, Structural elements involved in activation of the 
γ-aminobutyric acid type A (GABAA) receptor. Biochem. Soc. T., 2004. 32(3): p. 540-546. 
18. Absalom, N.L., et al., Role of Charged Residues in Coupling Ligand Bindig and Channel 
Activation in the Extraceullular Domain of the Glycine Receptor. J. Biol. Chem., 2003. 
278(50): p. 50151-50157. 
19. Schofield, C.M., J.R. Trudell, and N.L. Harrison, Alanine-Scanning Mutagenesis in the 
Signature Disulfide Loop of the Glycine Receptor α1 Subunit: Critical Residues for 
Activation and Modulation. Biochemistry, 2004. 43: p. 10058-10063. 
  61
20. Nowak, M.W., et al., In vivo incorporation of unnatural amino acids into ion channels in a 
Xenopus oocyte expression system. Methods Enzymol, 1998. 293: p. 504-529. 
21. Placzek, A.N., et al., A single point mutation confers properties of the muscle-type nicotinic 
acetylcholine receptor to homomeric alpha 7 receptors. Molecular Pharmacology, 2004. 
66(1): p. 169-177. 
22. Colquhoun, D., Binding, gating, affinity and efficacy: the interpretation of structure- activity 
relationships for agonists and of the effects of mutating receptors. Br J Pharmacol, 1998. 
125(5): p. 924-47. 
23. Chakrapani, S., T.D. Bailey, and A. Auerbach, Gating Dynamics of the Acetylcholine 
Receptor Extracellular Domain. J Gen Physiol, 2004. 123: p. 341-356. 
24. Corringer, P.J., N. Le Novere, and J.P. Changeux, Nicotinic receptors at the amino acid level. 
Annu Rev Pharmacol Toxicol, 2000. 40: p. 431-58. 
25. Kearney, P.C., et al., Determinants of nicotinic receptor gating in natural and unnatural side 
chain structures at the M2 9?position. Neuron, 1996. 17(6): p. 1221-1229. 
26. Karplus, P.A., Hydrophobicity regained. Protein Science, 1997. 6(6): p. 1302-1307. 
27. Radzicka, A. and R. Wolfenden, Comparing The Polarities Of The Amino-Acids - Side-Chain 
Distribution Coefficients Between The Vapor-Phase, Cyclohexane, 1-Octanol, And Neutral 
Aqueous-Solution. Biochemistry, 1988. 27(5): p. 1664-1670. 
28. Chothia, C., The nature of the accessible and buried surfaces in proteins  Journal of 
Molecular Biology, 1975. 105(1): p. 1-12. 
29. Zamyatnin, A.A., Protein volume in solution  1972. 24 p. 107-123  
30. Mitra, A., T.D. Bailey, and A. Auerbach, Structural Dynamics of the M4 Transmembrane 
Segment during Acetylcholine Receptor Gating. Structure, 2004. 12: p. 1909-1918. 
31. Grosman, C., et al., The extracellular linker of muscle acetylcholine receptor channels is a 
gating control element. J Gen Physiol, 2000. 116(3): p. 327-40. 
32. Castaldo, P., et al., A novel hyperekplexia-causing mutation in the pre-transmembrane 
segment 1 of the human glycine receptor alpha1 subunit reduces membrane expression and 
impairs gating by agonists. J Biol Chem. 2004 Jun 11;279(24):25598-604. Epub 2004 Apr 5. 
33. Bouzat, C., et al., coupling of agonist binding to channel gating in an ACh-binding protein 
linked to an ion channel. Nature, 2004. 430: p. 896-900. 
34. Xiu, X., et al., A Unified View of the Role of Electrostatic Interactions in Modulating the 
Gating of Cys Loop Receptors. J. Biol. Chem., 2005. 280(50): p. 41655-41666. 
35. Grosman, C. and A. Auerbach, Asymmetric and independent contribution of the second 
transmembrane segment 12' residues to diliganded gating of acetylcholine receptor channels.  
A single-channel study with choline as the agonist. J Gen Physiol, 2000. 115(637-651). 
36. Grosman, C., M. Zhou, and A. Auerbach, Mapping the conformational wave of acetylcholine 
receptor channel gating. Nature, 2000. 403(6771): p. 773-6. 
37. Filatov, G.N. and M.M. White, The role of conserved leucines in the M2 domain of the 
acetylcholine receptor in channel gating. Mol Pharmacol, 1995. 48(3): p. 379-384. 
38. Labarca, C., et al., Channel gating governed symmetrically by conserved leucine residues in 
the M2 domain of nicotinic receptors. Nature. 1995 Aug 10;376(6540):514-6. 
39. Campos-Caro, A., et al., A Single Residue in the M2-M3 Loop is a  Major Determinant of 
Coupling Between Binding and Gating in Neuronal Nicotinic Receptors. Proc. Natl. Acad. 
Sci. USA, 1996. 93: p. 6118-6123. 
40. Lummis, S.C.R., The transmembrane domain of the 5-HT3 receptor: its role in selectivity 
and gating. Biochemical Society Transactions, 2004. 32: p. 535-539. 
  62
41. Cashin, A.L., et al., Using physical chemistry to differentiate nicotinic from cholinergic 
agonists at the nicotinic acetylcholine receptor. Journal Of The American Chemical Society, 
2005. 127(1): p. 350-356. 
42. Kearney, P.C., et al., Dose-Response Relations for Unnatural Amino Acids at the Agonist 
Binding Site of the Nicotinic Acetylcholine Receptor: Tests with Novel Side Chains and with 
Several Agonists. Mol. Pharmacol., 1996. 50(5): p. 1401-1412. 
43. Tong, Y., et al., Tyrosine decaging leads to substantial membrane trafficking during 
modulation of an inward rectifier potassium channel. J Gen Physiol, 2001. 117(2): p. 103-18. 
 
 
  63 
Supplementary Table S 2.1: Sequences in the gating interface of the whole LGIC family, highlighting cationic (blue) and anionic (red) residues. 
          Loop2   Loop7     L9 preM1   M2-M3         postM4       D  E  K  R  +  -  N   Z 
ACH4_HUMAN DEKNQM IDVTFFPFDQ EW IRRLP STSLVIPLIGEY  FLPP  WLAGMI  3  3  1  2  3  6  -3  9   
ACH4_RAT  DEKNQM IDVTFFPFDQ EW IRRLP STSLVIPLIGEY  FLPP  WLAAC   3  3  1  2  3  6  -3  9   
ACH4_CHICK DEKNQM IDVTFFPFDQ EW IRRLP STSLVIPLIGEY  FLPP  WLAGMI  3  3  1  2  3  6  -3  9   
ACH2_CHICK DEKNQM IDVTYFPFDQ EW IRRLP STSLVIPLIGEY  FLPP  YLAGMI  3  3  1  2  3  6  -3  9   
ACH2_RAT  DEKNQM IDVTFFPFDQ EW IRRLP STSLVIPLIGEY  FLPP  FLAGMI  3  3  1  2  3  6  -3  9   
ACH2_HUMAN DEKNQM IDVTFFPFDQ EW IRRLP STSLVIPLIGEY  FLPP  FLAGMI  3  3  1  2  3  6  -3  9   
ACH3_CARAU DEVNQI MDITYFPFDY EW IRRLP STSLVIPLIGEY  FLQP  LIGFFS  3  3  0  2  2  6  -4  8   
ACH3_HUMAN DEVNQI IDVTYFPFDY EW IRRLP STSLVIPLIGEY  FLQP  LMARED  4  4  0  3  3  8  -5  11   
ACH3_BOVIN DEVNQI IDVTYFPFDY EW IRRLP STSLVIPLIGEY  FLQP  LMTRDD  5  3  0  3  3  8  -5  11   
ACH3_RAT  DEVNQI IDVTYFPFDY EW IRRLP STSLVIPLIGEY  FLQP  LMARDD  5  3  0  3  3  8  -5  11   
ACH3_CHICK DEVNQI IDVTYFPFDY EW IRRLP STSLVIPLIGEY  FLQP  LMTGDD  5  3  0  2  2  8  -6  10   
ACH6_HUMAN DEVNQI MDITFFPFDH EW IRRLP STSLVVPLVGEY  FLQP  LLGNTG  3  3  0  2  2  6  -4  8   
ACH6_RAT  DEVNQI MDITFFPFDH EW IRRLP STSLVIPLVGEY  FLQP  LLGNTG  3  3  0  2  2  6  -4  8   
ACH6_CHICK DEVNQI MDITFFPFDH EW IRRLP STSLVIPLVGEY  FIQP  LIADT   4  3  0  2  2  7  -5  9   
ACH6_RAT  HEREQI IEVKHFPFDQ EW IRRKP PTSLDVPLVGKY  FLQP  LFQNYT  2  4  3  3  6  6  0  12   
ACHN_HUMAN HEREQI IEVKHFPFDQ EW IRRKP PTSLDVPLVGKY  FLQP  LFQNYT  2  4  3  3  6  6  0  12   
ACHN_CHICK HEREQI IEVKHFPFDQ EW IRRKP PTSLDVPLVGKY  FLQP  LFQNYA  2  4  3  3  6  6  0  12   
ACHP_CHICK NEREQI IEVKHFPFDQ EW IKRKP PTSLDVPLIGKY  FLQP  LFQNHI  2  4  4  2  6  6  0  12   
ACHP_RAT  NEREQI IEVKHFPFDQ EW IKRKP PTSLDIPLIGKY  FLPP  LFQIHA  2  4  4  2  6  6  0  12   
ACHN_CARAU NEREQI IEVRNFPFDQ EW IKRKP PTSLAVPLIGKY  FVQP  LFQSYN  1  4  3  3  6  5  1  11   
ACH2_DROME NLKDQI IDVRYFPFDQ EW LRRKT STSLALPLLGKY  ILG    EAPSL  3  2  3  3  6  5  1  11   
ACH1_SCHGR NLKDQI IDVRYFPFDQ EW LRRKT STSLALPLLGKY  ILC    EAPAL  3  2  3  3  6  5  1  11   
ACH1_DROME NLKNQI IDVEYFPFDE EW LRRKT PTSLTVPLLGKY  IIL    QAPSL  2  3  3  2  5  5  0  10   
ACH4_DROME NLKNQV MNVEYFPYDE EW MRRKT PTSLAVPLLGKY  IDRQLSEIPLRK  2  4  4  4  8  6  2  14   
ACHO_RAT  DEKNQL MDVTFFPFDR EW LRRLP SSSKVIPLIGEY  FI P   ALKMW  3  3  3  3  6  6  0   12   
ACHO_CHICK DEKNQL MELTFFPFDR EW LRRLP SSSKVIPLIGEY  F TPALQMWLNS  2  4  2  3  5  6  -1  11   
ACHP_CARAU DEKNHL MDVTFFPFDR EW LKRLP SSSKVIPLIGEY  F TPALHMYLST  3  3  3  2  5  6  -1  11   
ACHO_CARAU DEKNQL MDVTFFPFDR EW LKRLP SSSKVIPLIGEY  F TPALKMFLRT  3  3  4  3  7  6  1   13   
ACH5_CHICK DEKNQL IDVTFFPFDL EW IRRLP SSSKVIPLIGEY  WASIIVPVHIGS  3  3  2  2  4  6  -2  10   
ACH5_HUMAN DEKNQL IDVTFFPFDL EW IKRLP SSSKVIPLIGEY  WANILIPVHIGN  3  3  3  1  4  6  -2  10   
ACH5_RAT  DEKNQL IDVTFFPFDL EW IKRLP SSSKVIPLIGEY  WANIIVPVHIGN  3  3  3  1  4  6  -2  10   
ACH3_DROME NEKNQV IDVTYFPFDQ TW IRRKT PTSLVLPLIAKY  LMDAPHIFEYVD  4  2  3  2  5  6  -1  11   
ACHA_BOVIN DEVNQI IIVTHFPFDE EW MQRLP STSSAVPLIGKY  FAGRLIELNQQG  2  4  1  2  3  6  -3  9   
ACHA_HUMAN DEVNQI IIVTHFPFDE EW MQRLP STSSAVPLIGKY  FAGRLIELNQQG  2  4  1  2  3  6  -3  9   
ACHA_MOUSE DEVNQI IIVTHFPFDE EW MQRLP STSSAVPLIGKY  FAGRLIELHQQG  2  4  1  2  3  6  -3  9   
ACHA_RAT  DEVNQI IIVTHFPFDE EW MQRLP STSSAVPLIGKY  FAGRLIELHQQG  2  4  1  2  3  6  -3  9   
ACHA_CHICK DEVNQI IIVTYFPFDQ EW MQRLP STSSAVPLIGKY  FAGRLIELNQQG  2  3  1  2  3  5  -2  8   
ACH2_XENLA DEVNQI IIVTYFPFDQ EW LQRLP STSSAVPLIGKY  FAGRIIEMNMQE  2  4  1  2  3  6  -3  9   
ACH1_XENLA NEVNQI MIVTYFPFDL EW LQRLP STSSAVPLIGKY  FAGRLIELHMQG  1  3  1  2  3  4  -1  7   
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ACHA_TORCA DEVNQI IIVTHFPFDQ EW MQRIP STSSAVPLIGKY  FAGRLIELSQEG  2  4  1  2  3  6  -3  9   
ACHD_RAT  KEVEET ISVTYFPFDW EW IRRKP ATSMAIPLVGKF  FLQGVYNQPPPQ  1  4  3  2  5  5  0  10   
ACHD_MOUSE KEVEET ISVTYFPFDW EW IRRKP ATSMAIPLVGKF  FLQGVYNQPPLQ  1  4  3  2  5  5  0  10   
ACHD_HUMAN KEVEET ISVTYFPFDW EW IRRKP ATSMAIPLIGKF  FLQGVYNQPPPQ  1  4  3  2  5  5  0  10   
ACHD_BOVIN KEVEET ISVTYFPFDW EW IRRKP ATSMAIPLIGKF  FLQGAYNQPPPQ  1  4  3  2  5  5  0  10   
ACHD_CHICK KEVDET INVNFFPFDW EW IKRKP ATSHAIPLIGKY  FLMGIYNHPPPL  2  3  4  1  5  5  0  10   
ACHD_XENLA KEADET INVNYFPFDW EW IERKP ETSFAIPLISKY  FLGGAYNLPPSL  2  5  3  1  4  7  -3 11   
ACHD_TORCA KETDET INVLYFPFDW EW IRRKP ETALAVPLIGKY  FVMGNFNHPPAK  2  4  4  2  6  6  0  12   
ACHG_CHICK NEREET IHVTYFPFDW EW IQRKP ETSQAVPLIGKY  FLMAHFNQAPAL  1  5  2  2  4  6  -2  10   
ACHG_XENLA NEKEEA VVVTYFPFDW EW IQRKP ETSTSVPLIVKY  FLAGHFNQAPAH  1  5  3  1  4  6  -2  10   
ACHG_MOUSE NEREEA ISVTYFPFDW EW IQRKP ETSQAVPLISKY  FLMAHYNQVPDL  2  5  2  2  4  7  -3  11   
ACHG_RAT  NEREEA ISVTYFPFDW EW IQRKP ETSQAVPLISKY  FLMAHYNQVPDL  2  5  2  2  4  7  -3  11   
ACHG_BOVIN NEREEA VSVTFFPFDW EW IQRKP ETSQAVPLISKY  FLMAHYNRVPAL  1  5  2  3  5  6  -1  11   
ACHG_HUMAN NEREEA ISVTYFPFDW EW IQRKP ETSQAVPLISKY  FLMAHYNRVPAL  1  5  2  3  5  6  -1  11   
ACHG_TORCA NEKEEA IAVTYFPFDW EW IQRKP ETSLNVPLIGKY  FLTGHFNQVPEF  1  6  3  1  4  7  -3  11   
ACHE_XENLA NEKEET IEITYFPFDW EW IQRKP ETSLSVPLIGKY  FLMGHFNTAPEH  1  7  3  1  4  8  -4  12   
ACHE_RAT  NEKEET VEVTYFPFDW EW IRRKP ETSLSVPLLGRY  FLGGYFNQVPDL  2  6  2  3  5  8  -3  13   
ACHE_MOUSE NEKEET VEVTYFPFDW EW IRRKP ETSLSVPLLGRY  FLGGYFNQVPDL  2  6  2  3  5  8  -3  13   
ACHE_HUMAN NEKEET VEVTYFPFDW EW IRRKP ETSLSVPLLGRF  FLGAYFNRVPDL  2  6  2  4  6  8  -2  14   
ACHE_BOVIN NEKEET VEVTYFPFDW EW IRRKP ETSLSVPLLGRY  FLGAYFNRVPQL  1  6  2  4  6  7  -1  13   
ACHB_MOUSE NEKDEE IQVTYFPFDW QW IRRKP ETSLAVPIIIKY  FLDATYHLPPPE  3  5  3  2  5  8  -3  13   
ACHB_RAT  NEKDEE IQVTYFPFDW QW IRRKP ETSLAVPIIIKY  FLDATYHLPPPE  3  5  3  2  5  8  -3  13   
ACHB_HUMAN NEKDEE IQVTYFPFDW QW IRRKP ETSLSVPIIIKY  FLDATYHLPPPD  4  4  3  2  5  8  -3  13   
ACHB_BOVIN NEKDEE IQVTYFPFDW QW IRRKP ETSLSVPIIIKY  FLDATYHLPPAD  4  4  3  2  5  8  -3  13   
ACHB_TORCA NEKIEE IKVMYFPFDW QW IQRKP ETSLSVPIIIRY  FLDASHNVPPDN  3  4  3  2  5  7  -2  12   
ACH8_CHICK DEKNQV IDVRWFPFDV EW MRRRT ATSDSVPLIAQY  LMSAPNFIEAVS  4  3  1  4  5  7  -2  12   
ACH7_CHICK DEKNQV IDVRWFPFDV EW MRRRT ATSDSVPLIAQY  LMSAPNFVEAVS  4  3  1  4  5  7  -2  12   
ACH7_HUMAN DEKNQV IDVRWFPFDV EW MRRRT ATSDSVPLIAQY  LMSAPNFVEAVS  4  3  1  4  5  7  -2  12   
ACH7_MOUSE DEKNQV IDVRWFPFDV EW MRRRT ATSDSVPLIAQY  LMSAPNFVEAVS  4  3  1  4  5  7  -2  12   
ACH7_RAT  DEKNQV IDVRWFPFDV EW MRRRT ATSDSVPLIAQY  LMSAPNFVEAVS  4  3  1  4  5  7  -2  12   
ACH7_BOVIN DEKNQV IDVRWFPFDV EW IRRRT ATSDSVPLIAQY  LMSAPNFVEAVS  4  3  1  4  5  7  -2  12   
ACH9_RAT  DERNQI VDVTYFPFDS EW LKRRS A SENVPLIGKY  IARAD         4  3  2  4  6  7  -1  13 
5HT3_RAT  DEKNQV LDIYNFPFDV EW IRRRP ATAIGTPLIGVY  LWSIWHYS      3  2  1  3  4  5  -1  9   
5HT3_MOUSE DEKNQV LDIYNFPFDV EW IRRRP AT IGTPLIGVY  LWSIWHYS      3  2  1  3  4  5  -1  9   
5HT3_HUMAN DEKNQV LDIYNFPFDV EW IRRRP ATAIGTPLIGVY  LWSIWQYA      3  2  1  3  4  5  -1  9   
GAA4_BOVIN SDVEME MRLVDFPMDG QY LRRKM KVSYATAM DWF  LSKDTMEKSESL  5  4  4  3  7  9  -2  16   
GAA4_HUMAN SDVEME MRLVDFPMDG QY LRRKM KVSYLTAM DWF  LSKDTMEKSESL  5  4  4  3  7  9  -2  16   
GAA4_RAT  SDVEME MRLVDFPMDG QY LRRKM KVSYATAM DWF  LSKDTMEKSESL  5  4  4  3  7  9  -2  16   
GAA6_HUMAN SDVEME MRLVNFPMDG QY LQRKM KVSYATAM DWF  LSKDTMEVSSSV  4  3  3  2  5  7  -2  12   
GAA6_RAT  SDVEME MRLVNFPMDG QY LQRKM KVSYATAM DWF  LSKDTMEVSSTV  4  3  3  2  5  7  -2  12   
GAA3_RAT  SDTDME MHLEDFPMDV QY LKRKI KVAYATAM DWF  VNRESAIKGMIR  5  3  4  3  7  8  -1  15   
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GAA3_HUMAN SDTDME MHLEDFPMDV QY LKRKI KVAYATAM DWF  VNRESAIKGMIR  5  3  4  3  7  8  -1  15   
GAA3_BOVIN SDTDME MHLEDFPMDV QY LKRKI KVAYATAM DWF  VNRESAIKGMIR  5  3  4  3  7  8  -1  15   
GAA5_RAT  SDTEME MQLEDFPMDA QY LKRKI KVAYATAM DWF  LNREPVIKGATS  4  4  4  2  6  8  -2  14   
GAA5_HUMAN SDTEME MQLEDFPMDA QY LKRKI KVAYATAM DWF  LNREPVIKGAAS  4  4  4  2  6  8  -2  14   
GAA2_BOVIN SDTDME MHLEDFPMDA QY LKRKI KVAYATAM DWF  LNREPVLGVSP   5  3  3  2  5  8  -3  13   
GAA2_HUMAN SDTDME MHLEDFPMDA QY LKRKI KVAYATAM DWF  LNREPVLGVSP   5  3  3  2  5  8  -3  13   
GAA2_RAT  SDTDME MHLEDFPMDA QY LKRKI KVAYATAM DWF  LNREPVLGVSP   5  3  3  2  5  8  -3  13   
GAA1_CHICK SDHDME MHLEDFPMDV QY LKRKI KVAYATAM DWF  LNREPQLKAPTP  5  3  4  2  6  8  -2  14   
GAA1_HUMAN SDHDME MHLEDFPMDA QY LKRKI KVAYATAM DWF  LNREPQLKAPTP  5  3  4  2  6  8  -2  14   
GAA1_BOVIN SDHDME MHLEDFPMDA QY LKRKI KVAYATAM DWF  LNREPQLKAPTP  5  3  4  2  6  8  -2  14   
GAA1_RAT  SDHDME MHLEDFPMDA QY LKRKI KVAYATAM DWF  LNREPQLKAPTP  5  3  4  2  6  8  -2  14   
GAC2_BOVIN NAINME LQLHNFPMDE QF LSRRM KVSYVTAM DLF  LYL           2  2  1  2  3  4  -1  7   
GAC2_HUMAN NAINME LQLHNFPMDE QF LSRRM KVSYVTAM DLF  LYL           2  2  1  2  3  4  -1  7   
GAC2_RAT  NAINME LQLHNFPMDE QF LSRRM KVSYVTAM DLF  LYL           2  2  1  2  3  4  -1  7   
GAC2_CHICK NAINME LQLHNFPMDA QF LSRRM KVSYVTAM DLF  LYL           2  1  1  2  3  3   0  6   
GAC1_RAT  DPINME LQLHNFPMDE QF LSRRM KVSYVTAM DLF  LYL           3  2  1  2  3  5  -2  8   
GAC3_RAT  SSINME LQLHNFPMDA QF LSRRM RVSYVTAM DLF  LYL           2  1  0  3  3  3   0  6   
GAC4_CHICK SVIQME LQLQNFPMDT QF LSRRM RVSYITAM DLF  LYL           2  1  0  3  3  3   0  6   
GAB_DROME  SEVLMD MNLQYFPMDR QF FVRSM KISY VKSIDVY  ILE           3  2  2  2  4  5  -1  9   
GAB4_CHICK SEVNMD MDLRRYPLDQ QF IKRNI KIPY VKAIDVY                4  1  3  3  6  5  1  11   
GAB3_RAT  SEVNMD MDLRRYPLDE QF LKRNI KIPY VKAIDMY  VN            4  2  3  3  6  6  0  12   
GAB3_HUMAN SEVNMD MDLRRYPLDE QF LKRNI KIPY VKAIDMY  VN            4  2  3  3  6  6  0  12   
GAB3_CHICK SEVNMD MDLRRYPLDE QF LKRNI KIPY VKAIDMY  VN            4  2  3  3  6  6  0  12   
GAB2_RAT  SEVNMD MDLRRYPLDE QF LKRNI KIPY VKAIDMY  VN            4  2  3  3  6  6  0  12   
GAB2_HUMAN SEVNMD MDLRRYPLDE QF LKRNI KIPY VKAIDMY  VN            4  2  3  3  6  6  0  12   
GAB1_BOVIN SEVNMD MDLRRYPLDE QF LKRNI KIPY VKAIDIY  VH            4  2  3  3  6  6  0  12   
GAB1_RAT  SEVNMD MDLRRYPLDE QF LKRNI KIPY VKAIDIY  VH            4  2  3  3  6  6  0  12   
GAB1_HUMAN SEVNMD MDLRRYPLDE QF LKRNI KIPY VKAIDIY  VN            4  2  3  3  6  6  0  12   
GAB_LYMST  SEVDMD MDLHNYPLDH QF LQRNI RISY VKAIDIY  LLT           5  1  1  2  3  6  -3  9   
GAD_RAT   SEANME MDLAKYPMDE QF LRRNR RAS AIKALDVY  TM            3  3  2  4  6  6   0  12   
GAR2_HUMAN SEVDMD MDFSHFPLDS QF LRRHI RVSY VKAVDIY  S             5  1  1  3  4  6  -2  10   
GAR2_RAT  SEVDMD MDFSHFPLDS QF LRRHI RVSY IRAVDIY  S             5  1  0  4  4  6  -2  10   
GAR1_RAT  SEVDMD MDFSRFPLDT QF LRRHI RVSY IKAVDIY  S             5  1  1  4  5  6  -1  11   
GAR1_HUMAN SEVDMD MDFSRFPLDT QF LRRHI RVSY IKAVDIY  S             5  1  1  4  5  6  -1  11   
GAR3_RAT  SEVNMD MDFSRFPLDT QF LRRHI QVSY VKAVDVY  V             4  1  1  3  4  5  -1  9   
GRB_HUMAN  QETTMD LDLTLFPMDT QF LRRQV KVSY VKALDVW  L             4  1  2  2  4  5  -1  9   
GRB_RAT   QETTMD LDLTLFPMDT QF LRRQV KVSY VKALDVW                  4  1  2  2  4  5  -1  9   
GRA3_RAT  AETTMD MDLKNFPMDV QF LERQM KVSY VKAIDIW  KILRHEDIHHQQ  5  3  4  2  6  8  -2  14   
GRA1_RAT  AETTMD MDLKNFPMDV QF LERQM KVSY VKAIDIW  KIVRREDVHNK   5  3  5  3  8  8   0  16   
GRA1_HUMAN AETTMD MDLKNFPMDV QF LERQM KVSY VKAIDIW  KIVRREDVHNQ   5  3  4  3  7  8  -1  15   
GRA2_HUMAN TETTMD MDLKNFPMDV QF LERQM KVSY VKAIDIW  KIIRHEDVHKK   5  3  6  2  8  8   0  16   
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GRA2_RAT  TETTMD MDLKNFPMDV QF LERQM KVSY VKAIDIW  KIIRHEDVHKK   5  3  6  2  8  8   0  16   
GluCl-alph DVVNME MYLQYYPMDV SF LKREF PVSY IKAIDVW       RFGQQNV  3  2  2  2  4  5  -1  9   
GluCl-beta DVVNME MRLQLYPLDY NF FKRQF PVSY VKVVDVW  LIMSANASTPES  3  2  2  2  4  5  -1  9   
 
Key:  + = number of cationic residues (K, R); – = number of anionic residues (D, E); Z = overall charge;  N = number of ionic residues. 
 
 
 
 
 CATION  CHANNELS    ANION CHANNELS  
 XC TM  TOT   XC TM  TOT 
+ 1.0  3.4  4.4   + 0.7 4.6 5.3 
- 4.9  1.4  6.3   - 4.6 1.9 6.4 
Z -3.9  2.0  -1.9   Z -3.9 2.8 -1.1 
N 6.0  4.8  10.7   N 5.3 6.5 11.8 
 
XC: extracellular part of the gating interface, containing loop2, loop 7 and loop 9. TM: trasmembrane part of the gating 
interface, containg preM1, M2-M3 linker and postM4. TOT: the total gating interface. 
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C h a p t e r  3  
NICOTINE IN THE CNS VS. THE NEUROMUSCULAR 
JUNCTION: A CATION-π INTERACTION AND A 
HYDROGEN BOND MAKE THE DIFFERENCE 
 
3.1 Abstract  
 The launching point for nicotine addiction is the activation by nicotine of a 
family of neuroreceptors in the CNS that normally respond to the neurotransmitter 
acetylcholine (ACh). The same family of neuroreceptors also governs the fast electric 
signal transmission at the neuromuscular junction. The long standing puzzle has been 
the mechanism underlining a significant increase of affinity for nicotine in the CNS 
compared with that at the neuromuscular junction. Here, by incorporating unnatural 
amino acids, we report a cation-π interaction and a hydrogen bond employed by 
nicotine with the α4β2 receptor specifically. These two key interactions are absent or 
significantly diminished in both the muscle type receptors and in the α7 form of 
neuronal receptor. These results provide unprecedented details regarding nicotine 
binding in the nervous system, with significant implications for efforts in drug 
discovery targeting nAChRs. 
3.2 Introduction  
The addictive properties of nicotine lead to over 4,000,000 smoking-related 
deaths annually and produce the largest source of preventable mortality in the western 
world.  Nicotine activates a family of neuroreceptors that normally respond to the 
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neurotransmitter acetylcholine (ACh).  These aptly named nicotinic acetylcholine 
receptors (nAChR) are ligand-gated ion channels that mediate fast synaptic 
transmission throughout the central and peripheral nervous systems.[1] Therapeutic 
strategies targeting nAChRs have been proposed for Alzheimer’s disease, 
schizophrenia, Parkinson’s disease, pain, attention deficit-hyperactivity disorder, 
epilepsy, depression, autism, Tourette’s syndrome, and smoking cessation[2-4]. Along 
with these central nervous system (CNS) indications, the nAChR also controls the 
neuromuscular junction, where ACh released from a motor neuron activates 
postsynaptic nAChRs in the muscle.  Dysfunctions of nAChRs at the neuromuscular 
junction of the peripheral nervous system are associated with a number of myasthenic 
syndromes.[5, 6]   
An important and curious feature of the nAChR is that sensitivity to nicotine is 
substantially reduced at the neuromuscular junction relative to receptors found in the 
CNS.  Of course, the cognitive and addictive effects of nicotine occur in the CNS, 
and it is the relative lack of activity at the neuromuscular junction that allows smokers 
to experience the CNS effects of nicotine without acute motor abnormalities[4].  
This unfortunate differential sensitivity to nicotine occurs despite the fact that the 
nAChRs of the CNS and neuromuscular junction are very highly homologous 
throughout their structures and are essentially identical in the immediate vicinity of 
the agonist binding site. (Figure 3.1)  
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Figure 3.1 Sequence alignments in the immediate vicinity of the agonist binding sites 
from AChBP, mouse muscle type, rat α4β2 and rat α7 nAChR.  
Here we describe studies of agonist activation of two prominent nAChRs of the 
CNS.  Using the powerful tool of unnatural amino acid mutagenesis, we establish a 
strong cation-π interaction between nicotine and a conserved tryptophan in the α4β2 
receptor, the nAChR type most strongly associated with nicotine addiction[7-10].  
Importantly, this potent binding interaction is absent in the nAChR of the 
neuromuscular junction.  In addition, we find that a hydrogen bond between nicotine 
and a backbone carbonyl of the agonist binding site is substantially strengthened in 
the α4β2 receptor compared to the comparable interaction with the muscle-type 
receptor.  Taken together, these two observations provide a molecular rationale for 
the differential sensitivities to nicotine of the two receptors.   
Surprisingly, we find that a second CNS nAChR (α7) displays a different 
binding pattern.  While a cation-π interaction is still important, it is made to a 
different aromatic amino acid of the receptor than is employed by the α4β2 or 
muscle-type receptors.  In addition, the strong hydrogen bond seen in the α4β2 
receptor is significantly diminished in α7. Along with providing a molecular 
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understanding of the differential actions of nicotine in the CNS and neuromuscular 
junction, these findings have significant implications for efforts in drug discovery 
targeting nAChRs. 
3.3 Results 
3.3.1 Background and approach 
nAChRs are pentameric, integral membrane, ligand-gated ion channels, whose 
overall layout and gross structural features have been established by cryoelectron 
microscopy[11].  There are 17 known human genes that code for nAChR subunits, 
termed α1-α10, β1-β4, γ, δ, and ε.  Not all possible pentameric combinations of 
subunits are viable, but as many as 20 different nAChRs have been established to be 
important in humans[3, 7]. The nAChR of the postsynaptic membrane of the 
neuromuscular junction is unique.  This “muscle-type” receptor has a precise 
stoichiometry of (α1)2β1γδ (fetal form; the adult form is (α1)2β1δε). The “neuronal” 
nAChRs of autonomic ganglia and cholinergic neurons throughout the CNS are 
formed from various combinations of α2-α10 and β2-β4 subunits[12] (Figure 1.2)   
Of the neuronal receptors, two appear to play especially prominent roles in the 
pathology of the diseases mentioned above:  the α4β2 and α7 receptors.  The α4β2 
receptors account for over 90% of the high affinity nicotine binding sites in the 
brain[3].  Activation of receptors containing α4 is known to be necessary and 
sufficient for nicotine-induced reward, tolerance, and sensitization[13].  Knocking 
out the β2 subunit in mice results in complete abolishment of nicotine 
self-administration[3]. Unlike the muscle-type receptor, with its precise stoichiometry, 
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the α4β2 receptor exists in at least two forms: (α4)2(β2)3 and (α4)3(β2)2.[14, 15]  
Another prominent CNS nAChR is the homopentameric receptor formed from 
α7 subunits.  This receptor has been implicated in schizophrenia and is considered a 
treatment target for Alzheimer’s disease and other cognitive disorders[16, 17].  It has 
a pharmacology that is distinct from that of α4β2. 
In previous work we have performed extensive studies of the muscle-type 
receptor.  Our primary tool has been a structure-function study using the subtle and 
precise tool of unnatural amino acid incorporation, made possible by nonsense 
suppression technology[18-28].  Through such studies, we established that the 
quaternary ammonium ion of ACh makes a cation-π interaction with Trp149 of the α1 
subunit.  This was established through a fluorination plot. A cation-π interaction is a 
stabilizing interaction between a cation and the face of a simple aromatic, and it is 
broadly utilized in stabilizing both protein secondary structure & receptor-ligand 
binding interactions[29-32]. It is well established that fluorine is deactivating in a 
cation-π interaction, and that multiple fluorines have an additive effect.  By 
successively replacing the wild type Trp with monofluoro, difluoro, trifluoro… 
analogues, we can probe for a cation-π interaction.  A positive result manifests as a 
linear “fluorination plot”, as shown in Figure 3.2.   
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Figure 3.2 Fluorination plots demonstrating a cation-π interaction of TrpB in the 
muscle nAChR with the cationic centers of ACh and Epibatidine, but not with 
nicotine. 
The fluorination plot established van der Waals contact between the quaternary 
ammonium of ACh and the side chain of α1Trp149.  Another useful probe of a 
potential cation-π interaction is the cyano/bromo (CN/Br) comparison [24].  When 
appended to an aromatic ring, CN and Br substituents present a similar steric 
perturbation.  However, CN is strongly deactivating in the cation-π interaction, while 
Br is much less so.  As such, a large CN/Br effect, i.e., a much larger rise in EC50 for 
CN than for Br, can also be taken as good evidence for a cation-π interaction.  In the 
muscle-type receptor, the ACh CN/Br effect is roughly a factor of 50 in EC50 for 
α1Trp149. 
Subsequent to our structure-function studies, the binding site of the acetylcholine 
binding proteins (AChBP) - small, soluble, homopentameric proteins that are 20-25% 
homologous to the extracellular domains of nAChRs - was revealed[33].  As 
anticipated, the binding site is rich in aromatics and occurs at the interface between 
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two subunits (the relevant interfaces are α/γ and α/δ in the muscle-type receptor). 
Gratifyingly, the analogue of α1Trp149 (TrpB) was shown to be a component of the 
“aromatic box” that forms the agonist binding site.  In fact, all five aromatic amino 
acids of the box – now referred to generically as A, B, C1, C2, and D - had previously 
been implicated as contributing to binding of ACh in the nAChR, confirming the 
relevance of AChBP to the nAChRs[34].   Crystallographic images of drugs bound 
to AChBP[33, 35-37] supported the viability of the cation-π interaction to the 
homolog to TrpB. (Figure 3.3)  
 
Figure 3.3 The “aromatic box” of the Cys-loop receptor. On the left, the five aromatic 
residues contributing to ligand binding, four from the principle subunit and one from 
the complementary subunit are shown as revealed in the AChBP crystal structure. On 
the right, the five residues are shown in VDW with generic nomenclature used in this 
thesis. The images are made from the crystal structure of AChBP from Lymnaea 
stagnalis in complex with carbamylcholine[38] .  (PDB code 1UV6).  
 
Given the well-established nicotinic pharmacophore, it might be assumed that 
the positive charge of nicotine – the protonated pyrrolidine nitrogen – would make a 
cation-π interaction with TrpB.  However, the fluorination plot clearly established 
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that no such interaction occurs in the nAChR of the neuromuscular junction[18] 
(Figure 3.2). 
The AChBP crystal structure also showed that the backbone carbonyl associated 
with TrpB points into the agonist binding site, and we and others inferred that this 
could act as a hydrogen bond acceptor for appropriate agonists.  To test this 
hypothesis, we converted the backbone amide carbonyl to a backbone ester by 
substituting an α-hydroxy acid at the i+1 position[19].(Figure 3.4)  This 
significantly weakens the hydrogen bonding ability of the carbonyl.  In the 
muscle-type nAChR both nicotine and epibatidine were modestly less potent when the 
backbone ester was present.  Interestingly, the receptor with the backbone ester 
showed an enhanced sensitivity to ACh, which cannot make such a hydrogen bond.  
These data supported the hydrogen bonding motif suggested by the AChBP structure, 
as did subsequent structures of small molecules bound to AChBP[33, 35-38]. 
ratio
Thr Tah Tah/Thr
ACh 0.83 0.25 0.30
Nicotine 57 92 1.6
Epibatidine 0.60 2.2 3.7
agonists
muscle
EC50 (μM)
 
Figure 3.4 Establishing a hydrogen bond between the backbone carbonyl and select 
agonists in the muscle nAChR. The left panel shows that the backbone amide 
carbonyl of TrpB is replaced with an ester carbonyl upon incorporation of 
α-hydroxythreonine (Tah) at position B+1. The right table shows EC50 values (μM) 
for testing H-bond interactions at TrpB in the muscle receptor. Data adapted from 
Cashin et al [19].  
The nAChR is the prototype of a larger family of Cys-loop receptors that 
includes the GABAA and GABAC (ρ) receptors, the glycine receptor, and two 
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receptors for serotonin – the 5-HT3 receptor that is found throughout the animal 
kingdom and a novel variant termed MOD-1 that is found in C. elegans. We have 
studied all of these except the glycine receptor, and in each case a fluorination plot 
reveals a cation-π interaction to the natural agonist[18, 39-41].  Interestingly, the 
exact location of the cation-π interaction within the aromatic box is variable.  It is at 
position B (like in the muscle-type nAChR) for the 5-HT3 and GABAC receptors.  
However, it has moved to position A in the GABAA receptor, and it has moved to 
position C2 in the MOD-1 receptor.  To date, every Cys-loop receptor we have 
probed has employed a cation-π interaction to bind its agonist.  However, the 
variable location of the cation-π interaction within the aromatic box indicates that one 
cannot assume that a binding interaction seen in one Cys-loop receptor will be 
observed in another, despite the high conservation in the agonist binding site region. 
3.3.2 Challenges in studying neuronal nAChRs 
While the nonsense suppression methodology has proven to be quite general, 
repeated attempts to apply the methodology to neuronal nAChRs were frustrated by 
several factors.  These include poor expression in Xenopus oocytes and some 
intrinsic pharmacological properties of the receptors.  We have now overcome these 
obstacles in both the α4β2 and α7 receptors. 
The α4β2 receptors present two challenges:  poor expression in Xenopus 
oocytes and ambiguous stoichiometry.  Concerning the former, recent studies by 
Fonck et al. showed that a mutation termed L9’A in the M2 transmembrane helix of 
the α4 subunit greatly improves expression without altering the pharmacology of the 
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receptor[42].  Therefore, all studies of α4β2 described here included this mutation.  
As with other mutations of L9’, the L9′A mutation lowers EC50 systematically by 
influencing receptor gating, a factor that does not perturb the present analysis[21, 22]. 
As noted above, the α4β2 receptor can have variable stoichiometry, but it is 
essential for the studies here to probe a homogeneous collection of receptors.  A 
recent definitive study by Moroni et al. established that there are two forms of α4β2, 
(α4)2(β2)3 and (α4)3(β2)2, which we will refer to as A2B3 and A3B2[43].  The A2B3 
form is the higher sensitivity form for nicotine, and chronic exposure to nicotine leads 
to upregulation of this form at the expense of A3B2 in a variety of contexts, including 
Xenopus oocytes[43, 44].  As such, the A2B3 form is most relevant to nicotine 
addiction, and our studies have focused on it. Several studies established that 
controlling the ratios of mRNAs injected into the oocyte can control subunit 
stoichiometry, and we have found similar results.  Injection of an mRNA ratio 
α4(L9’A):β2 of 10:1 or higher produces pure populations of A3B2, while a ratio of 
3:1 or lower guarantees a pure population of A2B3(Table 3.1).  Note that the 
α4(L9′A) mutation lowers EC50 in a multiplicative fashion, depending on how many 
α4 subunits are present.  As such, our A3B2 receptor (with three L9′A mutations) 
actually has a lower EC50 than our A2B3 receptor (with two L9′A mutations), even 
though the binding site from the A2B3 stoichiometry is clearly that of the high 
sensitivity receptor. 
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mRNA 
ratio ACh EC50 (μM) nH Stoichiometry 
100:1 0.02 ± 0 1.47 ± 0.18 
10:1 0.02 ± 0 1.33 ± 0.14 A3B2 
6:1 0.15 ± 0.02 0.67 ± 0.04 mixture 
3:1 0.44 ± 0.03 1.24 ± 0.07 
1:1 0.4 ± 0.01 1.22 ± 0.02 
α4L9'Aβ2 
1:10 0.43 ± 0.02 1.17 ± 0.06 
A2B3 
Table 3.1: Injection of various mRNA ratios α4(L9’A):β2 resulting in receptors of 
different stoichiometry.  
 
While varying mRNA ratios can control stoichiometry when expressing the wild 
type receptor, in a nonsense suppression experiment the subunit that contains the stop 
codon where the unnatural amino acid will be incorporated can experience variable 
expression levels.  As such, we sought a second, independent indicator of the 
stoichiometry of the α4β2 receptor.  We now report that the A2B3 and A3B2 forms 
of the α4(L9’A)β2 receptor show significantly different rectification behaviors.  As 
indicated by either voltage ramp or voltage jump experiments, A2B3 is substantially 
more inward rectifying than A3B2.  As such, at positive voltages A2B3 receptors 
pass much less outward current than A3B2 (Figure 3.5).  This difference is much less 
pronounced in fully wild type receptors, as others have seen. 
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Figure 3.5 Rectification behaviors of A2B3 and A3B2 α4L9’Aβ2 nAChR in Xenopus 
oocytes. A: IV curves for A2B3 (solid line) and A3B2 (dotted line). The inset shows 
the blowup of the region at positive voltages. B: Corresponding dose response curves 
and EC50s of the A2B3 (solid line) and A3B2 (dotted line) receptors. Sample traces of 
voltage jump experiments for A2B3 and A3B2 from which the IV curves (A) are 
derived are shown in C (A2B3) and D (A3B2).   
In all our experiments with unnatural amino acids, the stoichiometries of mutant 
receptors are closely monitored by performing voltage jumps. For every mutant 
receptor studied, we report the normalized current size at +70mV normalized to that at 
-110mV.  A value smaller than 0.1 establishes the desired A2B3 stoichiometry. 
(Table 3.2). 
A 
C 
B
D
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Studies of the α7 nAChR also presented several challenges, including poor 
expression and agonist concentration-dependent desensitization, which hampers the 
accurate measurement of dose-response relations.  To address the poor expression 
issue, we co-expressed the human homolog of the RIC-3 protein (hRIC-3), which 
others have shown enhances surface expression of α7 nAChRs, presumably by aiding 
the folding, assembly, and/or trafficking of the protein[45-49].  To address 
desensitization, we introduced an alternative M2 transmembrane helix mutation 
termed T6’S[50].  Previous studies established that this mutation decreases 
desensitization without disrupting channel conductance and pharmacology. 
Finally, we note that nicotine is not especially potent at α7 receptors expressed in 
Xenopus oocytes, with an EC50 on the order of 15-50 μM.  In addition, we have 
found that at concentrations approaching 1mM, nicotine can induce inward currents in 
naive (uninjected) oocytes.  While not a problem for wild type receptors, this 
complicates analyses of mutant receptors with elevated EC50 values.  As such, our 
studies of α7 have primarily employed epibatidine as a “nicotinic” agonist, which has 
a much lower EC50 and poses no special problems.  
3.3.3 A cation-π interaction in the α4β2 receptor 
Given the results with the muscle-type nAChR, a logical starting point to search 
for a cation-π interaction in the α4β2 receptor is at TrpB (α4Trp149).  With ACh as 
the agonist, both the CN/Br effect (10-fold ratio of EC50; Table 3.2) and the 
fluorination effect (Figure 3.6, right panel) clearly establish a cation-π interaction.  
In fact, an excellent linear correlation is seen when all the data are combined 
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(fluorination plus CN/Br), giving a straight line with a slope very similar to that seen 
for the muscle-type receptor. 
Mutation
A2B3 0.42 ± 0.01 1.2 ± 0.0 0.08 ± 0.01 1.2 ± 0.1 0.041 ± 0.005
A3B2 0.02 ± 0 1.3 ± 0.1 0.01 ± 0 1.7 ± 0.2 0.297 ± 0.041
Tyr 0.42 ± 0.03 1.2 ± 0.1 0.08 ± 0.01 1.7 ± 0.3 0.023 ± 0.009
Phe 12 ± 1 1.3 ± 0.1 0.77 ± 0.05 2.1 ± 0.3 0.064 ± 0.011
MeO-Phe 2.3 ± 0.2 1.2 ± 0.1 0.40 ± 0.02 1.7 ± 0.2 0.054 ± 0.032
F-Phe 15 ± 1 1.2 ± 0.1 0.32 ± 0.03 1.4 ± 0.2 -0.076 ± 0.046
F2-Phe 16 ± 2 1.8 ± 0.3 0.39 ± 0.05 1.8 ± 0.4 0.028 ± 0.005
F3-Phe 14 ± 1 1.2 ± 0.1 0.53 ± 0.04 1.4 ± 0.1 0.044 ± 0.010
Br-Phe 3.3 ± 0.2 1.2 ± 0.1 0.54 ± 0.04 1.5 ± 0.1 -0.003 ± 0.031
CN-Phe 73 ± 4 1.7 ± 0.1 8.8 ± 0.9 1.5 ± 0.2 0.075 ± 0.008
Trp 0.44 ± 0.03 1.3 ± 0.1 0.09 ± 0.01 1.5 ± 0.1 0.006 ± 0.014
F-Trp 1.9 ± 0.1 1.2 ± 0.1 0.26 ± 0.02 1.3 ± 0.1 -0.065 ± 0.047
F2-Trp 2.0 ± 0.1 1.3 ± 0.1 0.32 ± 0.04 1.3 ± 0.1 0.032 ± 0.025
F3-Trp 13 ± 1 1.3 ± 0.1 1.2 ± 0.1 1.4 ± 0.2 -0.073 ± 0.029
F4-Trp 29 ± 2 1.1 ± 0.1 4.2 ± 0.4 1.3 ± 0.2 -0.027 ± 0.023
CN-Trp 12 ± 1 1.2 ± 0.1 0.90 ± 0.07 1.4 ± 0.1 0.009 ± 0.017
Br-Trp 1.1 ± 0.1 1.3 ± 0.1 0.20 ± 0.02 1.3 ± 0.2 0.020 ± 0.005
Tyr 0.42 ± 0.03 1.5 ± 0.1 0.07 ± 0 1.3 ± 0.1 0.042 ± 0.014
Phe 53 ± 4 1.3 ± 0.1 3.3 ± 0.2 1.2 ± 0.1 0.059 ± 0.014
MeO-Phe 48 ± 5 1.4 ± 0.2 2.8 ± 0.4 1.2 ± 0.2 0.064 ± 0.028
CN-Phe 210 ± 10 1.6 ± 0.1 19 ± 2 1.6 ± 0.2 0.057 ± 0.011
Tyr 0.42 ± 0.03 1.3 ± 0.1 0.09 ± 0.01 1.6 ± 0.1 0.057 ± 0.016
Phe 0.32 ± 0.02 1.4 ± 0.1 0.14 ± 0.01 1.4 ± 0.1 0.014 ± 0.010
MeO-Phe 0.33 ± 0.02 1.3 ± 0.1 0.097 ± 0.006 1.7 ± 0.2 0.034 ± 0.033
CN-Phe 0.42 ± 0.04 1.4 ± 0.2 0.11 ± 0.01 1.6 ± 0.2 0.066 ± 0.046
Thr 0.41 ± 0.02 1.4 ± 0.1 0.09 ± 0.01 1.6 ± 0.1 0.044 ± 0.007
Tah 0.37 ± 0.02 1.3 ± 0.1 1.71 ± 0.14 1.2 ± 0.1 0.018 ± 0.013
a4L9'Ab2 
Wild type
ACh nH Nicotine nH
TyrC1 (Tyr195) A2B3
TyrC2 (Tyr202) A2B3
Thr (B+1) (Thr 155) A2B3
Norm. I (+70mV)
TyrA (Tyr98) A2B3
TrpB (Trp 154) A2B3
 
Table 3.2 EC50 values (μM), Hill coefficients and normalized current size at +70mV (normalized 
to current size at -100mV as -1) for selected mutants in α4L9’Aβ2 nAChR A2B3 receptors.  
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While the ACh results for α4β2 parallel those of the muscle-type receptor, a 
dramatic change is seen with nicotine.  In the α4β2 receptor, nicotine precisely 
mimics ACh, giving a linear fluorination plot and a strong CN/Br effect (Table 3.2; 
Figure 3.6, left panel).  These observations clearly establish a cation-π interaction 
between nicotine and TrpB of the α4β2 receptor.  Recall that in the nAChR of the 
neuromuscular junction there is no such cation-π interaction to TrpB, and so this 
specific noncovalent binding interaction provides a clear discriminator between the 
neuronal and muscle-type receptors.  With nicotine as agonist, the low sensitivity 
muscle-type nAChR lacks a key noncovalent interaction that evidently increases the 
nicotine sensitivity of the neuronal receptor.   
 
Figure 3.6 Fluorination plots demonstrating cation-π interactions of TrpB in 
α4β2 nAChR with nicotine (left) and ACh (right). In addition to fluorinated 
tryptophans, CN-Trp and Br-Trp are also included in these plots, which fitted 
excellently on the lines. On each plot, from the left to the right, each point represents 
F4-Trp, F3-Trp, CN-Trp, F2-Trp, F-Trp, Br-Trp and Trp.  
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We have performed extensive studies of other aromatic residues in and around 
the aromatic box (Table 3.2).  Briefly, when comparing α4β2 to the muscle-type 
receptor, very similar results are seen.  TyrC1 is very sensitive to substitution, 
establishing a key role for this residue, likely in receptor gating.  TyrA appears to be 
a hydrogen bond donor (large effects for Phe and MeO-Phe substitutions), and while 
it is generally more sensitive to perturbations in the neuronal receptor, the basic trends 
are the same.  TyrC2 is very permissive in both the muscle-type and α4β2 receptors.   
3.3.4 A strong hydrogen bond in the α4β2 receptor 
To probe a potential hydrogen bond to a backbone carbonyl we employ the 
strategy outlined in Figure 3.4.  By replacing the amino acid at the i+1 position with 
the analogous α-hydroxy acid, the carbonyl associated with residue i is converted to 
an ester carbonyl rather than an amide (peptide) carbonyl.  It is well established that 
ester carbonyls are much poorer hydrogen bond acceptors than amide carbonyls, and 
so if a hydrogen bond to this carbonyl is essential, the backbone ester mutation should 
influence agonist potency.  In the muscle-type receptor the mutation raised EC50 for 
nicotine and epibatidine by factors of 1.6 and 3.7, respectively.  Epibatidine is a 
much more potent agonist at the muscle-type receptor than nicotine, consistent with 
the relative magnitudes of the ester effect. 
In the α4β2 receptor, a much more dramatic effect is seen (Table 3.2).  With 
nicotine as the agonist, the backbone ester mutation causes a 19-fold increase in EC50.  
Importantly, the potency of ACh, which can not make a conventional hydrogen bond 
to the carbonyl, is essentially unperturbed by the backbone ester mutation.  This 
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establishes that the mutation does not globally alter the binding/gating characteristics 
of the receptor, supporting the notion that we are modulating a potential hydrogen 
bonding interaction between the receptor and nicotine. 
3.3.5. Single channel measurements 
The EC50 values for the various mutants described here represent a measure of 
receptor function and are thus a composite of ligand binding and receptor gating 
properties.  We have argued in the past that subtle mutations of residues that are 
intimately involved in forming the ligand binding site most likely are perturbing 
ligand binding rather than channel gating.  However, comparably subtle mutations of 
some other residues in or near the agonist binding site have been shown to influence 
gating. We cannot thus not rule out the possibility that the fluorination effects on EC50 
result from reductions in agonist efficacy (gating efficiency), rather than agonist 
binding. As such, we evaluated the gating behaviors of several key mutants using 
patch clamp techniques. 
We recorded single channel traces for the α4L9′Aβ2 receptor with Trp or F3-Trp 
at TrpB, the cation-π site (J. A. P. Shanata, personal communication).  In each case, 
nicotine is applied at its EC50. With Trp at position B, nicotine is a partial agonist, 
with Popen ~0.2 at EC50.  This is consistent with macroscopic (whole cell) studies, 
which also show nicotine to be a partial agonist relative to ACh.  With F3-Trp at 
TrpB, Popen increases to ~0.4. Thus, it appears that nicotine is slightly more 
efficacious in the F3-Trp mutant than in the Trp receptor, and so the rise in EC50 
cannot be a gating effect.  We conclude that fluorination has diminished the binding 
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affinity of nicotine for the receptor.   
3.3.6 Different behavior in the α7 receptor 
Again, the logical starting point in searching for a cation-π interaction in α7 was 
TrpB.  However, it is clear that there is no cation-π interaction to TrpB of the α7 
receptor with either ACh or epibatidine as agonist. (Table 3.3) Both CN-Trp and 
F2-Trp give essentially wild type behavior.  As noted above, nicotine can be 
problematical with the α7 receptor, but we were able to obtain convincing data to 
establish that EC50 is also unperturbed by the CN-Trp mutant with nicotine as the 
agonist. 
Since other Cys-loop receptors have employed site A or site C2 in cation-π 
interactions, we probed those locations in α7; both residues are natively tyrosines.  
We note that tyrosines have proven to be more challenging than tryptophans when 
probing for a cation-π interaction.  Directly fluorinating tyrosine will progressively 
lower the pKa of the side chain OH, such that the pKa for tetrafluorotyrosine is ~5.3.  
This could lead to ionization of the OH in substituted tyrosines, which would 
complicate the analysis.  To circumvent this potential problem in other systems, we 
considered the phenylalanine mutant as our starting point, since it can be fluorinated 
with no complications.  However, at site A of the α7 receptor, the Phe mutant is 
significantly compromised (factor of almost 50 in EC50 for ACh).  Interestingly, 
4-MeO-Phe, 4-Br-Phe, 4-Ac-Phe and, to a lesser extent, 4-Me-Phe rescue the wild 
type EC50. It thus appears that in α7, the 4-substituent of TyrA is an essential steric 
placeholder. This is a very different pattern from what is seen at TyrA in α4β2 or 
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muscle-type receptors, for which the OH appears to be a hydrogen bond donor, not a 
steric placeholder.  
We find strong evidence for a cation-π interaction between ACh and TyrA 
(Tyr92). (Figure 3.7, left panel)   There is a clear correlation in the fluorination plot, 
and the slope is comparable to that seen for other cation-π plots involving ACh. There 
is more scatter than in most other fluorination plots we have seen, but the steric 
impact of the 4-substituent is overlaid on this plot.   Note the large CN/Br ratio, 
which compensates to a considerable extent for that steric effect. 
The TyrA plot for epibatidine shows more scatter and a smaller slope. (Figure 3.7, 
right panel)  There appears to be an interaction, but it may be weaker than normal. 
 
Figure 3.7 Fluorination plots demonstrating cation-π interactions of TyrA in α7 
nAChR with ACh (left) and epibatidine (right). On each plot, from the left to the right, 
each point represents F3-Phe, CN-Phe, F-Phe, Tyr, and MeO-Phe.  
 
At TyrC2 (Y194) a different story emerges. There is no cation-π interaction 
involving ACh. (Table 3.3)  However, epibatidine shows a clear correlation, with a 
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larger slope than seen at TyrA and less scatter. (Figure 3.8)  We conclude there is a 
significant cation-π interaction to TyrC2 for epibatidine, but not for ACh. 
 
Figure 3.8 Fluorination plots demonstrating cation-π interactions of TyrC2 in α7 
nAChR with epibatidine. On the plot, from the left to the right, each point represents 
F3-Phe, CN-Phe, F-Phe, Tyr, and MeO-Phe. 
We also evaluated the potential hydrogen bond to the backbone carbonyl of TrpB.  
The results are much different than seen for α4β2.  For epibatidine, the backbone 
ester substitution raises EC50 only 2.1-fold.  Also, EC50 for ACh actually drops by a 
factor of 4.  This is precisely the pattern that was seen in the muscle-type receptor, 
and the implications of the ACh effect have been discussed previously (Table 3.3). 
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Mutation
Wild type 94 ± 3 1.8 ± 0.1 0.34 ± 0.01 2.5 ± 0.1
Tyr 93 ± 10 1.5 ± 0.2 0.38 ± 0.05 2.2 ± 0.5
Phe 4500 ± 200 3.1 ± 0.4 3.0 ± 0 3.4 ± 0.2
MeO-Phe 100 ± 0 2.3 ± 0.1 0.94 ± 0.09 2.2 ± 0.4
CN-Phe 1700 ± 100 2.1 ± 0.1 1.8 ± 0.2 1.7 ± 0.3
F-Phe 1400 ± 100 3.3 ± 0.4 3.0 ± 0.1 3.5 ± 0.4
F3-Phe 6000 ± 200 2.2 ± 0.2 15 ± 2 3.2 ± 0.7
Me-Phe 330 ± 30 1.8 ± 0.2 2.7 ± 0.1 2.8 ± 0.1
Ac-Phe 95 ± 9 2.2 ± 0.7 0.26 ± 0.01 3.0 ± 0.3
Br-Phe 78 ± 3 2.5 ± 0.2 0.34 ± 0.04 1.4 ± 0.1
3-MeO-Phe 33 ± 1 3.1 ± 0.2
mTyr 4700 ± 300 2.0 ± 0.1
COOH-Phe 4500 ± 200 2.3 ± 0.3 5.1 ± 0.1 2.8 ± 0.1
CHA
F2-Phe 4100 ± 200 2.6 ± 0.3 18 ± 1 2.0 ± 0.2
Trp 93 ± 9 1.7 ± 0.3 0.38 ± 0.02 2.1 ± 0.2
CN-Trp 63 ± 4 1.7 ± 0.2 0.14 ± 0.03 3.1 ± 1.4
F2-Trp 87 ± 5 1.7 ± 0.1 0.62 ± 0.04 2.4 ± 0.3
Tyr 98 ± 5 2.2 ± 0.2
Phe 8600 ± 600 2.7 ± 0.4
MeO-Phe
F3-Phe
F-Phe
Tyr 94 ± 2 2.3 ± 0.1 0.35 ± 0.04 2.6 ± 0.6
Phe 560 ± 20 2.6 ± 0.2 3.8 ± 0.4 1.6 ± 0.3
MeO-Phe 160 ± 10 2.1 ± 0.2 0.41 ± 0.01 3.2 ± 0.2
CN-Phe 150 ± 10 2.3 ± 0.2 2.1 ± 0 2.4 ± 0.2
F-Phe 86 ± 5 2.0 ± 0.2 1.1 ± 0 2.8 ± 0.1
F3-Phe 1300 ± 100 2.4 ± 0.3 16 ± 1 3.0 ± 0.4
Me-Phe 99 ± 7 2.7 ± 0.5 0.70 ± 0.04 2.2 ± 0.2
Br-Phe 51 ± 2 1.7 ± 0.1 0.32 ± 0.02 1.5 ± 0.1
3-MeO-Phe
mTyr 780 ± 80 1.7 ± 0.2
F2-Phe 870 ± 40 2.9 ± 0.4 13 ± 1 2.3 ± 0.2
Trp 92 ± 4 2.1 ± 0.2
CN-Trp 130 ± 10 2.4 ± 0.3
CN-Trp 56 ± 4 1.5 ± 0.2
Phe 430 ± 10 2.6 ± 0.1 1.6 ± 0.1 2.2 ± 0.3
F3-Phe 420 ± 40 1.4 ± 0.1 1.9 ± 0.1 3.1 ± 0.2
MeO-Phe 140 ± 20 1.4 ± 0.2 0.61 ± 0.09 1.4 ± 0.2
Me-Phe 110 ± 0 1.9 ± 0.1 0.75 ± 0.03 1.9 ± 0.2
Br-Phe 160 ± 0 2.1 ± 0.1 0.86 ± 0.04 2.1 ± 0.2
F3-Phe 120 ± 0 2.0 ± 0.1 0.37 ± 0.01 2.6 ± 0.1
F3-Phe 170 ± 20 1.6 ± 0.5 0.44 ± 0.02 2.8 ± 0.4
F3-Phe 140 ± 30 1.4 ± 0.4
Thr 47 ± 2 2.2 ± 0.1 0.45 ± 0.01 2.1 ± 0.12
Tah 11 ± 1 1.9 ± 0.3 0.95 ± 0.03 2.7 ± 0.2
Ser (B+1) (Ser 149)
Phe186
Phe145
Tyr150
TyrC2 (Tyr194)
TrpD (Trp54)
Phe103
no signal
no signal no signal
signal too small
Trp153
no signal
TrpB (Trp148)
no signal
signal too small
TyrC1 (Tyr187)
α7 T6'S
ACh nH Epibatidine nH
>5000
no signal
no signal
TyrA (Tyr92)
 
Table 3.3 EC50 values (μM) and Hill coefficients for selected mutants in α7 T6’S nAChR. 
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3.4 Discussion  
The diverse family of nAChRs provides an array of targets for pharmaceutical 
development.  In addition, an understanding of the physiological effects of nicotine 
requires insights into the differential actions of this powerful drug on the various 
forms of nAChR. How is it that nicotine and nicotinic analogues can target specific 
types of nAChRs, when the sequence similarity is considerable, especially in the 
region of the agonist binding site? The powerful tool of unnatural amino acid 
mutagenesis is ideal for addressing such questions.  The subtle and systematic 
modifications that the method enables can isolate specific binding interactions and 
provide compelling evidence for their absence or existence, as well as qualitative 
guidance on the relative magnitudes of specific interactions.  
The primary goal of the present work was to understand why nicotine is potent at 
the CNS receptor most associated with nicotine addiction, α4β2, but not at the 
neuromuscular junction. Concerning the binding of ACh, the muscle-type nAChR and 
α4β2 show very similar behaviors.  The quaternary ammonium ion of ACh makes 
van der Waals contact to the side chain of TrpB, providing an unambiguous anchor 
point for ACh docking.  The roles of the other components of the aromatic box also 
seem to be similar in the muscle-type and α4β2 receptors when binding ACh.   
When considering the binding of nicotine, however, a dramatic difference was 
seen.  In α4β2 nicotine makes the same cation-π interaction as ACh, consistent with 
the long-accepted nicotinic pharmacophore.  At the muscle-type receptor, however, 
this important interaction is absent.  Thus, a cation-π interaction to TrpB is a 
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clear-cut discriminator between receptors with high sensitivity to nicotine (α4β2) and 
those with lower sensitivity (muscle-type). 
Whenever EC50 is used to evaluate mutant receptors, it can be difficult to 
deconvolute binding effects from gating effects.  In previous efforts we have argued 
that the subtlety of the fluorination mutations, the proximity of the residues to the 
agonist binding site, and the strong correlation with what is clearly a binding 
phenomenon (a cation-π interaction) argue strongly that we are modulating binding, 
not gating.  Still, this is not an incontrovertible argument, and other subtle mutations 
in the agonist binding site region clearly impact gating. 
Here we have used single channel measurements to convincingly establish that 
the fluorination approach we have applied is modulating nicotine binding, not channel 
gating. Consider, for example, the F3-Trp mutation at TrpB of α4β2, which shows an 
increase in EC50 over wild type of ~13-fold. If this EC50 increase was caused by 
changes in channel gating, the gating equilibrium would have changed over 100 fold, 
and thus the Popen would have decreased significantly compared with the wild type. 
Our measurements show that at EC50 nicotine, F3-Trp at TrpB has a Popen higher than 
the wild type; therefore, the rise in EC50 must be caused by diminished binding 
affinity of nicotine for the receptor.  
We have also identified another discriminating factor in the binding of nicotine at 
α4β2 vs. muscle-type receptors.  Based on the AChBP structures it was proposed 
that nicotine makes a hydrogen bond to the backbone carbonyl associated with TrpB.  
To test this hypothesis, we employed a backbone ester strategy, converting the 
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carbonyl in question to a weaker hydrogen bond acceptor (ester vs. amide).  As with 
the fluorination strategy employed to evaluate a cation-π interaction, the advantages 
of the unnatural amino acid methodology are evident here.  To probe a potential 
hydrogen bonding interaction we do not ablate it, we simply modulate it in a 
controlled and predictable manner.  Importantly, in the present case when the agonist 
was ACh – a molecule that can not make a conventional hydrogen bond to a carbonyl 
– essentially wild type receptor behavior was seen.  This indicates that the backbone 
mutation did not alter receptor function, i.e., gating. 
In the muscle-type receptor nicotine is a very weak agonist, and it shows a 
modest 1.6-fold rise in EC50 due to the backbone ester mutation.  The more potent 
agonist epibatidine, which is clearly a “nicotinic” agonist, shows a larger 3.7-fold 
shift in the muscle-type receptor.  In contrast, at α4β2 nicotine shows a 19-fold 
increase in EC50 in response to the ester mutation.  To appreciate the significance of 
this difference, if we put these shifts on an energy scale, the effects are 0.28 kcal/mol 
at the muscle-type vs. 1.7 kcal/mol at α4β2.  We conclude that while nicotine is able 
to make a hydrogen bond to the carbonyl in question in both receptors, the interaction 
is much stronger in the α4β2 receptor than in the muscle-type, and that this is an 
additional contributor to the enhanced potency of nicotine at α4β2. 
We also considered a second neuronal nAChR, the homopentameric α7 receptor.  
Along with being an intrinsically interesting target, our previous experience with 
Cys-loop receptors established that it is risky to assume that a binding interaction seen 
in one member of a family will carry over to other members.  Indeed, we find a 
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dramatic change in the binding mode on going from α4β2 to α7.  Remarkably, the 
strong cation-π interaction that ACh and nicotine make to TrpB in α4β2 is completely 
absent in α7.  This result is quite unambiguous; both CN substitution and difluoro 
substitution have no effect on EC50 for ACh and epibatidine, and nicotine is oblivious 
to CN substitution (the stronger perturbation of the two).  So, despite complete 
identity among the five residues that form the aromatic box, ACh adopts two different 
binding modes in the neuronal nAChRs. 
To date, every Cys-loop receptor we have studied makes a cation-π interaction, 
so we assumed one must be present in α7.  For ACh as agonist, that site is now TyrA.  
Fluorination has a strong, additive effect, and given the complications associated with 
modulating this tyrosine site, the fit to the fluorination plot is good. Also, the CN/Br 
ratio is large. 
The situation with epibatidine is more complicated, and, to some extent, 
unprecedented.  It is clear that fluorination at TyrA impacts epibatidine potency, and 
more fluorines have a bigger effect.  However, the correlation is not nearly as 
compelling as in other systems, and the slope is less than any other we have seen.  
We propose that the diminished slope indicates a weaker than usual cation-π 
interaction.  A weaker cation-π interaction would make the fluorination plot more 
susceptible to other variations such as steric effects, accounting for the generally 
poorer quality of the fit. 
At TyrC2, however, a much more compelling plot is obtained with epibatidine.  
The fit is better, and the slope is well within the normal range for a cation-π 
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interaction.  It thus appears that epibatidine interacts with two contributors to the 
aromatic box:  strongly with TyrC2 and less strongly with TyrA.  While we have 
not seen such behavior before in a Cys-loop receptor, these two tyrosines are quite 
near each other,(Figure 3.3) and the epibatidine molecule is large enough to contact 
both residues simultaneously.  Note that the energetic fall off of the cation-π 
interaction with distance between the cation and the aromatic is not especially steep, 
and so even a cation that is not in direct van der Waals contact with an aromatic can 
experience a significant stabilization. 
The α7 receptor is also different from α4β2 with regard to hydrogen bonding.  
The very strong interaction to the TrpB backbone carbonyl seen in α4β2 is greatly 
diminished in α7.  In fact, with regard to hydrogen bonding (but not the cation-π 
interaction), α7 is qualitatively similar to the muscle-type receptor. 
We have now studied three members of the nAChR family:  muscle-type, α4β2, 
and α7.  The pharmacologies of these vary, and we have identified structural features 
of the receptor that discriminate among the three.  The three receptors make different 
use of the cation-π interaction to recognize agonists.  In the muscle-type receptor, 
TrpB makes a cation-π interaction to ACh, but not to nicotine.  In α4β2, the TrpB 
cation-π interaction to ACh remains, but now nicotine also makes a strong cation-π 
interaction. Finally, the α7 receptor eschews the cation-π interaction to TrpB, and 
agonists have moved their cationic center across the aromatic box to TyrA and TyrC2.  
As we have seen with other Cys-loop receptors, there is considerable risk in 
extrapolating too heavily from one model structure, AChBP, to a large family of 
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receptors.  Such a model structure provides extremely valuable guidance, but not 
definitive answers. 
A second discriminating feature of the family is the hydrogen bonding 
interaction to the backbone carbonyl of TrpB.  While this interaction is modest in the 
muscle-type and α7 receptors, it is much stronger in α4β2, the most sensitive of the 
receptors studied here. 
What features of the nAChRs produce these differing binding behaviors?  As 
noted above, the five aromatic residues, three tyrosines and two tryptophans that form 
the aromatic box are completely conserved in the nAChR family.  Clearly, one must 
think outside of the box to find the answers.  It must be that other features of the 
receptor are reshaping the box, facilitating interactions with particular agonists and 
discouraging others.  The beautiful aromatic box of AChBP must in fact be 
deformable and adaptable to specific receptor requirements.  There is considerable 
variability in loop C among the three receptors probed here.  Also, many workers 
have proposed that the “non-α” subunit is more responsible for subtype specificity.  
Here, that would be subunits δ and γ in the muscle-type, β2, and α7 in the neuronals.  
Loop D and other non-α regions (loops E and F) do show significant sequence 
variability among the various subtypes. 
In summary, we have identified key noncovalent binding interactions that 
contribute to the differential pharmacology of three nAChRs.  The critical factor that 
makes nicotine potent in the brain but not at the neuromuscular junction can be traced 
to a cation-π interaction that is strong in the α4β2 neuronal receptor but absent in the 
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muscle-type receptor.  Additionally, a hydrogen bond to the agonist that is present in 
all receptors is significantly enhanced in the high sensitivity α4β2 receptor. A cation-π 
interaction is also important in another neuronal receptor, α7, but the interaction has 
moved across the agonist binding site to a different aromatic residue(s).  These 
results provide valuable insights into the molecular basis of nicotine addiction and 
should provide useful guidance to efforts to develop subtype-selective drugs that 
target nAChRs. 
3.5 Experimental procedures 
3.5.1 mRNA synthesis and mutagenesis 
Rat α4, β2 and α7 mRNA were obtained from linearizations of the expression 
vector pAMV with Not1, followed by in vitro transcription using the mMessage 
mMachine T7 kit from Ambion (Austin, TX). The mutations for each subunit were 
introduced according to the QuikChange mutagenesis protocol (Stratagene). The 
cDNA for hRIC-3 was obtained from Dr. Miller Treinin at Hebrew University and the 
mRNA was in vitro transcribed from XhoI linearized expression vector pGEM. 
3.5.2 Ion channel expression 
To express the ion channels with a wild type ligand binding box, α4L9’A mRNA 
was coinjected with β2 mRNA at various ratios (total mRNA 10-25ng/cell). 10-25ng 
α7 T6’S mRNA was coinjected with 20ng of hRIC-3 mRNA per cell. Stage V-VI 
oocytes of Xenopus Laevis were employed and the injected cells were allowed 24-48 
hour incubation at 18°C before characterization. 
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3.5.3 Unnatural amino acid / α-hydroxy acid incorporation 
Nitroveratryloxycarbonyl (NVOC) protected cyanomethyl ester form of 
unnatural amino acids and α-hydroxythreonine cyanomethyl ester were synthesized, 
coupled to dinucleotide dCA, and enzymatically ligated to 74-mer THG73 tRNACUA 
as detailed previously.  The unnatural amino acid-conjugated tRNA was deprotected 
by photolysis immediately before co-injection with mRNA containing the TAG 
mutation at the site of interest.  Typically, about 10-25 ng mRNA and 25 ng 
tRNA-amino acid or tRNA-hydroxy acid were injected into stage V–VI oocytes in a 
total volume of 50 nL. For all the α7 T6’S mutant channels, 20ng of hRIC-3 mRNA 
was coinjected with the mRNA/tRNA mixture. 
The fidelity of unnatural amino acid incorporation is confirmed at each site with 
a so-called “wild type recovery” experiment and a read-through test. In the “wild type 
recovery” experiment, TAG mutant mRNA was coinjected with tRNA charged with 
the amino acid that is present at this residue in the wild type protein. Generation of 
receptors that are indistinguishable from the wild type protein indicates that the 
residue carried by the suppressor tRNA is successfully and exclusively integrated into 
the protein. In a read-through test, the TAG mutant mRNA was introduced with no 
tRNA or with tRNA THG73 that is not charged with any amino acid or with tRNA 
THG73 enzymatically ligated with dinucleotide dCA. Lack of currents in these 
experiments validates the reliability of the nonsense suppression experiments. 
3.5.4 Electrophysiological characterizations of the channels 
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Agonist induced currents were recorded in two-electrode voltage clamp mode 
using the OpusXpress 6000A (Molecular Devices Axon Instruments) at a holding 
potential of -60mV. In the case of α4L9’Aβ2 receptors, agonists were prepared in 
ND96 Ca2+ free buffer, applied for 12s, and followed by a 2 minute wash with ND96 
Ca2+ free buffer between each concentration. For α7 T6’S receptors, agonists were 
prepared in ND96 buffer and applied for 30s or 12s. 5 minutes of wash with ND96 
buffer was allowed between each concentration. Acetylcholine chloride, (-)-nicotine 
tartrate, and (±)-epibatidine dihydrochloride were purchased from Sigma/Aldrich/RBI 
(St. Louis, MO). Dose-response data were obtained for at least 6 concentrations of 
agonists and for a minimum of 5 oocytes. Mutants with Imax of at least 100 nA of 
current were defined as functional. EC50 and Hill coefficient were calculated by fitting 
the dose-response relation to the Hill equation. All data are reported as means ± S.E. 
Voltage jump experiments were performed in the absence of ACh and at EC50 
concentration of ACh. The membrane potential was held at -60mV, and stepped to 10 
test potentials at 20mV increments between +70mV and -110mV for 400ms each. 
600ms at -60mV holding potential was allowed between each test potential. 
Background subtracted traces were used to measure the steady-state amplitudes of the 
ACh-induced currents near the end of the test pulses. Normalized I-V curves were 
generated using current amplitudes normalized to that at -110mV. For each α4L9’Aβ2 
mutant, normalized I+70mV ± S.E. from at least 5 cells was reported.  
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C h a p t e r  4  
CONTRASTING DRUG-RECEPTOR INTERACTIONS AT 
NEURONAL VS. MUSCLE-TYPE NICOTINIC 
ACETYLCHOLINE RECEPTORS: THE α4β4 NEURONAL 
RECEPTOR* 
*This chapter is a brief description of a project in collaboration with Neurion 
Pharmaceuticals and Eli Lilly & Company, which predated the α4β2 and α7 nAChR 
research reported in the previous chapter. 
4.1 Background 
The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand 
gated ion channels, which also includes GABAA and GABAC, glycine, and 5-HT3 (serotonin) 
receptors.[1] The nAChRs are found in both the central and peripheral nervous systems, 
where they mediate fast synaptic transmission and muscular contraction, respectively. 
Malfunctions of nAChRs have been implicated in a wide variety of “channelopathies”, 
including addiction, Parkinson’s disease, schizophrenia, Alzheimer’s disease and congenital 
myasthenic syndromes.[2] 
Like other Cys loop receptors, nAChRs are pentameric ion channels, each of the five 
homologous subunits containing a large extracellular domain and a transmembrane domain. 
There are 17 known subunits of nAChRs: α1-α10, β1-β4,δ, γ and ε. While the muscle-type is 
well defined as (α1)2β1γδ (fetal form; (α1)2β1εδ in adult cells), many different types of 
neuronal nAChRs can arise from varying combinations of the remaining α2-α10 and β2-β4 
subunits[3]. Among the numerous neuronal nAChRs characterized in the mammal brain, α4 
and β4 nAChR subunits were recently found to colocalize in different species in various brain 
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regions [4]. α4β4-containing receptors account partially for the type 4 currents in the mouse 
brain in the β2 knockout mice[5]. The physiological relevance of this receptor, however, is 
not known in great detail. The basic pharmacology of the α4β4 receptor differs significantly 
from that of the muscle type receptor we have probed previously. For example, in the muscle 
receptor ACh is a much more potent agonist than nicotine, while in α4β4, nicotine is almost 
8-fold more potent than ACh, more typical of neuronal receptors.  
Among the many tools that have been used to probe the nAChR and related structures, 
unnatural amino acid mutagenesis using nonsense suppression has proven to be an especially 
powerful tool for structure function studies of ion channels at the atomic level. [6-8] Well in 
advance of the crystal structures of AChBP [9, 10], a small protein that is highly homologous 
to the extracellular domain of the nAChRs, the unnatural amino acid methodology 
established that ACh binds to the muscle-type nAChR through a cation-π interaction to Trp 
α149, a residue now identified as TrpB [6].  In subsequent studies of other Cys-loop 
receptors, it was found that agonists bind the receptors through strong cation-π interactions 
within the “aromatic box” (Chapter 3). As is shown in Table 4.1, three of these established 
cation-π interactions involve a homologous tryptophan or tyrosine on loop B[11, 12], but 
other receptors employ a different aromatic[13, 14]. Interestingly, the same ligand can bind 
highly homologous receptors differently, as illustrated by serotonin forming cation-π 
interactions with two different tryptophans in the MOD-1 and 5-HT3 receptors.  Other 
interactions that are important for ligand binding, e.g., hydrogen bonds, have also been 
established by unnatural amino acid incorporations[15, 16].  
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  A B C1 C2 D 
m-nAChR Y93 W149 Y190 Y198 W55 
5-HT3R E129 W183 F226 W234 W90 
MOD-1 C120 Y180 Y221 W226 F83 
GABACR F138 Y198 Y241 Y247 Y102 
GABAAR Y97 Y157 F200 Y205 F65 
Table 4.1 Amino acids in the aromatic box of the agonist binding site in five different 
Cys-loop receptors, including the generic nomenclature of each amino acid according to the 
structural ”loop” that contains it.  Bold and blue residues make a cation-π interaction with 
the natural agonist. Table adopted from [17] 
The “aromatic box” for ligand binding is completely conserved in these and all other 
nAChRs. Here we report the first studies of a neuronal nAChR using unnatural amino acid 
mutagenesis, probing the agonist binding site of the α4β4 receptor. In addition to ACh and 
nicotine, we study epibatidine and cytisine, the lead compound for development of the 
anti-smoking drug varenicline (Figure 4.1).  
 
Figure 4.1: Compounds tested in the current study. Shown for each agonist are the chemical 
formula, ball-and-stick representation, and the electrostatic potential surface. Values for the 
electrostatic potential range from 0 (red) to +170 (blue) kcal/mol. 
 
 
104
 
4.2 Results 
4.2.1 Establishing the viability of unnatural amino acid incorporation in the α4β4 
receptor 
Human α4β4 nAChR were heterologously expressed in Xenopus oocytes by introducing 
wild type α4 and β4 mRNA at a ratio of 1:1, yielding functional receptors with a Hill 
coefficient around 1.5. The measured EC50s of four different agonists are shown in Table 4.2 
in comparison with the muscle type receptor.  Next, unnatural amino acids (Figure 4.2) were 
introduced at positions of interest in either α4 or β4 subunits. For example, the amber stop 
codon (TAG) was introduced at position 153 of α4, a Trp site that corresponds to Trp α149 of 
the muscle-type receptor, the site of the ACh cation-π interaction. This is generically referred 
to as TrpB. When mutant mRNA was injected into a Xenopus oocyte along with the 
suppressor tRNA THG73 that is charged with Trp, receptors that are indistinguishable from 
wild type were obtained. Note that the subunit carrying the TAG mutation is usually injected 
into oocytes in 2 to 3 fold excess to ensure a sufficient incorporation of this subunit. This 
wild type recovery experiment establishes that nonsense suppression techniques are viable for 
the α4β4 receptor, and analogous wild type recovery experiments were performed at all sites 
probed. As negative controls for suppression, mutant mRNA was injected into oocytes 
without tRNA at all, with tRNA THG73 that is not charged with any amino acid, or with 
tRNA THG73 ligated with dCA. In no case was any response to agonists detected.  
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Receptor 
subtype ACh Nicotine Epibatidine Cytisine 
Muscle-type 50 ~2000 26  
α4β4  13 1.7 0.01 0.08 
Table 4.2: Comparison of muscle type nAChR (α1)2β1γδ and the neuronal nAChR α4β4 
EC50s in Xenopus oocytes. EC50 in μM.  
 
 
Figure 4.2: Tryptophan and phenylalanine analogs incorporated in the current study. 
In this study we measure the EC50s of the mutant α4β4 receptors and compare them with 
the wild type values. The EC50 value represents a functional assay, and as such it is a 
composite of equilibria for both binding and gating. In residues that define the agonist 
binding site, when subtle changes are introduced by incorporating unnatural amino acids, we 
interpret changes in EC50 values to reflect changes in agonist affinity rather than influencing 
gating processes.  
4.2.2 TrpB 
 An aforementioned fluorination plot (chapter 3) is the most accurate indicator of a 
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cation-π interaction, therefore, progressively fluorinated tryptophan residues were 
incorporated at site B in the α4β4 receptor (Table 4.3). In the cases of ACh and epibatidine, 
progressive fluorination did not lead to a systematic increase in EC50 as was seen in the 
muscle-type receptor. The response was “flat”, in that adding more electron-withdrawing 
fluorine atoms on the tryptophan did not correlate with a weakened binding of the agonist to 
the receptor. In addition, CN-Trp produces only a modest effect when ACh or epibatidine is 
the agonist. 
 Nicotine and cytisine are both only minimally affected by fluorination at TrpB, much like 
ACh and epibatidine.  However, in the case of nicotine, CN-Trp produces a 22-fold drop in 
potency, while Br-Trp produces only a 3-fold drop.  While not as dramatic as the effect seen 
with ACh at the muscle-type receptor[6], these results do suggest a significant electrostatic 
interaction between nicotine and TrpB in the α4β4 receptor.  The CN/Br effect is even more 
dramatic with cytisine, being roughly comparable to that seen with ACh in the muscle-type 
receptor.  This is the first time the CN/Br and fluorination strategies have not produced 
consistent results.  
4.2.3. TyrA 
 In the α4β4 receptor, we studied the potential of TyrA to form both cation-π and 
hydrogen bonds (Table 4.3).   
 Mutating Tyr to MeO-Phe evaluates the role of a Tyr as a potential hydrogen bond donor.  
In muscle-type receptor this causes an 8-fold decrease in ACh potency[8].  In α4β4, all 
agonists show diminished potency in response to this mutation, with effects ranging from 3- 
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to 11-fold. 
 As mentioned in Chapter 3, substituted Phe derivatives instead of fluorinated tyrosines 
were used to evaluate the cation-π interaction at the tyrosine site. Fluorination shows no 
consistent effect with ACh or epibatidine (remembering that Phe is the proper reference 
point).  CN/Br comparisions are varied.  With ACh CN-Phe has a 16-fold bigger effect 
than Br-Phe, suggesting a possible electrostatic effect, but again the fluorination study is not 
consistent with this.  The CN/Br ratios are relatively modest with the other agonists.    
4.2.4. TyrC1 and TyrC2 
 Consistent with effects seen in the muscle receptor, in the α4β4 receptor the sensitivity 
of residue C1 persists (Table 4.3), in that for ACh, nicotine and cytisine, replacing the 
hydroxyl with a methoxy, a bromo or a cyano group causes the EC50 to increase over 100 fold. 
The effects are less dramatic with epibatidine, but still substantial. 
 In the α4β4 receptor, TyrC2 is again found to be very tolerant to mutagenesis. Replacing 
the hydroxyl group with either a methoxy, bromo or cyano group doesn’t change the EC50 for 
ACh, nicotine or epibatidine significantly. Cytisine appears to be a bit more sensitive to these 
substitutions, but the effects are still relatively small.  
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α4β4  
Mutation ACh  Nicotine Epibatdine Cytisine 
TyrA (Tyr 97) 
MeO-Phe 3.5 3 6 11 
Br-Phe 2.7 5 3 78 
CN-Phe 45 32 9 210 
Phe 20 4.3   
F-Phe 20 2.7   
F2-Phe 12 7.1   
F3-Phe 10 2.2   
TrpB (Trp 153) 
F-Trp 3.4 3 2 4.4 
F2-Trp 2.7 3 3 3.3 
F3-Trp 2.2 7 1 4.4 
Br-Trp  3  8 
CN-Trp 7.1 22 4 210 
TyrC1 (Tyr 194) 
MeO-Phe > 10 mM* >1 mM* 7 120 
Br-Phe >10 mM* >1 mM* 30 590 
CN-Phe > 10 mM* >1 mM* 80 560 
TyrC2 (Tyr 201) 
MeO-Phe 0.8 1 1 2.2 
Br-Phe 0.3 0.5 1 1.1 
CN-Phe 0.8 1.5 1 5.6 
Table 4.3 Ratios of mutant EC50 over the wild type EC50 for selected mutants in 
α4β4 receptors. The bold and underlined numbers are from recordings from our lab and the 
other numbers are from our collaborating labs at Neurion Pharmaceuticals and Eli Lilly and 
Company.  (*approximate EC50 values.) 
4.2.5 TrpD 
The fifth contributor to the “aromatic box” comes from the complementary subunit. In the 
muscle receptor, this is the Trp 55/57 from γ/δ subunits, and in the α4β4 receptor it is Trp 59 
in the β4 subunit. In the muscle-type receptor, the EC50 values for both CN-Trp and Br-Trp 
are very near wild type for ACh and nicotine. Similarly, for the analogous residue in the 
5-HT3 receptor (Trp90), tetrafluorinated tryptophan showed a wild type like EC50. In α4β4 
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receptor, when CN-Trp is incorporated at this position, no response to agonists (ACh and 
Nicotine tested) could be detected, while wild type recovery is successful. The detailed 
function of this residue needs further investigation. 
4.3 Discussion 
The remarkable complexity of the CNS is evident at all levels:  anatomical, cellular, and 
molecular.  Dozens of different neurotransmitters target cognate receptors.  Even for a 
single neurotransmitter like ACh, there are nicotinic receptors, studied here, but also 
muscarinic receptors (GPCRs).  And the nicotinic receptors are themselves diverse.  The 
muscle-type is well defined, but many different types of neuronal nAChRs can arise from the 
α2-α10 and β2-β4 subunits. While certainly not all combinations are viable, it seems likely 
that a dozen or more neuronal nAChR subtypes play a role in the mammalian CNS.  A 
critical issue, then, in efforts at drug discovery around the nAChR family is targeting specific 
receptor subtypes. 
The present work preceded the work in α4β2 and α7 nAChR reported in Chapter 3, and it 
describes the first application of the nonsense suppression, unnatural amino acid 
methodology to a neuronal nAChR, the human α4β4 receptor.  Many previous studies of the 
muscle-type nAChR have established that this approach can provide powerful insights into 
structure and function.  The primary goal of the present work was to establish that nonsense 
suppression is viable in the neuronal receptors.  Secondarily, we wished to determine 
whether the well-defined structure-function relationships seen in the muscle-type receptor, 
such as the cation-π interaction between TrpB and ACh, carry over to the neuronal family.  
Finally, we hoped to begin an investigation of the structural features that produce the 
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substantially differing pharmacologies of the muscle-type and neuronal receptors.  Since 
there is absolute conservation of the five aromatics that define the agonist binding site “box”, 
and since all models emphasize these residues as providing the sole side chains that contact 
the agonist, the effects will necessarily be subtle, and these early studies can only hope to 
provide guidance for future work. 
We report that the nonsense suppression approach to unnatural amino acid incorporation 
for receptors expressed in Xenopus oocytes is applicable to a neuronal nAChR, the α4β4 
receptor.  This receptor was chosen for initial studies because it had been known that 
receptors expressing the β4 subunit express well in Xenopus oocytes.  More recently, we 
have established successful nonsense suppression in homopentameric α7 receptors and α4β2 
receptors (Chapter 3). For the α4β4 receptor, expression is robust, and a number of unnatural 
amino acids have been successfully incorporated and evaluated. 
This first round of studies on a neuronal receptor has produced some surprising results.  
Most remarkably, the compelling cation-π interaction seen between ACh and TrpB of the 
muscle-type receptor is clearly absent in the α4β4 receptor. No other side chain probed in the 
α4β4 receptor shows strong evidence for an equally strong cation-π interaction with ACh. 
Note that the muscle-type result is not an isolated anomaly.  Equally compelling results have 
established cation-π interactions between serotonin and the aligned tryptophan of the 5-HT3 
receptor; between GABA and the aligned tyrosine of the GABAC receptor; and between 
serotonin and a Trp at site C2 in the MOD-1 receptor; and more recently, between GABA and 
TyrA in the GABAA receptor.   
A possibility is that the cation-π site has moved in α4β4 relative to the muscle-type.  This 
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would be precisely analogous to what we have seen with two homologous serotonin receptors.  
Both receptors bind serotonin with a cation-π interaction and the magnitude of the effect is 
the same.  However, in the 5-HT3 receptor TrpB is responsible, while in MOD-1 it is TrpC2.  
The present results indicate that the only possible candidate for a cation-π interaction to ACh 
in α4β4 is TyrA.  An attempted fluorination plot produced no trend.  However, the starting 
point for the experiment was Phe, not Tyr, and the Phe mutant is already 20-fold less potent 
with ACh.  It may be that a substituent at the 4 position of tyrosine is essential, and so the 
fluorination series is compromised from the start.  Consistent with this, Br-Phe is only 
3-fold worse than Tyr. The isosteric, but much more deactivating, CN-Phe is 45-fold worse.  
This CN/Br ratio of ~15 is not as large as seen with TrpB in the muscle-type (57-fold).  First, 
Tyr is an intrinsically weaker cation-π binding site than Trp, so it may be ACh is picking up a 
moderate cation-π interaction at TyrA. Secondly, as reported in the previous chapter, at TrpB 
site in α4β2 receptor where ACh and nicotine show an unambiguous cation-π interaction, the 
CN/Br ratio is 11 fold and 4.5 fold, respectively. For α7 nAChR, epibatidine shows cation-π 
interactions at both TyrA and TyrC2 sites and the CN/Br ratio is 5.3 fold and 6.6 fold 
respectively. Therefore, the 15 fold ratio of CN/Br at TyrA in α4β4 may indeed indicate a 
cation-π interaction.  
In other ways, the binding of ACh is similar for the two receptors. TyrC1 is quite sensitive 
to substitution, while TyrC2 is quite tolerant. 
We have also evaluated three other agonists – nicotine, epibatidine, and cytisine – to 
further compare and contrast the muscle-type and neuronal receptors.  A hallmark of the 
muscle-type receptor is its insensitivity to nicotine.  However, epibatidine, clearly a nicotine 
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analogue, is potent at the muscle-type receptor.  In earlier work we showed that the cation-π 
interaction at TrpB displayed by ACh is absent for the weak agonist nicotine but present for 
the potent agonist epibatidine[15].  Both nicotine and epibatidine appear to make a hydrogen 
bond to the backbone carbonyl of TrpB in the muscle-type; an interaction that is not possible 
for ACh. 
In the α4β4 receptor, all three additional agonists are insensitive to progressive 
fluorination at TrpB. This would appear to rule out a cation-π interaction.  However, for 
nicotine to some extent and definitely for cytisine, CN-Trp causes a very large drop in 
potency.  Coupled in each case with the much smaller drop for Br-Trp, this observation 
could be interpreted as indicating a cation-π interaction. Alternatively, both nicotine and 
cytisine have polarized C(sp2)-H bonds that could experience a π-π interaction with the TrpB 
side chain.  This is much weaker than a cation-π interaction, and perhaps the fluorination 
series is unable to reveal it, but the strongly perturbing CN substituent is. 
Alterations of TyrA in α4β4 have similar consequences for all the additional agonists 
considered here. MeO-Phe is detrimental, as seen before.  Nicotine produces no consistent 
fluorination effect.  CN-Phe has varying effects, but they are tracked by Br-Phe, such that 
the large CN/Br ratio seen with ACh is absent with the other agonists.  We conclude there is 
no strong interaction to TyrA with nicotine, epibatidine, or cytisine. 
As with ACh, all other agonists are significantly impacted by changes to TyrC1 and 
relatively unaffected by changes to TyrC2. 
Taken together, the evaluation of α4β4 leads to several conclusions.  Most important is 
the danger of extrapolating observations from one receptor to another, despite high homology 
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and absolute identity for the supposedly key residues.  The cation-π interaction at TrpB seen 
for both ACh and epibatidine in the muscle-type receptor is not manifest in α4β4.  Both 
agonists show no fluorination trend, and a ≤7-fold change for CN-Trp, vs. 95-fold for ACh at 
the muscle-type.  The other agonists nicotine and cytisine do show a hint of an interaction in 
an elevated CN/Br ratio, but that is not mirrored in the fluorination trend. This may indicate a 
π-π rather than a cation-π interaction.  
It may also be that the cation-π interaction for ACh seen in the muscle-type receptor has 
moved from TrpB to TyrA.  The evidence is not as compelling as seen with other systems, 
but it is suggestive. 
Certainly, the four agonists probed here do not experience identical interactions with the 
α4β4 receptor.  Given the somewhat “generic” appearance of the aromatic box, it may not 
be surprising that different drugs can find different ways to bind to and activate the receptor.  
An interesting trend is that, in most cases, cytisine is the most sensitive of the agonists to 
mutation.  Cytisine is also the only completely rigid agonist and is fairly large, so perhaps it 
is more limited in the ways it can adapt to perturbations of the binding site.   
The overarching conclusion from these and other studies of the agonist binding site of 
Cys-loop receptors is that they seem to be much more adaptable than the beautiful but static 
image from the AChBP structures.  Certainly some variation in structure has been implied 
by different structures and by simulations, but the differences from ligand to ligand and 
receptor type to receptor type are quite remarkable.  The results present an intriguing but 
cautionary tale for those engaged in efforts to specifically target selected receptors. 
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C h a p t e r  5  
IMPROVING NONSENSE SUPPRESSION BY 
SUPPRESSING eRF-1 WITH siRNA 
5.1 Abstract 
Introducing unnatural amino acids into proteins by nonsense suppression has proven to 
be an effective and powerful tool to study protein structure-function relationships on the 
chemical scale. In our lab, this strategy has greatly facilitated the structure-function 
studies of a series of membrane bound ion channels. The research reported here describes 
efforts to increase nonsense suppression efficiency in Xenopus laevis oocytes and human 
embryonic kidney (HEK) cells using RNA interference to target eukaryotic release factor 
1 (eRF1).  In particular, we designed multiple 21nt small interfering RNAs (siRNA) 
targeting both Xenopus and human eRF1, and monitored the nonsense suppression 
efficiency in vitro and in vivo by RNA PCR, Western blotting, fluorescence and 
electrophysiology. 
5.2 Introduction 
5.2.1 Unnatural amino acid incorporation by nonsense suppression 
Introducing unnatural amino acids into proteins by nonsense suppression is an 
effective and powerful tool to study protein structure-function relationships on the 
chemical scale[1]. By introducing a stop codon into the mRNA at the site of interest, 
together with a misacylated tRNA chemically ligated with a synthesized unnatural amino 
acid, proteins can acquire chemical properties that are not represented by any of the 20 
natural amino acids (Figure 5.1). This methodology has greatly facilitated our study of 
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membrane ion channels, a family of physiologically important but structurally complex, 
multisubunit proteins that are embedded in lipid bilayers.  
 
  
Figure 5.1. Schematics of the unnatural amino acid incorporation in vivo by nonsense 
suppression. 
 
A limitation of nonsense suppression methodology is that the aminoacylated tRNA is 
stoichiometric, such that each aminoacylated tRNA can be used only once.  Therefore, to 
generate enough proteins for characterization, either large quantities of aminoacylated 
tRNA is required or a very sensitive assay needs to be adopted. In our lab, we primarily 
study ion channels that can be assayed by very sensitive electrophysiological recordings. 
Furthermore, the majority of experiments are performed in Xenopus laevis oocytes in 
which relatively large amounts of aminoacylated tRNA can be injected. Utilizing this 
system with an engineered orthogonal Tetrahymena thermophila tRNA charged with 
 117
unnatural amino acids[2], over 20 of ion channels, including the nAChR (nicotinic 
acetylcholine receptor), serotonin receptor (5-HT3AR)[3], MOD-1[4], Shaker [5] and 
Kir2.1 potassium channels [6] and so on[7, 8] have been studied, and information on 
ligand binding and ion channel gating mechanisms has been obtained. 
5.2.2 Nonsense suppression efficiency 
One complication of the nonsense suppression experiments is that there is great 
variability of suppression efficiency. Efficiency varies from channel to channel, from 
residue to residue, and in some cases an amino acid may be replaceable by some 
unnatural side chains but not by others[9]. Factors associated with this variability include 
1) codon context, 2) read-through of the stop codon and 3) the production of truncated 
proteins when the UAG codon is recognized by protein translation termination machinery 
instead of the aminoacylated tRNA. These factors are quite difficult to control.   
First of all, there have been many reports correlating codon context and suppression 
efficiency. In our lab, however, no obvious correlation has been found[9]. 
Secondly, read-through of the engineered stop codon causes the production of full 
length proteins without incorporation of desired unnatural amino acid. This may result 
from the recognition of the stop codon by an endogenous tRNA even without a perfect 
codon:anticodon match, or by the replacement of the unnatural amino acid by a natural 
amino acid, or by the deletion of the desired incorporation site. It has been difficult to 
generate systematic rules to predict the likelihood of erroneous full length protein 
production. In our lab, we control read-through expression by varying the amount of 
injected mRNA and the ratio of receptor subunits to each other.   
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Finally, it was found that suppression efficiency can be affected by termination at the 
introduced stop codon. The resultant truncated protein not only lacks function, but also 
may have deleterious effects on cell death or possible dominant negative effects. In the 
case of membrane proteins such as receptors, partial-length proteins may be trafficked to 
the surface and interfere with experimental results.   
Misfolding, misassembly and the failure of trafficking may complicate suppression 
efficiency too. These can be partially evaluated by Western blotting the membrane 
fraction of proteins expressed, but are generally difficult to analyze.  
5.2.3 Improving nonsense suppression efficiency in Xenopus oocytes  
Increasing nonsense suppression  efficiency of this methodology would be beneficial 
in multiple ways. First of all, it would facilitate the study on functionally important yet 
poorly expressed ion channels, such as neuronal ACh receptors α4β2 and α7 (Chapter 3 
describes our work on these two receptors later). It would also enable us to explore 
regions of receptors that are less tolerant of unnatural amino acids, and to incorporate 
unnatural amino acids with more structural diversity.  Furthermore, improved yield of 
nonsense suppression would allow for characterizations of products using a less sensitive 
assay than electrophysiology. 
A lot of efforts have been put into improving nonsense suppression efficiency in our 
lab. These included optimizing the expression vector, overexpressing elongation factors, 
trying to reduce clatherin-mediated endocytosis by co-expression of a dominant-negative 
dynamin, overexpression of ER-chaperones (BiP), insertion of forward-trafficking signals 
for greater surface expression, construction of a chimera of the poorly expressed ion 
channel with a better expressed ion channel,  and multiple injections into oocytes. In the 
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case of α4β2, only multiple injections had a measurable effect, but the whole-cell currents 
were still too small to generate reliable dose-response relations[9]. Another strategy to 
improve suppression efficiency is to use a four-base codon instead of an amber stop 
codon in mRNA to avoid recognition by protein translation stop machinery.  Recently, 
simultaneous incorporation of three amino acids in vivo by frame shift suppression has 
been established in our lab[10].  
5.2.4 Improving nonsense suppression efficiency in mammalian cells 
In addition to utilizing nonsense suppression in Xenopus oocytes, our lab expanded the 
exploration into mammalian human embryonic kidney (HEK) cells as well. A 
mammalian cell expression system is a more relevant environment for many proteins of 
mammalian origin and would allow for studies of cell-specific signal transduction 
pathways.  Therefore there is much interest in our lab to extend the nonsense suppression 
technology into a mammalian system. However, mammalian cells are much smaller than 
oocytes, meaning that fewer aminoacylated tRNA will be able to enter the cells. Also, 
hydrolysis of the aminoacyl-ester bond is quite rapid at the physiological pH which is 
required for handling of mammalian cells. The first successful mammalian nonsense 
suppression experiment delivering unnatural amino acid to the nAChR site-specifically 
was reported in our lab by Dr. Monahan in 2003[11]. However, similar experiments 
performed on α4β2 had no observable nonsense suppression, although wild type α4β2 
subcloned into mammalian expression vector pCO-neo did express. In order to obtain 
observable nonsense suppression, Dr. Monahan substantially increased the mRNA/tRNA 
concentration in the trasfection solution, but under no circumstances was any sign of 
suppression observed[12].  
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5.2.5 Improving nonsense suppression efficiency by suppressing eRF1 
One way to improve suppression efficiency is to decrease the production of the 
truncated protein, due to translation termination at the incorporated stop codon.  
When the ribosome elongation machinery encounters a stop codon, protein synthesis 
typically terminates (Figure 5.2 A). The eRF1-eRF3 complex binds to the A site of the 
ribosome, where eRF1 directly interacts with the stop codon (eRF3 has a stimulating 
effect). This leads to hydrolysis of the peptidyl-tRNA bond, and then the formation of 
eRF1/eRF3 complex with poly(A) binding protein or PABP. Interaction of PABP with 
translation initiation factors mediates the ribosome recycling and re-initiation of 
translation[13].  
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Figure 5.2. A: A general scheme of the translation termination complex. (adapted 
from[13]). B: siRNA structure. C: A scheme of RNA interference mechanism. (adapted 
from[14]) 
 
UAG stop codon has been chosen to be the nonsense stop codon, and it is recognized 
by eRF1 only. Therefore diminution of eRF1 could lessen competition with the 
misacylated suppressor tRNA and thus promote the incorporation of the unnatural amino 
acid into proteins[15].  
In an in vitro experiment performed in the Hecht lab, the suppression efficiency was 
improved 11-fold when release factors were partially inactivated by heat shock in an E. 
coli-derived extract with a thermo sensitive eRF1. Interestingly, along with the great 
improvement of nonsense suppression efficiency they also reported a decrease of protein 
translation accuracy, assayed by the specific activity of suppressed HIV-1 protease. They 
proved that this was due to the increasing ability of endogenous tRNA to read through the 
engineered stop codon as the eRF1 is depleted[16].  
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5.2.6 Using RNA interference (RNAi) to suppress eRF1 in mammalian cells 
It has also been shown by the Yarus lab that in cultured HEK (human embryonic 
kidney) cells, RNAi can decrease levels of eRF1 and increase read-through of UAG stop 
codons. In this experiment, three siRNAs designed to target different positions of human 
eRF1 were separately transfected into HEK cells. Read-through of a UAG codon was 
assayed by the expression of a luciferase gene located right after the UAG codon. 
Although the read-through of the UAG codon was not perfectly correlated with the 
mRNA level of eRF1 detected by RNA PCR, the largest effect seen was a 90% eRF1 
degradation that correlated with a 150% increase of UAG read-through[17]. 
The success of this experiment suggests that RNAi is potentially an effective way of 
suppressing endogenous eRF1 in nonsense suppression systems. We decided to use this 
new yet fast developing technology, RNAi, to improve the suppression efficiency both in 
Xenopus oocytes and in HEK cells. 
In 2004, the Vogel lab reported that by suppressing eRF1 in HEK cells, a five-time 
higher level of unnatural amino acid incorporation, demonstrated by EGFP fluorescence 
recovery was achieved[18].  
5.2.7 Using RNAi to suppress endogenous proteins in Xenopus laevis oocytes 
Suppressing eRF1 of Xenopus laevis has no precedent, but the first siRNA experiment 
targeting an endogenous protein in Xenopus oocytes was reported in 2003 in which the 
expression of an ion channel xMiRP2 was reduced 5 fold by a chemically synthesized 
21nt siRNA[19] (Figure 5.2 B).  
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The most recent application of siRNA suppressing an endogenous protein in Xenopus 
oocytes is reported by the Boehmer lab[20]. They knocked down an endogenous 
ubiquitin ligase Nedd4-2 (xNedd4-2) expression to increase the activity of a transporter 
(EAAT4) mediating glutamate uptake through the action of a serum and glucocorticoid 
kinase (SGK) 1. The reduction was about 50% as revealed by Western blotting.   
5.2.8 RNA interference 
RNA interference is a post-transcriptional gene silencing (PTGS) initiated by the 
introduction of double-stranded RNA. PTGS occurs in both plants and animals and has 
roles in viral defense and transposon silencing mechanisms.  
The understanding of RNA interference mechanism includes two steps (Fig. 5.2 C). 1) 
Initial step. The long double stranded RNA introduced either directly, via a transgene, or 
with a virus, is digested into 21-23 nucleotide small interfering RNAs (siRNAs) by an 
enzyme called Dicer. Dicer belongs to RNase III family of RNA-specific ribonucleases. 
It cuts the dsRNA in an ATP-dependent processive manner. The structure of siRNA 
contains 2 nucleotide overhangs at the 3’-end and a phosphate at the 5’-end, which is the 
typical structure of the digestion products of this family of enzymes. 2) Effecter step. The 
siRNA binds to a nuclease complex known as the RNA-induced silencing complex, or 
RISC. An ATP-depending unwinding of the siRNA duplex is required for the activation 
of the RISC. The active RISC then targets the homologous transcript by base pairing and 
then cleaves the mRNA 10 nucleotides from the 5’-end of the siRNA[14, 21, 22]. 
After being discovered as a factor for gene silencing, double stranded RNAs have been 
used in various organisms. Chemically synthesized small interfering RNA is the most 
commonly used[23]. Long double stranded RNAs are used also but they need to be 
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processed into small interfering RNAs by Dicer. It was also found that siRNA based 
hairpins with perfectly matched or imperfectly matched stem can be cut by Dicers[24]. 
In recent years, RNA interference has become an almost-standard method for in vitro 
knock down of any target gene of interest. Recent efforts in this area have focused on 
developing efficient delivery of target gene-specific siRNAs. [25] 
Herein, we will use chemically synthesized 21nt siRNAs to decrease eRF1 both in 
Xenopus oocytes and in HEK cells in efforts to improve nonsense suppression efficiency. 
5.3. Experimental Design 
5.3.1 siRNA molecules designed to target human and Xenopus laevis eRF1. 
The siRNA Si1187h targeting human eRF1 was reported to reduce human eRF1 
mRNA in HEK cells by 90% and to increase UAG readthrough by about 150%[17].  A 
second siRNA, si36h, reduced human eRF1 mRNA by 40% and increased UAG 
readthrough by 80%. The numbers in the two names denote the distance from the A of 
the translation start codon AUG in eRF1 mRNA, and “h” means “human”, to distinguish 
from “x” meaning “Xenopus”.  
These two 21nt sequences were ordered from Dharmacon Research as desalted and 
deprotected double stranded RNAs with two nucleotide overhangs at the 3’-end. These 
molecules were dissolved in DEPC water to a concentration of 1 μg/μl. 
Xenopus laevis eukaryotic release factor 1 was first sequenced in 1993 and it is highly 
homologous to human eRF1 sequence. Therefore, two siRNAs targeting the same 
positions as in human eRF1 were ordered. Si1187x (antisense strand: 
CACAAGAAGGCUCUCAGUUdTdT) has one nucleotide difference from si1187h 
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(antisense strand: CACAAGAAGGGUCUCAGUUdTdT) and si36x (antisense 
strand:GGAGAUCUGGAAGAUCAAGdTdT ) has the same sequence as si36h. 
Finally, two more siRNA molecules were designed and ordered, si1151x (antisense 
strand: UUCGGAGCAACACUGGAGAdTdT) and si450x 
(UUGAUGGGAGUGGAGCACUdTdT). siControl is a 21 nt non-targeting siRNA of 
comparable GC content as the targeting siRNAs. This serves as a negative control for 
non-sequence-specific effects. (Figure 5.3 A) 
 
Figure 5.3 A: Different positions of siRNA targets on eRF1 mRNA (both human and 
Xenopus homologs were used, see text) B: Different time delays between the siRNA 
injection and the mRNA/tRNA injections were applied. 
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5.3.2 Coinjection of siRNA molecules with nonsense suppression experiments into 
Xenopus oocytes  
In order to test if the presence of siRNA could help to increase the nonsense 
suppression efficiency, siRNA molecules targeting Xenopus laevis eRF1 were coinjected 
into Xenopus oocytes.  
The nonsense suppression experiment selected here is a wild type recovery experiment 
where the nicotinic acetylcholine receptor (nAChR) α1 subunit mRNA with a UAG 
codon at position 149 was suppressed by a suppressor tRNA charged with wild type 
tryptophan. W149 is located in the extracellular domain of the nAChR (Chapter 3). 
Successful and efficient suppression should yield wild type nAChR whose function can 
be monitored using a two electrode voltage clamp electrophysiology.  
Specifically, 12.5ng of mRNA with UAG codon, 25ng of tryptophan charged tRNA 
and 500pg of siRNA (or siControl) are mixed in 0.05 μl of DEPC water and coinjected 
into Xenopus oocytes using a micropipette. mRNA, tRNA and siRNA were either 
coinjected simultaneously, or injected at different time intervals between the siRNA 
injection and mRNA/tRNA injection. Experiments were performed where siRNA 
molecules were injected 24 hours, 10 hours or 3 hours prior to mRNA/tRNA injections 
(Figure 5.3 B).  
The amount of siRNA molecules introduced into oocytes was also varied; 25 ng, 5 ng, 
500 pg, 50 pg, 5 pg of si1187 and si36 were injected at different time delays of 3 hours, 
10 hours and 24 hours. 
5.3.3 Recording currents in Xenopus oocytes of nAChR introduced by 50 μM ACh 
and 250 μM ACh. 
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The expression of nAChR was tested using two electrode voltage clamp 
electrophysiology. We use a high throughput OpusXpress system (Axon Instruments) 
with automated drug delivery, which records simultaneously from 8 oocytes. The 
currents introduced by 50 μM ACh (EC50) and 250 μM ACh (saturating concentration) 
were recorded as indications of nAChR expression level. The recordings were always 
performed 24 hours after the injection of mRNA and tRNA.  
5.3.4 RNA PCR on eRF1 both in Xenopus oocytes and in HEK cells. 
In order to estimate the siRNA efficiency, RNA PCR was performed to look at the 
mRNA of eRF1 in both oocytes and HEK cells.  RNA PCR is also called RT PCR or 
reverse transcription PCR. It uses RNA as template to perform in vitro reverse 
transcription followed by conventional PCR on the cDNA. In order for RNA PCR to be 
semi quantitative, a calibration experiment has to be performed to find a point where the 
reagents in the PCR mixture begin to be saturated by the RNA templates, so that later in 
the PCR product comparison experiment, the amount of PCR product is solely dependent 
on the amount of RNA templates, i.e. there is a linear correlation between the mRNA 
template and PCR product.  
5.3.4.1 General strategy 
Figure 5.4 shows the two major steps of this strategy. First, in order to achieve a linear 
correlation between mRNA templates (the total mRNA extracted from cells) and the 
product, total RNA was extracted from uninjected oocytes or untreated HEK cells. 
Amplification primers for eRF1 mRNA were 5’-AGCTGGATCCGCTGACTTTAAA-3’ 
and 5’-ATACCTCCAATTCCACCAAATC-3’ for HEK cells and were 5’-
GGCTGGATCCGCAGATTTTAAA-3’ and 5’-ATCCCTCCAATTCCACCAAATC-3’ 
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for Xenopus laevis. RNA PCR was performed under the same conditions using a titration 
of total RNA (1 μg, 0.2 μg, 40 ng, 8 ng, 1.6 ng and etc) as templates. By observing the 
band intensities of the PCR product on the gel, the amount of mRNA template that is 
sensitive to a 5 fold decrease was found, which determined the amount of RNA template 
used in step 2. In the second step, oocytes and HEK cells were introduced with siRNAs 
and their total RNA was extracted. Comparing the RNA PCR products of these samples 
with that of the control, a decrease of about five fold of the eRF1 mRNA was detected. 
The details of each are shown below. (Figure 5.4) 
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Figure 5.4 Strategy of RNA PCR experiments to detect eRF1 mRNA decrease by injecting 
siRNAs.  
 
 
5.3.4.2 Extract total RNA from injected oocytes 
Oocytes were injected with 500 pg of siRNA or siControl using classic micropipette 
injection. 3 hours or 24 hours after injection, 20 oocytes were lysed with 1ml of Trizol® 
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reagent (Invitrogen), followed by 200 μl of chloroform extraction and 500 μl of 
isopropanol precipitation. The RNA pellet was washed with 75% ethanol and dissolved 
in 30 μl of DEPC water. The remaining DNA was further cut with DNase I (RNase free) 
(Qiagen) and the RNA was purified using RNeasy Mini Kit (Qiagen). The concentration 
of RNA was measured by UV spectrometry. 
5.3.4.3 Extract total RNA from transfected HEK cells 
For the purpose of total RNA extraction and RNA PCR, HEK cells were transfected 
with siRNA using Lipofectamine (Invitrogen). 1.2 μg of each siRNA and siControl were 
transfected into 2.4×105 HEK cells on one 35 mm tissue culture plate using standard 
Lipofectamine transfection protocol. 3 hours or 24 hours after transfection, all the cells 
on the plate were lysed with 1ml of Trizol® reagent (Invitrogen), followed by the RNA 
extraction described before. 
5.3.4.4 RNA PCR on the extracted total RNA 
To detect the amount of eRF1 mRNA, GeneAmp® RNA PCR Kit (Applied 
Biosystems) was used following the standard protocol. Briefly, in the first step, reverse 
transcription was performed using a random hexamer as primer (provided) and the 
reaction was incubated in 42°C for 15 minutes and denatured at 99°C for 5 minutes. In 
the second step, PCR primers for the corresponding eRF1 and AmpTaq DNA polymerase 
were added and a traditional PCR reaction was performed.  
5.3.5 SDS-PAGE and Western blot in Xenopus laevis oocytes  
In order to look at the full length protein and truncated protein on Western blots, an 
HA tag (YPYDVPDYA) was subcloned to the N-terminus of α subunit of acetylcholine 
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receptor with a UAG stop codon at the position of tryptophan 149. The vitelline/plasma 
membranes were manually stripped from oocytes expressing nAChR. After removing the 
yolks of the oocytes by centrifuge, the samples containing only the vitelline/plasma 
membrane were analyzed by SDS-PAGE, followed by immunoblotting with the anti-
hemagglutinin antibody and visualized using an ECL detection kit (Amersham). Note that 
the full-length proteins observed in this experiment will include not only the correctly 
suppressed functional protein, but also proteins produced from UAG read-through by 
endogenous tRNA. Observing membrane protein only instead of proteins from the whole 
cell excludes the full-length proteins that are not trafficked correctly to the cell surface.  
5.3.6 Co-electroporation of siRNA with TAG29 GFP-TAG plasmid DNA and HSAS 
tRNA and microscopy in HEK cells 
Because a mammalian cell is a more relevant environment for proteins of mammalian 
origin and would allow for studies of cell-specific signal transduction pathways, testing 
the effect of RNAi suppression in mammalian cells in efforts to enhance nonsense 
suppression is worthwhile. Before using large amounts of chemically aminoacylated 
tRNA necessary for electrophysiology recordings on mammalian cells, an HSAS (human 
serine amber suppressor) assay was applied. In this experiment, HSAS was used to 
suppress a TAG codon at serine 29 of EGFP DNA. HSAS is recognized by the serine 
synthetases (SerRS) of mammalian cells so it does not require chemical aminoacylation 
prior to delivery[11]. The wild type recovery of EGFP can be observed by the appearance 
of green cells under a fluorescent microscope. Nonsense suppression using HSAS is 
catalytic and therefore yields enough EGFP for observation. 
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Specifically 1.2 μg of siRNA molecules or siControl are co-precipitated with 10 μg 
Ser29TAG-EGFP plasmids and 20 μg of HSAS tRNA. This is then dissolved in 5 μl of 
CO2 independent media, and electroporated into HEK cells as reported previously. 
Visualization of the transfected HEK cells was performed using a video imaging system 
in our lab equipped with an inverted microscope (Olympus IMT2). For fluorescence, a 
250 W Hg/Xe lamp was used, operating at 150W.  A GFP filter set (Chroma) with an 
excitation bandpass of 450 to 490 nm, and an emission bandpass of 500 to 550 nm was 
used.  
5.4. Results and discussion 
5.4.1 Electrophysiology of siRNA treated oocytes 
Although si1187 and si36 were previously reported to be effective in suppressing eRF1 
mRNA and to be able to increase UAG codon suppression effectively in HEK cells[17], 
they failed to show any increase of acetylcholine induced currents from nAChR produced 
in the nonsense suppression experiment. The size of maximal currents from each oocyte 
varied from 2 μA to 9 μA. The large variability of the current size required a large 
number of samples to give a sound statistic result. At least 6 cells were recorded in each 
experiment, and the ability of OpusXpress recording 8 cells each time highly facilitates 
the recording process. However, observed either individually or as a group, there was no 
consistent change of average current size in the siRNA treated oocytes, although results 
differed slightly from day to day. The treatment of siControl in parallel did not show any 
noticeable cytotoxicity. (data not shown) 
The reasons that these two siRNAs did not increase the currents might include 1) the 
possibility that different amount of injected siRNA was needed. 500 pg of siRNA 
 133
injection was previously reported to effectively decrease the xMiRP channel expression 
in Xenopus oocytes[19]. But eRF1 is a very important protein in the cell; therefore maybe 
a larger amount of siRNA is needed to produce a comparable decrease. It could also be 
possible that a smaller amount of siRNA is needed because depletion of eRF1 may have 
compromised the translation accuracy.  
Another reason might be that time delays were needed between the siRNA injection 
and mRNA/tRNA injection so that the eRF1 that had already been translated would have 
time to turn over before the nonsense suppression took place.  Different time delays as 
shown in Figure 5.3 were tested.  
The absence of improvement seen from different injection amounts (25 ng, 5 ng, 50 pg, 
5 pg and 0.5 pg) combined with different time delays between the two injections (3 hours, 
10 hours and 24 hours) left no choice but designing new siRNA molecules. 
The newly designed si1151x shows an increase of average current size of about 30%. 
si450x, however, shows a very small effect, and siControl shows comparable signals to 
the control of no siRNA. The increase, of course is not as dramatic as we would hope, 
and the error bars shown here are large. These results are repeatable and varying the 
amount of siRNA by 10 folds does not have a big effect on the current sizes. (Figure 5.5) 
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Figure 5.5 The average currents of mouse muscle nAChR α1 149 TAG mutant recovered 
by tryptophan charged tRNA with and without siRNA injected. There are at least 8 cells 
in each experiment. 
 
It is not surprising that different siRNAs targeted toward the same gene have varying 
effects.  For example, an enzymatically created small hairpin RNA (shRNA) library that 
contained 262 independent shRNAs was generated to be processed into siRNAs by Jurkat 
T cell machinery targeting GFP gene. In these experiments, it was found that only 30% of 
the constructs managed to decrease the GFP expression by a factor of larger than 2, and 
56% of the constructs decreased GFP by a factor of less than 1.5[26].  Similarly, in an 
experiment where two sets of siRNAs were designed to target two different genes, each 
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set containing at least 90 independent siRNA designs, statistic analysis showed that a 
two-base shift in the target mRNA is sufficient to alter RNAi efficiency[27].  
Unfortunately, not enough is known about the RNAi mechanism to allow such a 
strategy. Because of the wide usage of RNAi technology, an enormous number of 
experiments has been performed in search for a systematic “rational” siRNA design 
strategy that can “guarantee” effective target suppression. From such studies, a series of 
criteria was developed to aid in siRNA design, including the requirement of a low GC 
content, a bias towards low internal stability at the sense strand 3’-terminus, and the lack 
of inverted repeats. Other criteria, although proven to be valid in some specific analysis, 
failed to display experimental support[27]. 
5.4.2 RNA PCR results of uninjected oocytes and siRNA treated oocytes. 
Figure 5.6 A shows a successful calibration experiment of RNA PCR on eRF1 mRNA 
extracted from uninjected oocytes. The number below each lane indicates the amount of 
total RNA used as templates. From this gel we can see that 40 ng of total RNA is a 
threshold where a 5 fold of decrease will cause a corresponding decrease of band 
intensity on the gel.  
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Figure 5.6 RNA PCR and Western blottting show different effects of designed siRNA 
molecules in Xenopus oocytes and in HEK cells. A: Different amount of total RNA 
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from uninjected oocytes used as RNA PCR templates. This experiment was performed 
to find the right amount of templates for RNA PCR so that a 5 fold decrease of eRF1 
mRNA causes a decrease of RNA PCR product on the agarose gel. Numbers show the 
amount of total RNA extracted from non-injected oocytes used as templates for RNA 
PCR. B: RNA PCR results show that Xenopus eRF1 mRNA was not reduced with the 
injection of 500pg of si1187x or si36x. In each lane, the numbers indicate the amount 
of total RNA used as templates in each RNA PCR experiment. The amount of each 
siRNA used is 500ng. 3 hour and 24 hour time delays are used and 40ng and 8 ng of 
total RNA are used. C: RNA PCR results show that Xenopus eRF1 mRNA was 
reduced with the injection of 500pg of si1151x and si450x. The reduction was about 5 
fold. There is no noticeable difference between simultaneous injections or 24 hour 
delay injections. Numbers outside the parentheses indicate the amounts of total RNA 
used and the ones inside the parentheses indicate the amounts of siRNA injected. D. 
RNA PCR result of si1187h and si36h suppressing HEK eRF1 mRNA. 40ng of total 
RNA was used in each lane. The HEK cells were lysed 24 hours after transfection. E. 
Western blot showing both full length α nAChR and truncated α nAChR the translation 
of which stopped at position 149. 3 oocytes were used in each lane and 500 pg of 
siRNAs were injected for the oocytes on the right three lanes. 
 
 
The RNA PCR performed on si1187x and si36x injected oocytes explained the lack of 
effect on the electrophysiology level. Figure 5.6 B shows that si1187x or si36x do not 
decrease eRF1 mRNA in oocytes. These two siRNA molecules, although capable of 
inducing release factor reduction in HEK cells (the human analogs) [17], are not able to 
suppress release factor mRNA in oocytes. 
The RNA PCR results of the newly designed siRNAs correlated with the 
electrophysiology readings (Figure5.6 C). However si450x, although it does not show 
much effect on current increase, turns out to have reduced the mRNA level of release 
factor, similar to si1151x. 
 Figure 5.6 D shows the RNA PCR result of si1187h’s and si36h’s effect in HEK cells. 
24 hours after transfection, si1187h suppressed eRF1 in HEK cells by about 5 fold while 
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si36h has a much smaller effect. This result correlates with the previously reported result 
by the Yarus lab [17].   
5.4.3 Western blots for siRNA treated oocytes 
The Western blot (Figure 5.6 E) shows both the full length proteins and truncated 
proteins. The full length protein includes both the functional protein and the proteins with 
read-through by endogenous tRNA. So far, an increase in the ratio of full length protein 
over truncated protein has not been seen. 
One explanation for the lack of difference on Western blots is that a similar calibration 
process to that  performed with the RNA PCR experiment is needed here, and that it has 
to be confirmed that the proteins are not saturating the antibodies. Once a linear 
correlation between the amount of α nAChR protein and the darkness of the band seen on 
the SDS-PGE gel is established, the results will be more informative.  
If it is the case that there is no ratio change of full length proteins over truncated 
proteins, then the increased electric signal is probably caused by increased ratio of 
correctly suppressed protein within this full length band. Then the decreased release 
factor could have increased the fidelity of the codon:anticodon recognition.  
5.4.4 HSAS/TAG EGFP experiments 
As is shown in Figure 5.7, si1187h has increased the number of green cells compared 
to no siRNA, while si36 does not seem to have an obvious effect. In this experiment, wild 
type EGFP and EGFP TAG mRNA transfected cells serve as a positive control (dark blue 
line) and a negative control (pink line ) respectively. The numbers of green cells from the 
si1187h treated cells (light blue line), the si36h treated cells (purple line), no siRNA 
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treated cells (yellow line) and the random siRNA treated cells (brown line) were 
compared. The data here are quite preliminary and lack certain controls such as a 
transfection with EGFP TAG and siRNA.  More importantly, an assay more accurate 
than counting green cells is needed for this experiment. 
  
Figure 5.7 Preliminary results of Ser29TAG EGFP suppressed by HSAS. 
 
5.5 Conclusion and future direction 
From these preliminary studies performed, we found that reducing functional 
eukaryotic release factor 1 in vivo by RNAi potentially increases nonsense suppression 
efficiency both in Xenopus oocytes and in HEK cells, and the effect is more promising in 
HEK cells. We developed an RNA PCR experiment to look at the mRNA level of eRF1 
both in Xenopus oocytes and in HEK cells, which can be expanded to other endogenous 
proteins in the future.  
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The experiments that will be performed in the future include: 
1. In oocytes, another suppression experiment can be performed where tRNA acylated 
with a charged residue is incorporated into a restrictive site of the TAG mutant.  
2. In oocytes, poorer-expressed ion channels (possibly a neuronal ion channel) can be 
studied. The wild type recovery experiment reported here has obtained high efficiency in 
our lab so far. Therefore, it is possible that an increase will be more obvious to see in a 
case where nonsense suppression efficiency is lower.  
3.  For EGFP/HSAS experiment in HEK cells, a more quantitative and a more accurate 
assay than counting the green cells under the microscope will be designed.   
4. In HEK cells, nonsense suppression of one or more ion channels will be explored 
with the help of RNAi.  
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